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ABSTRACT 
Lalitha Iyer 
Loyola University Chicago 
PHARMACOKINETICS AND PHARMACODYNAMICS 
OF RECOMBINANT HIRUDIN VARIANT 2 (rHV2) 
IN ANIMAL MODELS 
Hirudin is reportedly the most potent and specific natural inhibitor of 
thrombin (Ila), with an inhibitory constant (Ki) in the picomolar range. This 
65/66 amino acid polypeptide, extracted from the medicinal leech, Hirudo 
medicinalis, was used in ancient medicine as an anticoagulant. More recently, 
the development and production of recombinant forms of hirudin variants have 
brought hirudin back into the focus of research interest. 
The primary objective of this dissertation was to investigate the 
relationship between pharmacokinetics (PK) and pharmacodynamics (PD) of 
recombinant hirudin variant 2 (rHV2) in valid animal models. To accomplish 
this, anticoagulant, antithrombin and enzyme-linked immunosorbent assay 
(ELISA) methods were developed and optimized. The PK and PD analysis of 
rHV2 was performed in three animal models: rats, rabbits and dogs, using two 
routes of administration: i.v. (bolus) and s.c. 
A polyclonal antibody based competitive ELISA method was 
v 
experimentally validated and used to measure absolute concentrations of rHV2 
in plasma. This enabled the determination of true pharmacokinetic 
characteristics of rHV2. The in vitro and ex vivo pharmacodynamics of rHV2 
were studied using coagulation tests such as activated partial thromboplastin 
time (APTT), thrombin time (TT) and calcium thrombin time (Ca+ 2TT), and an 
amidolytic antithrombin assay. The in vivo antithrombotic and hemorrhagic 
profile of rHV2 were studied using a modified Wessler's jugular vein stasis 
thrombosis model and ear blood loss model in rabbits, respectively. Renal 
function status after rHV2 administration was evaluated using 3H-inulin 
clearance analysis in rats. In addition, clinical laboratory profile was obtained 
after rHV2 administration in dogs and rats. 
Utilizing a newly developed thrombin titration method, the potency of 
rHV2 was determined to be = 15,873 antithrombin units/mg. Species and 
assay dependent antithrombin effects were observed in the concentration-
response studies after in vitro supplementation of rHV2. 
The observations from this dissertation revealed that rHV2 produced 
dose dependent antithrombotic and bleeding effects in rabbits, with a broad 
therapeutic window. In the pharmacokinetic studies, rHV2 exhibited a 
terminal elimination half-life of = 45 to 60 minutes after i.v. administration. 
The biological residence time of rHV2 was increased to = 3 hours after s.c. 
administration. Significant extravascular distribution of rHV2 was evident 
after both routes of administration, in all three species. rHV2 exhibited linear 
vi 
pharmacokinetics after escalating i.v. and s.c. administration in rats and dogs. 
In the PK/PD studies, it was found that rHV2 displayed a dose, time and 
route dependent ex vivo antithrombin profile. The time course of ex vivo 
antithrombin activity of rHV2 paralleled the time course of plasma rHV2 
concentrations, indicating a direct relationship between PK and PD of this 
agent, in all three animal models. 
Repeated, daily administration of rHV2 in dogs did not produce any 
major accumulation of rHV2, or attenuation of anticoagulant activity. rHV2 
did not produce renal compromise in rats after both routes of administration. 
Furthermore, there were no significant fluctuations in clinical laboratory profile 
after single dose administration in rats and multiple dose administration in 
dogs. 
These studies indicate that rHV2 is a potent anticoagulant and 
antithrombotic agent with a predictable pharmacokinetic/pharmacodynamic 
profile, and exhibits a desirable therapeutic index. 
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CHAPTER I 
REVIEW OF LITERATURE 
History of Hirudin 
Hirudin is the first anticoagulant known to man that was discovered over 
a hundred years ago, in 1884, in the salivary gland of the medicinal leech, 
Hirudo medicinalis (Haycraft, 1884; Sawyer, 1988). Leeches were commonly 
used in the once widespread practice of phlebotomy or bloodletting. The art 
of bloodletting dates back to the Stone Age, when the ancients believed in its 
ability to purge bad humors from the body (Adams, 1989). An early 
documentation of the use of leeches for medicinal purposes appears in a 
painting in an Egyptian tomb around 1500 BC (Sawyer, 1988; Fields, 1991). 
Leeching has also been documented in the ancient Indian medical encyclopedia 
known as Sushruta Samhita, compiled between 500 BC and AD 200 (Fields, 
1991 ). This was followed by the Romans, Greeks, and most other Europeans. 
Figure 1 illustrates the use of leeches in ancient medicine, depicting the 
placement of live leeches on the neck of a patient. Soon, the ugly, 
bloodsucking leech became the aspirin of the day, as it was being used to treat 
all kinds of maladies ranging from headaches to insomnia and obesity. 
Consequently, by the beginning of the 20th century, leech populations in 
Europe were almost completely depleted, and by 1910, Hirudo medicinalis was 
..... ,,.J.--
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Figure 1. Use of leeches in ancient medicine . 
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(Reproduced, by permission, from the lithograph by Louis Bailly, Clements C. 
Fry Collection, Yale Medical Library, Bailly, Lou is Leopold (1761-1845) "Les 
Sangsues") 
declared extinct in Britain (Sawyer, 1988). 
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The overcollection and 
indiscriminate use of leeches led to the inclusion of this species of the leech 
in the Red Data Book of Endangered Species. The use of leeches in 
bloodletting was advantageous as their bite was less painful than the wound 
inflicted by conventional bloodletting instruments. Besides, one can apply the 
leech to less accessible areas such as tonsils, cervix and hemorrhoids (Adams, 
1989). Even today, leeches are being used to restore circulation after 
microsurgery, plastic surgery and surgical reattachment of amputated 
extremities (Coniff, 1987; Lent and Dickinson, 1988; Sawyer, 1988; Garcia, 
1992; West et al., 1994). 
The leech owes this wide popularity to the remarkable array of 
biologically active constituents of its salivary secretion. The most important 
among these is hirudin, that was discovered from leech extracts by John B. 
Haycraft in 1884. Haycraft ( 1884) demonstrated that the active constituent 
of leech salivary secretion possessed potent anticoagulant properties. This 
compound was named "hirudin" by Karl Jacoby in 1904 (Jacoby, 1904). This 
makes hirudin the world's first anticoagulant (Sawyer, 1988), as heparin was 
isolated from liver in 1916 (Mclean, 1916) and bishydroxycoumarin was 
produced from fermented clover in the late 1930s (Link, 1959). It is 
interesting to note that Abel et al. ( 1914) had attempted to use hirudin to 
prevent clotting of blood during research with an "artificial kidney". 
The other constituents of the leech salivary secretion include other 
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proteinase inhibitors such as bdellins which are inhibitors of plasmin and 
trypsin, eglins which are antagonists of lysosomal polymorphonucleocyte 
elastase and cathepsin G, pancreatin, chymotrypsin, as well as bacterial 
subtilin (Seemuller et al., 1986; Fink et al., 1988). The leech salivary secretion 
also contains other substances that inhibit the amidolytic and kininogenase 
activities of plasma kallikrein (Baskova et al., 1981 ), those that have lipase and 
cholesterol esterase activities (Baskova et al., 1984), and still others that have 
local anesthetic and hyaluronidase-like activity (Fields, 1991). 
Attempts to isolate pure hirudin from leeches were severely hampered 
due to the shortage of Hirudo medicinalis and the lack of sophisticated 
technical facilities required for such an endeavor. Eventually, Markwardt 
succeeded in isolating hirudin from medicinal leeches in 1955. Different 
methods for the isolation and purification of hirudin from leech heads as well 
as whole leeches, including affinity and ion-exchange chromatography on 
matrix-bound thrombin have been used (Markwardt and Walsmann, 1967; 
Bagdy et al., 1973; Walsmann and Markwardt, 1985). Markwardt studied the 
anticoagulant and antithrombotic properties of hirudin extensively. He showed 
that hirudin was a highly specific inhibitor of thrombin, which is the end point 
of the first stage of coagulation, thereby preventing the conversion of 
fibrinogen to fibrin (Markwardt, 1970). 
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Structural Analysis and Biotechnology of Hirudin 
Hirudin is not a single entity, but a group of structurally similar single-
chain polypeptides ("hirudins") of a length of 65 or 66 amino acids with an 
average molecular weight of = 7000 daltons. The complete amino acid 
sequence of hirudins was determined using automated liquid phase Edman 
degradation of color-carboxymethylated hirudin and its tryptic peptides (Dodt 
et al., 1984). The amino acid composition showed an unusually high content 
of dicarboxylic acids and the absence of arginine, methionine, and tryptophan 
(Dodt et al., 1984; Seemuller et al., 1986). 
Hirudin preparations with different specific thrombin inhibitory activities 
and different amino-terminal residues have been described (Markwardt and 
Walsmann, 1967; Bagdy eta/., 1973; Graf eta/., 1973). Dodt (1984) purified 
hirudins extracted from whole leeches by gel filtration on Sephadex G-75 and 
Biogel P 10, as well as anion-exchange chromatography on diethylaminoethyl 
(DEAE)-cellulose and DEAE-Sephadex A-25. This effort demonstrated the 
presence of a non-homogeneous population of hirudins with two different 
amino-terminal residues, valine and isoleucine, in the ratio of 3: 1. The hirudin 
with amino-terminal valine was termed "hirudin" and the hirudin with amino-
terminal isoleucine was termed "hirudin PA". Closely related isoforms of 
hirudin and hirudin PA were designated as hirudin variant 1 (HV1), hirudin 
variant 2 (HV2), etc., and hirudin PA-1, hirudin PA-2, etc., respectively 
(Seemuller et al., 1986). 
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Dodt et al. ( 1986) also determined the structural features of hirudin PA 
and noted an 82 % homology between the acid residues of hirudin and hirudin 
PA. The more distinct differences are the amino-terminal isoleucine, an 
additional amino acid (total= 66 amino acids) and the exchange of lysine for 
glutamine in position 24 in hirudin PA. The tyrosine in position 64 of hirudin 
PA was found to be sulfated. 
Baskova et al. (1983) have demonstrated the existence of "pseudo-
hirudin" in whole leech extracts with physico-chemical properties similar to 
hirudin; however, it has virtually no antithrombin activity. "Pseudo-hirudin" 
could probably be a metabolite of hirudin, as it has been shown to have 20 
amino acids less than hirudin and has been found only in the bodies of leeches. 
lsoleucine is the dominant amino-terminal amino acid residue in the hirudin 
extracted from leech heads alone, while valine is the dominant amino-terminal 
residue in "pseudo-hirudin" (Baskova et al., 1983). In whole leeches, Baskova 
et al. ( 1983) found the ratio of "pseudo-hirudin" to hirudin to be (3-4): 1. 
Despite the isolation and characterization of the anticoagulant properties 
of hirudin in the 1950s, active research on hirudin progressed at a slow pace 
due to the limited availability of natural hirudin. During the past ten years, 
advances in molecular biological techniques have produced a dramatic 
improvement, resulting in the production of sufficient quantities of hirudin in 
the recombinant form (for reviews, see Rieger et al., 1988; Courtney et al., 
1989; Johnson et al., 1989; Marki and Wallis, 1990). Harvey et al. (1985) 
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found that there were at least three distinct hirudin transcripts detectable in 
leech ribonucleic acids (RNAs) that were different in size, site of synthesis, 
inducibility by starvation and relationship to hirudin activity. This led to the 
creation of a complementary deoxyribonucleic acid (cDNA) bank isolated from 
leech heads. The primary structures of three variants of natural hirudin have 
been determined and designated as hirudin variant 1 (HV1 ), hirudin variant 2 
(HV2) and hirudin variant 3 (HV3). Figure 2 illustrates the amino acid 
sequence of HV1, HV2 and HV3. It is clear from Figure 2 that the three 
variants of hirudin exhibit considerable homology ( = 85 %) . HV3 is composed 
of 66 amino acids, while HV1 and HV2 contain 65 amino acid residues. HV1 
differs from HV2 and HV3 by 9 and 12 amino acids, respectively. HV2 differs 
from HV3 by 9 amino acids (Figure 2). 
Natural hirudins are mixtures of variants, but recombinant hirudins (rHs) 
are homogeneous preparations (Rydel et al., 1990). Several laboratories have 
succeeded in the cloning, expression and characterization of rHs from vectors 
such as Escherichia coli (Harvey et al., 1985; Bergmann et al., 1986; Fortkamp 
et al., 1986; Rieger et al., 1988), Saccharomyces cerevisiae (loison et al., 
1988; Reihl-Bellon et al., 1989), and Bacillus subtilis (Furutani et al., 1988). 
Figure 3 shows a comparison between the structures of natural hirudin 
and recombinant hirudin. A unique structural feature of natural hirudin is the 
sulfated tyrosine residue at position 63 (Petersen et al., 1976; Dodt et al., 
1984). The covalent structure of hirudin indicates the presence of three 
1 1 0 20 30 40 50 60 
HV1 VVYTDCTESG QNLCLCEGSN VCGQGNKCIL GSDGEKNQCV TGEGTPKPQS HNDGDFEEIP EE YLQ 
1 10 20 30 40 50 60 
HV2 ITYTDCTESG QNLCLCEGSN VCGKGNKCIL GSNGKGNQCV TGEGTPNPES HNNGDFEEIP EE YLQ 
1 1 0 20 30 40 50 60 
HV3 ITYTDCTESG QNLCLCEGSN VCGKGNKCIL GSQGKDNQCV TGEGTPKPQS HNQGDFEPIP EDAYDE 
Figure 2. Amino acid sequences of hirudin variants 1, 2 and 3 (HV1, HV2 and HV3). 
(Reproduced, by permission, from Marki and Wallis, 1990, "The anticoagulant and antithrombotic 
properties of hirudin", Thromb. Haemost., 64:p345) 
00 
Natural Hirudin 
(HV2) 
Recombinant Hirudin 
(rHV2-Lys 47) 
Figure 3. A comparison of structural sequences of natural hirudin and recombinant hirudin 
variant 2 (rHV2). 
(Modified, by permission, from Rydel et al., 1990, "The structure of a complex 
of recombinant hirudin and human a-thrombin", Science, 249:p278). 
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disulfide bridges between Cys6-Cys 14, Cys 16-Cys28 and Cys22-Cys39 (Dodt 
et al., 1985). Hirudins appear to have an unusual asymmetry of structural 
elements consisting of a compact, hydrophobic amino-terminal core region that 
has alternating polar and non-polar segments, with the three disulfide bonds, 
and a more extended and highly acidic carboxy-terminal region (Johnson et al., 
1989). 
All recombinant hirudins produced to date by genetic engineering 
methods lack the sulfate group on the tyrosine residue at the terminal end, and 
hence are designated as "desulfatohirudins". The solution structural 
conformation of desulfatohirudins is similar to that of native hirudins, as 
determined using nuclear magnetic resonance (NMR) spectroscopy (Haruyama 
and Wuthrich, 1989). The recombinant form is secreted from the vector with 
the same unusual asymmetry in structure with a compact amino-terminal 
region accommodating three disulfide bridges, and an acidic carboxy-terminal 
(Figure 3). 
The amino acid sequence of recombinant form of HV2 (rHV2) is depicted 
in Figure 4. This variant has been used in all experiments reported in this 
dissertation. The sequence of rHV2 (and HV2) is also illustrated in Figure 3, 
indicating the presence of lysine, instead of asparagine, in the recombinant 
form. Most of the literature on hirudin refers to rHV2 as "rHV2-Lys 47", 
emphasizing the presence of the lysine group in position 4 7. The importance 
of this lysine residue in the mechanism of action of hirudin is discussed later. 
1 5 10 
/le-Thr-Tyr-Thr-Asp-C'l:(s-Thr-Clu-Ser-Cly 
\ 15 20 
Cln-Asn-Leu-Cys-Leu-Cys-Clu-Cly-Ser-Asn 
I 
25 \ 30 
Val-Crs-Cly-Lys-Cly-Asn-Lys-Cys-Ile-Leu 
35 I 40 
Cly-Ser-Asn-Cly-Lys-Cly-Asn-Cln-Cys-Val 
45 50 
Thr-Cly-Clu-Cly-Thr-Pro-Lys-Pro-Clu-Ser 
55 60 
His-Asn-Asn-Cly-Asp-Phe-Clu-Clu-/le-Pro 
65 
Clu-Clu-Tyr-Leu-Cln 
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Figure 4. Primary structure of recombinant hirudin variant 2 (rHV2). 
(Reproduced, by permission, from Tuong et al., 1992, "Characterization of the 
deamidated forms of recombinant hirudin", Biochemistry, 31 :p8291.) 
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The reason for the existence of different isoforms of hirudin is really not 
known. However, it does suggest the existence of a gene family of thrombin 
inhibitors (Seemuller et al., 1986). Scharf et al. ( 1989) have identified the 
primary structures of 10 new hirudins from a native hirudin extract and have 
supported the hypothesis of a family of hirudins or "isohirudins". 
It is important to note that both natural hirudins, as well as their 
recombinant counterparts may be multimeric in aqueous solution (Johnson et 
al., 1989), with apparent molecular weights of 51,000 daltons (Braun, 1990). 
Using circular dichroism spectroscopy, Kun no et al. ( 1988) have demonstrated 
the cooperative nature of the thrombin-hirudin binding process, suggesting the 
possibility that the initial binding of thrombin is to the multimeric form of 
hirudin followed by the dissociation of the multimer to give a tighter binding 
1: 1 complex (Johnson et al., 1989). 
The Coagulation Cascade 
Normally, blood flows in a fluid state within a closed vascular system. 
Upon injury to a blood vessel, two principal mechanisms come into play in 
order to reduce blood loss (Davie et al., 1991): 
i) Activation, adhesion and aggregation of platelets at the site of 
injury to form a platelet plug that temporarily reduces blood loss, 
and 
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ii) Triggering of a complex series of reactions involving blood 
clotting factors that lead to fibrin formation and generation of an 
insoluble fibrin clot, thereby strengthening the platelet plug. 
In 1964, two similar, yet independent mechanisms were proposed to explain 
the process of blood coagulation. These mechanisms came to be known as 
the 'waterfall' (Davie and Ratnoff, 1964) and 'cascade' (Macfarlane, 1964) 
theories of blood coagulation. Both theories were based on the observation 
that inactive precursors (zymogens) of blood clotting factors (denoted with 
Roman numerals) were sequentially activated to their corresponding active 
forms (denoted with Roman numerals and suffix 'a') by a process of limited 
proteolysis. All events were directed toward the conversion of soluble 
fibrinogen to insoluble fibrin (Roberts and Lozier, 1992). 
The various stages in the coagulation cascade are illustrated in Figure 5. 
In a broad sense, the coagulation scheme can be separated into two pathways, 
the intrinsic and extrinsic pathways. The two pathways converge at the level 
of factor X, leading to the generation of thrombin and fibrin through a single 
common pathway. In the intrinsic pathway of coagulation, all substances 
required for clotting are normal constituents of blood or are 'intrinsic' to blood. 
This pathway is triggered by exposure to foreign surfaces such as glass, kaolin, 
barium carbonate, celite, bentonite and asbestos (Davie and Ratnoff, 1964), 
or artificial surfaces such as prosthetic heart valve or during blood dialysis 
(Davie et al., 1991). Four plasma proteins (contact factors) are involved in 
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Figure 5. The Coagulation Cascade 
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such surface contact, namely, factor XII (Hageman factor), factor XI (plasma 
thromboplastin antecedent, PTA), prekallikrein (Fletcher factor) and high 
molecular weight kininogen (HMW-K, Fitzgerald, Flaujeac or Williams factor) 
(Saito, 1994). It has been proposed that the intrinsic system is activated in 
vivo by contact of factor XII with collagen, chondroitin sulfate, sebum or 
platelets (Ratnoff, 1974). Upon surface contact, prekallikrein gets activated 
to kallikrein, which converts factor XII to Xlla in the presence of HMW-K, 
again, upon surface contact (Saito, 1994). In turn, factor Xlla activates factor 
XI to factor Xia (Figure 5). There is recent evidence that factor XI activation 
can occur independent of factor XII by thrombin in the presence of negatively 
charged substances such as heparin or dermatan sulfate, or by autoactivation 
(Naito and Fujikawa, 1991). The generated factor Xia converts factor IX 
(Christmas factor, hemophilic factor B, plasma thromboplastin component, 
PTC) to factor IXa in the presence of calcium ions (factor IV). Factor IXa and 
calcium ions are assembled in close proximity to factor X (Stuart-Prower factor) 
on platelet surface, in the presence of activated factor VIII (VIiia), thereby 
promoting the conversion of factor X to Xa. 
The extrinsic pathway of coagulation requires the presence of tissue 
factor (TF, factor Ill, thromboplastin) that is located in tissue adventitia and 
comes in contact with blood only after vascular injury. Hence, this pathway 
is known as the tissue factor pathway of coagulation (Braze, 1994). Tissue 
factor is an integral membrane glycoprotein that is tightly associated with 
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phospholipids. During vascular injury, tissue factor is released to form a 1: 1 
stoichiometric complex with factor VII (proconvertin, stable factor) in the 
presence of calcium ions, leading to the activation of factor VII to factor VIia 
(Nemerson and Repke, 1985). It has also been proposed that factor VII, in 
complex with tissue factor, is activated by factor Xa circulating in trace 
amounts in plasma (Roberts and Lozier, 1992). Factor VIia also binds to tissue 
factor with equal affinity as inactivated factor VII. The TF/Vlla complex 
(convertin) activates substrates factor X to Xa as well as factor IX to IXa, 
presumably by tissue factor's cofactor effect of inducing a conformation 
change in factor VII (Broze, 1994). The activation of factor IX by TF/Vlla 
complex is a demonstration of extrinsic-to-intrinsic activation in the coagulation 
cascade (Roberts and Lozier, 1992). 
The intrinsic and extrinsic pathways converge at the step of activation 
of factor X to Xa. The generated Xa forms a 1: 1 complex with activated factor 
V (Va), in the presence of calcium ions and phospholipids, known as 
prothrombinase complex. This complex activates prothrombin (factor II) to 
thrombin (factor Ila) (Davie et al., 1991). It is important to note that factors 
II, VII, IX, X, as well as protein C and protein S (see below) require Vitamin K 
for the formation of their active forms (Roberts and Lozier, 1992). 
The generated thrombin transforms fibrinogen (factor I) to fibrin 
monomers. The individual monomeric fibrin units are polymerized into tough, 
elastic fibers, resulting in clot formation. The stabilization of the clot occurs 
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when fibrin monomers, in the presence of calcium ions, are linked side-to-side 
by factor XIII a (fibrinase, fibrin stabilizing factor). Factor XIII a combines the 
beta-carboxyl group of asparagine in one fibrin monomer to an amino-terminal 
glycine residue in an adjacent monomer (Ratnoff, 1965). The fibrin clot is 
dissolved by fibrinolytic enzymes such as plasmin as part of a process of 
wound healing. 
Feedback activation by thrombin. Once formed, thrombin plays a major 
role in sustaining coagulation through feedback activation of coagulation 
factors. Thrombin activates factor V (proaccelerin) to Va' factor VIII 
(Hemophilic factor A, antihemophilic factor, AHF) to VIiia and factor XIII to 
Xllla. As mentioned above, there is recent evidence that thrombin also 
activates factor XI to Xia (Naito and Fujikawa, 1991). 
Other feedback mechanisms. The coagulation cascade exhibits certain 
other feedback mechanisms such as the activation of prekallikrein by factor 
Xlla (Cochrane et al., 1973) as well as the activation of factor VII by factor Xa 
(Roberts and Tozier, 1992). 
Regulation of the coagulation cascade. The endothelium expresses a 
transmembrane protein known as thrombomodulin which serves as a receptor 
to thrombin. Thrombin, bound to thrombomodulin, is changed from a 
procoagulant to an anticoagulant, as it activates protein C to protein Ca 
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(activated protein C, APC) (Davie et al., 1991). Protein Ca is a key component 
of a natural anticoagulant pathway (Dahlback and Stenflo, 1994) that catalyzes 
the proteolytic degradation of factors Va and VIiia (Figure 5). Protein C 
requires protein S for this activity (Walker, 1981). As coagulation proceeds 
and more thrombin is formed at higher concentrations, thrombin inhibits 
cofactors Va and VIiia by this negative feedback mechanism. 
Recently, there has been another new evidence for a balance between 
procoagulant and anticoagulant properties of clotting factors (Dahlback and 
Hildebrand, 1994). Factor V has been shown to be a cofactor to protein Ca 
(APC cofactor, protein Ca cofactor). A defect in anticoagulant response to 
protein Ca (APC resistance) was observed in familial thrombophilia patients. 
Plasma from APC-resistant patients has been shown to have normal factor V 
procoagulant activity and abnormal factor V anticoagulant activity, indicating 
a possible mutation(s) in factor V gene affecting factor V anticoagulant 
function, selectively (Dahlback and Hildebrand, 1994). This new finding will 
have a substantial impact on our current knowledge of blood coagulation and 
its regulation (Bauer, 1994). 
Antithrombin Ill (AT-Ill) is a protein that inhibits not only thrombin but 
also other serine proteases such as factors Xa, IXa, Xia, and Xlla, and protein 
Ca. The anti-thrombin and anti-Xa activity of AT-Ill is markedly enhanced by 
heparin (Bick, 1992a, 1992b). Another endogenous thrombin inhibitor is 
heparin cofactor II (HC-11) that also inhibits chymotrypsin (Bick, 1992a, 1992b). 
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Other plasma serine protease inhibitors (serpins) that play a significant role in 
the regulation of coagulation include ai-macroglobulin, protein C8 inhibitor, C1-
esterase inhibitor and a1-antitrypsin (Davie et al., 1991). 
Most blood coagulation reactions occur on a phospholipid surface. 
Activation of platelets by small amounts of thrombin causes internal 
phospholipids to be flipped out to the outside of platelets. Platelets are rich in 
phospholipids such as phosphatidylserine and phosphatidylcholine (Roberts and 
Lozier, 1992). The endothelium also contributes significantly to hemostasis by 
expression of thrombomodulin, tissue factor pathway inhibitor (TFPI), TF 
(induced by endotoxins, tumor necrosis factor), platelet activating factor (PAF), 
van Willebrand factor (vWF), tissue plasminogen activator (tPA), plasminogen 
activator inhibitor-I (PAI-I), cytokines, as well as by providing binding sites to 
coagulation factors V 8 , X8 and IX8 (Pearson, 1994). 
Revised hypothesis of blood coagulation. The discovery of a protein 
known as tissue factor pathway inhibitor (TFPI) led to a revised hypothesis of 
blood coagulation (Braze, 1992). TFPI, produced by endothelial cells, is also 
known as anticonvertin, antithromboplastin, factor X8 -dependentfactorVll 8 /TF 
inhibitor, the tissue factor inhibitor, the extrinsic pathway inhibitor (EPI) or the 
lipoprotein-associated coagulation inhibitor (LACI). It was found that patients 
with defects in either the intrinsic pathway (factor VIII and IX deficiency) or 
extrinsic pathway (factor VII deficiency) exhibit bleeding whereas people 
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lacking one of the 'contact' factors do not bleed excessively (Braze, 1992, 
1994). This observation demonstrated that the earlier 'waterfall' and' cascade' 
hypotheses did not describe in vivo hemostatic mechanisms, accurately. 
According to the revised theory, factor VII or Vila bind to TF exposed due to 
blood vessel damage. The Vlla/TF complex activates factor X to Xa and factor 
IX to IXa. Once factor Xa is formed, TFPI inhibits the Vlla/TF complex in a Xa-
dependent manner that also requires calcium ions (Figure 5) (Braze et al., 
1988). Further production of factor Xa and IX a by the Vlla/TF complex is 
prevented. Additional factor Xa is generated through the alternative intrinsic 
pathway via factor IXa and VIiia. 
The revised model explains the requirement of both intrinsic and extrinsic 
factors in vivo for normal hemostasis (Braze, 1992). This model integrates all 
the factors into a single pathway triggered by the factor Vlla/TF complex 
eliminating the requirement for contact factors. The initially formed factor Xa 
generates sufficient thrombin to induce platelet aggregation and factor V and 
factor VIII activation. However, for sustained hemostasis, additional factor Xa 
is required to be produced through factor VIiia and factor IXa (Braze, 1992). 
Mechanism of Antithrombin Activity of Hirudin: 
The Hirudin-Thrombin Interaction 
Hirudin is a highly specific inhibitor of thrombin, the serine protease 
glycoprotein that plays a key regulatory role in hemostasis and thrombosis. 
Hirudin forms a 1: 1 stoichiometric complex with a-thrombin with a dissociation 
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constant, Ki= 50 pM/L, indicating an exceedingly strong and high-affinity 
complex (Markwardt and Walsmann, 1958). Hirudin activity is expressed as 
a function of thrombin activity which is expressed in National Institutes of 
Health (NIH) units. One antithrombin unit (ATU) of hirudin corresponds to the 
amount of hirudin which neutralizes one NIH unit of thrombin (Markwardt, 
1970). 
The scheme of interaction between hirudin and thrombin, as reported by 
Markwardt (1991 b), is illustrated in Figure 6. The structure of hirudin 
complements the structure of thrombin. Winant et al. (1991) have shown that 
specific segments within both the amino- and the carboxy-terminal residues of 
hirudin interact with thrombin. The secondary and tertiary structural 
conformations of hirudin are important for its antithrombin activity as the 
activity is lost during oxidation and reduction of the disulfide bridges, and 
proteolytic degradation of the peptide (Chang, 1983; Markwardt, 1988). 
Hirudin inactivates thrombin by a two-step process. In the first step, the 
C-terminal region of hirudin binds to the anion-binding (fibrinogen binding) 
exosite region of thrombin (Figure 6). This results in a slight conformational 
change in the enzyme (Johnson, 1994). The second step involves the binding 
of the hydrophobic core of the amino-terminal region of hirudin to the active 
site (catalytic) domain of thrombin. Upon hirudin binding, a loop of ten amino 
acid residues from the catalytic site of thrombin is displaced, resulting in loss 
of thrombin catalytic activity (Johnson, 1994). 
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Extensive structural studies have been performed to study the 
mechanisms involved in the hirudin-thrombin interaction (Rydel et al., 1990; 
Rydel et al., 1991; Johnson et al., 1989; Johnson, 1994; Stone and 
Maraganore, 1994). The crystallographic structure of a complex of rH (rHV2) 
and human a-thrombin was studied by Rydel eta/. (1990, 1991). It was found 
that the primary basic specificity pocket ("arginine side chain pocket") of 
thrombin is not occupied by hirudin, in contrast to that shown in Figure 6. The 
lysine residue in position 47 was not found to occupy the basic specificity 
pocket of thrombin. Instead, thee-amino group in lys-47 was found to help 
maintain the conformation of the amino-terminal tripeptide to penetrate and 
form a hydrogen bond with serine-195 of the thrombin active site region (Rydel 
et al., 1991). A conformational change in thrombin has been observed after 
its interaction with hirudin, using circular dichroism (Kunno et al., 1988). In 
all, 27 of the 65 amino acids of rHV2 were found to have contacts that were 
0 
less than 4.0 A with thrombin, with 10 ion pairs and 23 hydrogen bonds (Rydel 
et al., 1990). These abundant interactions may explain the specificity and 
high affinity of hirudin for thrombin. 
Alterations in the amino-terminal region of hirudin can destabilize the 
interaction of other regions with thrombin. Nitration of tyrosine-3 increases the 
polarity and hence, may destabilize hirudin's interaction with the apolar binding 
site of thrombin. Replacing the tyrosine-3 residue with tryptophan or 
2.4 
Figure 6. Scheme of hirudin-thrombin interaction. 
(Reproduced, by permission, from Markwardt, 1991 b, "Past, present and 
future of hirudin", 21(suppl. 1):p13.) 
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phenylalanine increases the affinity of hirudin for thrombin (3-6 fold), whereas 
substituting with threonine resulted in 450-fold increase in the Ki (Lazar et al., 
1991). Replacement of lys-4 7 with glutamic acid in rH results in a 200-fold 
loss in affinity (Dodt et al., 1988), indicating that this lysine group contributes 
to the overall affinity of hirudin for thrombin. 
The interaction between recombinant form of hirudin and thrombin is 
considerably strong, despite a 10-fold increase in Ki, as the Ki for the natural 
hirudin-thrombin complex is in the picomolar range (Markwardt, 1991 b). The 
significance of the sulfation of tyrosine-63 in native hirudin is not clear. 
Nitration or iodination of tyrosine-63 of rH restores hirudin-thrombin affinity to 
levels similar to or exceeding that of native hirudin (Winant et al., 1991). 
Cleavage of arginine residues within the anion-binding exosite of 
thrombin results in the formation of P-thrombin with a loss of fibrinogen 
clotting activity. In humans, P-thrombin is subsequently converted to v-
thrombin, for which hirudin has 2-3 fold lesser affinity than for a-thrombin 
(Fenton II, 1989; Fenton II et al., 1991 ). 
Thrombin is the activated form of prothrombin and it modulates a variety 
of functions including activation of plasma proteins such as fibrinogen, 
coagulation factors such as factors V, VIII, and XIII and protein C, stimulation 
of blood cells such as leukocytes and platelets, and the stimulation of 
endothelial cells and smooth muscles. Thrombin also exhibits receptor-
mediated hormone-like actions including monocyte and neutrophil chemotaxis. 
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Most of the actions of thrombin are controlled by physiological inhibitors such 
as antithrombin Ill, heparin cofactor II and a2-macroglobulin (Fenton II, 1989). 
The anticoagulant effect of hirudin is unique as it is highly specific for 
a-thrombin without any significant effect on other serine proteases. In 
addition, hirudin is a direct antagonist of thrombin, without requiring the 
presence of cofactors like antithrombin Ill and heparin cofactor II. Once hirudin 
binds to thrombin, all proteolytic functions of thrombin are blocked. Hence, 
not only does hirudin block the formation of the fibrin clot by inhibiting the 
conversion of fibrinogen to fibrin, but hirudin also blocks thrombin-catalyzed 
activation reactions like feedback activation of factors V, VIII, and XIII (Figure 
5), thrombin-induced platelet, endothelial and smooth muscle cell reactions. 
(Markwardt, 1988; Markwardt, 1991 b). Hirudin also prevents the activation 
of the endogenous anticoagulant, protein C, to protein C8 by thrombomodulin-
thrombin complex (Figure 5). However, it has been reported that this may not 
attenuate the anticoagulant effects of hirudin as protein C inactivates only the 
activated forms of factors V and VIII, which are absent in the presence of 
hirudin (Markwardt, 1991 b). 
The ultimate physiological mechanism of the anticoagulant action of 
hirudin has been proposed to be the inhibition of thrombin generation (Fenton 
II et al., 1991). The reason for this is the blockade, by hirudin, of thrombin-
mediated feedback activation to form more thrombin, via the activation of 
factor V to Va and the formation of the prothrombinase complex (Figure 5). 
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Laboratory Assays for Hirudin 
Table 1 lists the different assay methods that are applicable for 
monitoring hirudin activity and concentration. Most earlier assay methods for 
hirudin were based on global coagulation tests, such as thrombin time (TT), 
activated partial thromboplastin time (APTT), and more recently, the modified 
TT, known as calcium thrombin time (Ca+ 2TT). Also available is the 
amidolytic anti-Ila assay, based on the cleavage of p-nitroaniline from a 
thrombin-specific substrate, in the presence of hirudin. The above assay 
methods are based on indirect pharmacodynamic measurements. 
A major breakthrough in the development of laboratory methods to 
monitor hirudin was the generation of hirudin-specific antisera in sheep, despite 
the fact that hirudin was a poor immunogen (Spinner et al., 1986). 
Immunological methods enable the direct measurement of rH concentration in 
biological fluids. Radioimmunoassays (RIA) (Bichler et al., 1988) and enzyme-
linked immunosorbent assays (ELISA) (Spinner et al., 1986; Spinner et al., 
1988; Amiral et al., 1991; Berscheid et al., 1992; Mille et al., 1994; Iyer et al., 
1995) are currently being developed for rH measurement. 
The functional assays have an advantage of being able to evaluate the 
actual functionality of rH as an anticoagulant. This is particularly important in 
the clinical setting as the anticoagulant effect of rH is the only useful 
TABLE 1 
LABORATORY ASSAYS FOR THE DETERMINATION OF 
RECOMBINANT HIRUDIN 
Functional Assays 
Whole Blood Clotting Time 
Bleeding Time 
Prothrombin Time (PT) 
Tissue Factor Clotting Time 
(TFCT) 
Activated Partial Thromboplastin 
Time (APTT) 
Thrombin Time (TT) 
Calcium Thrombin Time 
(Ca + 2TT) 
Heptest 
Anti-Ila (amidolytic) Assay 
Thrombin Generation Assay 
Ecarin Clotting Time (ECT) 
Non-functional Assays 
Radioimmunoassay (RIA) 
Enzyme-Linked 
lmmunosorbent Assay 
(ELISA) 
High Performance Liquid 
Chromatography (HPLC) 
Circular Dichroism (CD) 
Spectroscopy 
Mass Spectrometry 
Photometric Assay 
X-ray Crystallography 
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(Modified, by permission, from Fareed et al., 1991 b, "An objective perspective 
on recombinant hirudin: a new anticoagulant and antithrombotic agent", Blood 
Coag. Fibrinol., 2:p138.) 
parameter in this situation (Fareed et al., 1991 b; Walenga et al., 1991 a). On 
the other hand, the immunoassays, if designed to be specific for the parent 
drug without cross-reactivity to other peptides or rH metabolites, offer a direct 
measurement of absolute concentration of rHs in biological fluids. This would 
aid in the study of pharmacokinetic characterization of rHs. 
High performance liquid chromatography (HPLC) is another method 
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(Chang, 1991; Groetsch et al., 1991) that is being developed to assay rH. 
This method could prove to be more useful in the study of the integrity and 
stability of hirudin in solution and in biological fluids. However, unlike the 
ELISA or comparable methods, HPLC lacks the ability to discriminate between 
active and inactive forms of hirudin. More recently, newer methods are being 
developed to study the structural features of hirudin and binding characteristics 
of hirudin with thrombin, such as mass spectrometry (Van Dorsselaer et al., 
1989), photometric assay (Span nag I et al., 1991), crystallography (Rydel et al., 
1990, 1991) and circular dichroism spectroscopy (Kunno et al., 1988). 
Pharmacokinetics of Hirudin 
Like any therapeutic agent, the efficacy of an antithrombotic agent 
depends on the maintenance of adequate levels of the drug in the blood, 
which, in turn, is likely the site of action of antithrombotic drugs. At the same 
time, the drug must not exceed therapeutic concentrations in the plasma as, 
ultimately, too high concentrations in the plasma may lead to toxic effects. To 
achieve these goals, a complete working knowledge of the pharmacokinetic 
behavior of the drug is essential. This is important in the selection of a dose, 
a dosage form, frequency of administration, and route of administration during 
its clinical use. The relationship between pharmacokinetics and 
pharmacodynamics of hirudins is not fully understood despite the fact that 
many research groups have published information regarding the disposition of 
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this drug after intravenous (i. v. bolus and i. v. infusion) and subcutaneous (s.c.) 
administration. Tables 20 to 23 in Appendix I highlight the features of some 
of the pharmacokinetic studies performed on hirudin. 
With regard to absorption, hirudin, being a polypeptide, is not expected 
to be absorbed significantly after oral administration. Markwardt et al. ( 1988a) 
found that there was no marked absorption after rectal administration of rH 
( 1 mg/kg) in rats, despite the hydrophobic nature of the hirudin molecule .. 
There have been conflicting reports in the literature about the bioavailability of 
hirudins after s.c. administration. Markwardt et al. (1984) reported a 36% 
bioavailability of natural hirudin in humans, while the same group of workers 
reported almost complete absorption of rH in humans (Markwardt et al., 
1988b) and in rats ( 1988a). Bichler et al. ( 1988) have reported a 
subcutaneous bioavailability of 85% in humans with natural hirudin. 
Markwardt et al. ( 1984) studied the disposition of natural hirudin in rats, 
rabbits, and dogs (1982) and in humans. After i.v. administration, natural 
hirudin appears to be rapidly distributed into the tissue compartment, with a 
t 112(a) of about 10 minutes, followed by a slower elimination phase (t 112ml) of 
about 60 minutes. The plasma concentrations, after being determined by 
chromogenic thrombin substrate assay were fit to a biexponential equation, 
CP = Ae-at + Be-13t, where CP is the concentration at time t, A and B are 
constants and a and B are the distribution and elimination rate constants, 
respectively. Similarly, other investigators have described hirudin 
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pharmacokinetics using an open two compartment model after i. v. 
administration (Bichler et al., 1988; Nowak et al., 1988; Richter et al., 1988; 
Meyer et al., 1990). However, one group of researchers has not excluded the 
existence of a third compartment (Meyer et al., 1990), predicting a y phase of 
elimination. 
The volume of distribution of about 0.2 L/kg in humans indicates that 
hirudin distributes in the extracellular fluid compartment (Bichler et al., 1988). 
The distribution characteristics of rH were studied by Markwardt et al. ( 1988b) 
five hours after i.v. administration of 1 mg 1251-rH/kg in rats, when a relatively 
uniform pattern of distribution was seen in fat, brain, heart, liver, lungs, spleen, 
skeletal muscle and pancreas, with a certain amount of accumulation in the 
kidneys. Markwardt et al. ( 1990) prepared a conjugate of recombinant hirudin 
with dextran. Dextran-hirudin exhibited a lower volume of distribution than rH, 
thereby allowing for the drug to be restricted to the effector site, i.e., blood. 
Both natural as well as recombinant hirudin have been found to be 
eliminated unchanged, predominantly via the kidneys. Up to 70 to 90% 
recovery of hirudin was found in the urine after i.v. administration in different 
species, including humans (Markwardt et al., 1982; Richter et al., 1988; 
Markwardt et al., 1988a). Nowak et al. (1988) have shown that plasma rH 
levels remain unchanged for up to 120 minutes after i.v. and s.c. 
administration in nephrectomized dogs, thereby substantiating the evidence for 
the role of kidneys in the clearance of hirudin. However, urinary excretion of 
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hirudin has been found to be lower ( = 15 %) in rats (Richter et al., 1988; 
Markwardt et al., 1988a). Urinary recovery of hirudin after s.c. administration 
is lower ( = 30-40%) than that obtained after i.v. administration. It appears 
that the renal clearance of rH is more pronounced (25 % increase) than natural 
hirudin. The lack of the sulfate group in recombinant hirudin in position 63 has 
been speculated to be the cause of this finding (Nowak et al., 1988; 
Markwardt et al., 1988a). 
The elucidation of the pharmacokinetic characteristics of hirudins has 
been hampered due to the lack of availability of a specific assay methodology 
to determine exact levels of hirudin in the central compartment. Most 
pharmacokinetic studies employed the use of thrombin clotting tests or the 
chromogenic thrombin substrate assay method. Bichler et al. (1988) were the 
first to use a direct method (radioimmunobioassay/RIBA) to measure plasma 
and urine concentrations of this drug. Newer studies, including the 
experiments reported in this dissertation, are being developed using an ELISA 
method to measure plasma concentrations of rH. It remains to be established 
whether different isoforms of natural hirudin and rH would exhibit different 
absorption, distribution, metabolism and excretion patterns. Markwardt et al. 
( 1989) have reported the pharmacokinetic characteristics of rHV1 (Appendix 
I). More studies are required to address the influence of different structural 
features in the disposition of hirudins after different modes of administration. 
Furthermore, it is essential to study the disposition of rHs in a target patient 
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population. 
Comparison of Hirudin with Heparin 
The major differences between rH and heparin in terms of their chemical 
composition, mechanism of action, and other factors, are listed in Table 2. 
The most significant advantage that hirudins offer when compared to the 
conventional anticoagulant, heparin, is that unlike heparin, the anticoagulant 
action of hirudin is not mediated by circulating AT-Ill or HC-11. When the 
anticoagulant properties of rH and heparin were evaluated in AT-Ill depleted 
human plasma, HC-11 depleted human plasma, and purified human fibrinogen 
as compared to normal human plasma, heparin exhibited only a 28%, 74%, 
and 0% recoverable activity, respectively (Walenga et al., 1990). On the 
other hand, rH exhibited a 100% recoverable activity in all three systems. 
Hence, rH can be used conveniently in AT-Ill and HC-11 deficient patients. 
Moreover, hirudin is resistant to platelet factor 4 which neutralizes the 
anticoagulant activity of heparin. The anticoagulant effect of hirudin is more 
uniform than that of heparin as the activity does not appear to be mediated by 
physiological factors (Doutremepuich et al., 1991). 
Doutremepuich et al. ( 1989) compared the antithrombotic activity of rH 
with that of heparin in an experimental model of stasis-induced venous 
thrombosis in rats. Hirudin, at a dose of 12.5 µg/kg produced a comparable 
antithrombotic effect, measured in terms of reduction in thrombus weight, to 
TABLE 2 
COMPARISON OF RECOMBINANT HIRUDIN WITH HEPARIN 
Recombinant Hirudin 
Monocomponent protein with single target 
(thrombin) 
Not dependent on cofactors 
Known activity against clot-bound thrombin 
Activity not affected by endogenous factors such 
as platelet factor 4, factor VIII and other proteins 
No known interaction with endothelium, other 
than indirect blockade of protein ca and 
thrombomodulin-bound thrombin 
Relatively inert, not altered by metabolic 
processes 
May not require neutralization 
No major allergic reactions 
No known profibrinolytic effects 
Does not release TFPI 
Dose adjustments required in patients with 
compromised renal failure 
Heparin 
Multicomponent sulfated polysaccharide with 
multiple sites of action (thrombin, X8 , Xll 8 ) 
Cofactor dependent (A T-111 and HC-11) 
Limited activity against clot-bound thrombin 
Marked modulation by endogenous factors, such 
as platelet factor 4 
Significant interactions with endothelium 
Transformed by several enzymes reducing 
anticoagulant action 
Bleeding complications, requires neutralization 
Known allergic reactions (thrombocytopenia) 
Known profibrinolytic effects 
Known to release TFPI 
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400 µg/kg of unfractionated heparin. Porta et al. (1990) found that the in vivo 
antithrombotic activity of hirudin matches that of heparin, measured in terms 
of ED50 values (ED50 =0.205-heparin and 0.290-rH) in rats. However, the in 
vitro anticoagulant properties of rH were found to be greater than that of 
heparin using clot-based functional assays such as activated partial 
thromboplastin time (APTT) and thrombin time (TT). 
The observed side effects of heparin such as bleeding, thrombocytopenia 
and alopecia are not observed with rH. The antithrombotic and hemorrhagic 
effects of three variants of rH were compared with that of heparin in rats 
(Doutremepuich et al., 1991). The reduction in thrombus size produced by the 
rHs varied, depending on the rH used. Higher doses of heparin (400 µg/kg), 
but not of the rHs, produced increased bleeding time in a rat tail bleeding 
model. Walenga et al. ( 1990) found that the hemorrhagic effect of rH was 
much weaker than heparin at equivalent gravimetric doses. It was found that 
approximately 4-fold higher gravimetric doses of rH would be needed to obtain 
the same bleeding effect as heparin (Walenga et al., 1990). However, there 
have been recent reports of hirudin exhibiting severe hemorrhagic effects in a 
target patient population, as discussed later. 
Heparin has been shown to release TFPI (Valentin et al., 1992; Zitoun 
et al., 1994), whereas there is no evidence of TFPI being released by hirudin 
(Fa reed, 1994). Another important aspect in the differences between heparin 
and hirudin is the pharmacokinetic behavior exhibited by these agents. Heparin 
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exhibits non-linear pharmacokinetics that is dose and time dependent 
(Bjornsson and Levy, 1979a; Bjornsson and Levy, 1979b), requiring close 
monitoring of the patient. On the other hand, the results from Meyer et al. 
( 1991), as well as some of the results reported in this dissertation, indicate 
that hirudin may exhibit linear pharmacokinetics. This fact can be utilized for 
a more efficient selection of a dose and dosing schedule for hirudin than for 
heparin. 
A major limitation of heparin is its ineffectiveness to inhibit fibrin-bound 
thrombin (Weitz et al., 1990; Johnson, 1994). The fibrin that is formed after 
cleavage of fibrinogen by thrombin, binds to thrombin at a site distinct from the 
catalytic site. Fibrin-bound thrombin is enzymatically active and may cleave 
fibrinogen in the presence of AT-Ill or HC-11, that would inhibit free thrombin 
(Johnson, 1994). On the other hand, hirudin was found to be effective against 
clot-bound thrombin, as neither hirudin nor the carboxy-terminal fragment of 
hirudin, displaced thrombin from fibrin. It may be possible that thrombin binds 
fibrin in a manner permitting the fibrinogen-thrombin interaction, at another 
distinct exosite region (Johnson, 1994). 
Neutralization of Recombinant Hirudin 
rH has an extremely short half-life of about 30 to 45 minutes. Hence, 
it may not require an antagonist to neutralize its effects. Fareed et al. ( 1991 a, 
1991 b) have proposed that in normal individuals without any hemostatic 
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deficit, rH at therapeutic levels should not produce any effect on bleeding. 
However, considering the crucial indications it is proposed to be used for, an 
antagonist to neutralize its anticoagulant action may be necessary. A hirudin 
antidote may be essential in case of accidental overdose or in case of patients 
with renal disease. Potential candidates that are currently being investigated 
as possible hirudin antagonists include di-isopropylphosphoryl-thrombin (DIP-
thrombin; Bruggener et al., 1989), recombinant factor VIia (Fareed et al., 
1991 a), 1-desamino-8-arginine vasopressin (DDAVP; Ibbotson et al., 1991; 
Butler et al., 1993), factor VIII (Butler et al., 1993), batroxobin (Markwardt et 
al., 1992), ecarin-induced formation of meizothrombin (Nowak and Bucha, 
1994) and activated prothrombin complexes such as factor VIII inhibitor bypass 
activator (FEIBA®; Fareed et al., 1991 a; Stuever et al., 1995) and autoplex® 
(Diehl et al., 1994). Further studies are needed to evaluate these antidotes in 
a more clinical situation. 
Potential Clinical Use of Recombinant Hirudin (rH) 
The importance of antithrombotic drugs in clinical use can be realized 
from the fact that "thrombosis is a major cause of death and disability resulting 
from the occlusion of diseased arteries and veins which leads to myocardial 
infarction, stroke, peripheral ischemia, and pulmonary embolism" (Fuster and 
Verstraete, 1992). 
In terms of its clinical antithrombotic and anticoagulant activity, rH offers 
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some obvious advantages over the conventional anticoagulant, heparin, as 
described earlier in this review. However, despite the fact that rH is a stronger 
antithrombotic agent than heparin, the thrombin generation pathways in the 
coagulation cascade appear to be inhibited only under certain conditions. rH 
has been shown to be not as effective as heparin in the generation of thrombin 
(Kaiser et al., 1992). This could mean that a higher dose of rH may be 
required as compared to heparin for effective antithrombotic activity, as only 
one target site can be inhibited by rH (Fareed et al., 1989; Fareed et al., 
1991 a). 
Vogel et al. ( 1988) showed that natural hirudin produced therapeutic 
effects in chronic disseminated intravascular coagulation (DIC) patients at a 
dose of 1,000 ATU/kg (s.c., three times daily). rHs have also been proposed 
to be useful in prevention of restenosis after coronary angioplasty. Rabbits 
receiving rH ( 1 mg/kg i. v. bolus, 1 mg/kg/hour i. v. infusion for 1 hour) at the 
time of experimental balloon angioplasty exhibited significantly less restenosis 
than rabbits treated with heparin ( 150 U/kg, i. v. bolus), using angiography and 
quantitative histopathology (Sarembock et al., 1991). rH totally inhibited 
arterial thrombosis and limited platelet aggregation to a single layer in a pig 
model of balloon angioplasty with deep arterial injury (Chesebro et al., 1991 a, 
1991 b). However, many investigators proposed a very cautious use of rH in 
the treatment of DIC and the prevention of reocclusion after percutaneous 
transluminal coronary angioplasty (PTCA) at a discussion forum on rH, held at 
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the Loyola University Chicago, Maywood, IL (Walenga et al., 1991 c). 
rH may be used in the prophylaxis of deep venous thrombosis in high 
thrombotic risk patients (Raake et al., 1991). rH is being investigated as an 
alternative to heparin to provide anticoagulation in a canine cardiopulmonary 
bypass model (Walenga et al., 1991 b). It may be used as an adjunct drug to 
enhance the antithrombotic properties of other anticoagulant and thrombolytic 
agents which may be useful in the prevention of reocclusion during 
thrombolysis (Fa reed et al., 1991 a). 
The use of rH in microvascular surgery is also being investigated. 
Hubbard et al. ( 1991) showed that rH ( 125 µg/kg i. v. bolus, 75 µg/kg/hour i. v. 
infusion) produced a similar patency rate as heparin in a rabbit anastomosis 
model. A promising biomedical application of rH is in the coating of artificial 
surfaces to provide a non-thrombogenic surface (Fa reed et al., 1991 a). rH may 
be used to provide a non-thrombogenic coating surface in surgical tubing, 
catheters, membranes, extracorporeal oxygenators, blood collection apparatus, 
hemodialysis units, Jarvik® (artificial) hearts and other cardiac devices. Unlike 
heparin, which is currently being studied for use in such devices, rH may not 
activate platelets and does not require an endogenous cofactor to exert its 
anticoagulant activity. Buch a et al. ( 1990) studied the use of rH as an 
anticoagulant in hemodialysis in nephrectomized dogs. In contrast to heparin, 
rH did not induce thrombocytopenia or bleeding in such dogs. 
rH has been proposed to be useful in diagnostic tests. Hirudin may be 
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used as a tool for the control of catalytic and non-enzymatic activities of 
thrombin (Stocker, 1991). As rH is highly specific in its action against 
thrombin, it may be used, in conjunction with chromogenic substrates, to 
discriminate between actions mediated by thrombin, its precursors, cofactors 
and effectors and actions of other enzyme systems. rH may be a very useful 
anticoagulant for experimental biomedical research applications. Unlike heparin 
and calcium chelating agents such as citrate and EDTA (ethylenediamine 
tetra acetic acid), rH does not produce any chelation with trace metals, in 
particular, magnesium and calcium, which are important in biological functions 
of cells and intact preparations. Thus, rH may be an anticoagulant of choice 
for experimental pharmacological preparations such as tissue culture and 
isolated tissue preparations. 
Clinical trials with rH. A major concern over the use of antithrombotic 
drugs is the risk of bleeding, particularly when used in conjunction with 
thrombolytic agents, invasive procedures and patient's own predisposing 
factors (Johnson, 1994). In particular, additional precautions may be required 
during use of specific thrombin inhibitors such as rH, due to the strong 
antithrombotic potency of such drugs. rH is currently undergoing clinical trials 
for indications such as myocardial infarction, unstable angina, and PTCA 
(Lefkovits and To pol, 1994). 
The phase I studies performed on normal, human volunteers indicated 
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that rHs were well tolerated, without any adverse effects in therapeutic doses 
(Markwardt et al., 1984; Bichler et al., 1988; Verstraete et al., 1993; Hoet et 
al., 1994). Bleeding time was not prolonged even after use of rH at a dose of 
0.5 mg/kg (Verstraete et al., 1993). The results from phase II clinical trials 
using rH were encouraging, as angiographic improvement was evident in 116 
patients with unstable angina (0.05, 0.1, 0.2 or 0.3 mg/kg/hr, rH infusion) 
(Topal et al., 1994). 
Based on the results from the phase I and II trials, a number of major, 
multicenter phase Ill trials were organized, such as the Global Use of Strategies 
to Open Occluded Arteries (Gusto), Organization to Assess Strategies for 
lschemic Syndromes (OASIS), Hirudin for Improvement of Thrombolysis (HIT), 
Thrombolysis In Myocardial Infarction (TIMI) and Hirudin in a European 
Restenosis Prevention Trial Versus Heparin Treatment in PTCA Patients 
(HELVETICA). The results from some of these studies have not been as 
encouraging as those of the phase I and II trials. The Gusto Ila trial had to be 
stopped due to the excessive hemorrhagic stroke incidences in patients with 
ischemic coronary syndromes tested with rH, when compared with heparin. 
rH and heparin were used at i.v. doses of 0.6 mg/kg plus 0.2 mg/kg/hr 
infusion, and 5000 U plus 1000- to 3000 U/hr infusion, respectively (Aylward, 
1993; Gusto Ila investigators, 1994). Excessive intracranial hemorrhage was 
also found in the rH treated group in the HIT-Ill study, where patients with 
acute myocardial infarction were treated with rH. rH was used at an i.v. bolus 
42 
dose of 0.4 mg/kg and 0.15 mg/kg/hr infusion (Neuhaus et al., 1994). 
In the TIMI-SA trial, intra- and non-intracranial bleeding were observed 
in rH treated groups, when used as an adjunct to thrombolysis in myocardial 
infarction, at an i.v. bolus dose of 0.6 mg/kg and 0.2 mg/kg/hr infusion 
(Antman et al., 1994). A new TIMI trial (TIMl-98) has been configured with 
a lower dose of 0. 1 mg/kg (bolus) and 0. 1 mg/kg/hr (infusion). 
The results from the major phase Ill trials have led to the design of 
newer clinical trials using reduced doses of rH. The subjects in these trials 
were patients with the target disease, involving serious cardiovascular defects. 
It may be speculated that the clearance of rH in these patients may be reduced 
due to possible renal malfunctions accompanying such major situations. Most 
of the above clinical trials employ the use of the activated partial 
thromboplastin time (APTT) to monitor rH activity. It may be useful to measure 
the absolute levels of rH in plasma and urine of such patients. Several newer 
studies are in progress to determine the efficacy of this agent in the prevention 
of post-surgical DVT and different forms of arterial thrombosis. 
Hirudin Related Agents 
Structure-activity relationship studies with hirudin have led to the 
development of related agents that are direct inhibitors of thrombin or have 
antiplatelet activity. A derivative of hirudin, known as hirulog, is composed of 
the terminal 12 amino acid residues of hirudin, which bind to the thrombin 
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anion-binding exosite, and the sequence: D-Phe-Pro-Arg-Pro, capable of binding 
to the thrombin catalytic site. A linker segment of glycyl residues is used to 
bridge the above two peptide fragments (Witting et al., 1992; White, 1993; 
Johnson, 1994). Hirulog, similar to hirudin, is a bivalent thrombin inhibitor, 
that binds to thrombin with high affinity (Ki values in the nanomolar range). 
Hirulog is being investigated for clinical use in unstable angina pectoris (Sharma 
et al., 1993) and prevention of restenosis after coronary angioplasty (Topal et 
al., 1993). 
Hirugen is another synthetic derivative of hirudin that is composed of the 
terminal dodecapeptide region of hirudin. Hence, hirugen binds to the anion-
binding exosite region of thrombin. However, the in vivo antithrombotic 
activity of hirugen was found to be considerably weaker than hirudin and 
hirulog (Kelly et al., 1992), and therefore, it is not being investigated in clinical 
studies (lefkovits and Topal, 1994). 
Hirudisins are derivatives of hirudin, that are being investigated for their 
anti platelet activity (Knapp et al., 1992). Hirudisins were developed by 
incorporation of an Arg-Gly-Asp-Ser (RGDS) sequence into the finger-like 
domain of hirudin (residues 27 to 40). These peptides have the ability to 
inhibit thrombin-independent platelet aggregation and activation observed in 
arterial thrombosis via the glycoprotein !lb/Illa receptor (Johnson, 1994). 
A chemical conjugate of rH with two molecules of polyethylene glycol 
(PEG) has been shown to possess the main characteristic of hirudin, i.e., 
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selective thrombin inhibition. In addition, PEG-hirudin has been shown to have 
extended duration of antithrombotic action (up to 24 hours), when compared 
with rH (Rubsamen et al., 1994). Another chemical conjugate of dextran with 
hirudin, known as dextran-hirudin, has been shown to exhibit a lower volume 
of distribution (25 to 36 ml ) and a longer half-life ( = 6 hours) in rats, when 
compared with free hirudin (Markwardt et al., 1990). 
Other Site-Directed Antithrombotic Agents 
There is considerable interest in the development of antithrombotic drugs 
that have direct inhibitory action on thrombin. Thrombin plays a crucial role in 
platelet activation and thrombus formation that lead to coronary artery 
syndromes (Lefkovits and Topal, 1994). Besides hirudin, hirulog, hirugen and 
PEG-hirudin, there are other site-directed thrombin inhibitors that are currently 
undergoing investigation, such as efegatran, argatroban, and PPACK. 
Efegatran is a tripeptide (D-methyl-phenylalanyl-prolyl-arginal) that was found 
to exhibit dose dependent anticoagulant effects in animal studies, and is 
currently undergoing phase I human studies (Jackson, 1994). 
( 2R,4R)-4-methyl-1 -{ N 2-[ (RS )-3-m ethyl-1 , 2, 3, 4-tetra h yd ro-8-
quinolinesulfonyl]-L-arginyl}-2-piperidinecarboxylic acid hydrate, or 
argatroban, is a synthetic direct thrombin inhibitor that binds at the apolar-
binding site of thrombin (Lefkovits and Topal, 1994: Plachetka, 1994). 
Argatroban was found to exhibit significant correlations between dose and 
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anticoagulant effects in animal models (Plachetka, 1994). PPACK (D-
phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone) is yet another direct 
thrombin inhibitor (irreversible) that binds to the catalytic site of thrombin 
(Powers and Kam, 1992). PPACK's in vivo activity has been shown to be 
attenuated due to reactions with other plasma constituents (Hauptmann and 
Markwardt, 1992). 
CHAPTER II 
STATEMENT OF PURPOSE 
The primary purpose of this dissertation was to investigate the 
pharmacokinetics and pharmacodynamics of recombinant hirudin variant 2 
(rHV2) in valid animal models. To accomplish this, anticoagulant, antithrombin 
(anti-Ila) and enzyme-linked immunosorbent assay (ELISA) methods were 
developed and optimized. 
Hirudin is reportedly the most potent and specific natural inhibitor of 
thrombin (factor Ila) that was used in ancient medicine as an anticoagulant in 
the form of dry preparations and aqueous extracts from the medicinal leech, 
Hirudo medicinalis. More recently, the development and production of 
recombinant forms of hirudin variants using biotechnology have brought 
hirudin back into the focus of research interest again. A comprehensive 
review of published literature on rH with regard to structure, mechanism of 
action, available data on pharmacokinetics, assay methods and potential 
clinical uses, is included as part of this dissertation. 
rHV2 investigated in this dissertation, was prepared by recombinant 
technology utilizing a yeast expression vector at Transgene, Strasbourg, 
France, and was provided by Dr. J.-P. Maffrand (Sanofi Recherche, Toulouse, 
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(France). This agent was studied in three animal species: rabbits, rats and 
dogs using two different routes of administration: i.v. (bolus) and s.c. 
administration. Until now, the pharmacokinetic/pharmacodynamic relationship 
of natural hirudin and rH has not been fully investigated, despite the efforts 
of a few groups of researchers to characterize the absorption, distribution, 
metabolism and elimination of this drug in human and animal subjects. Most 
pharmacokinetic studies have used an indirect method to analyze plasma 
concentrations of natural hirudin and rH, for example, thrombin clotting time 
(Markwardt et al., 1989) or chromogenic anti-Ila assay (Markwardt et al., 
1982, 1984, 1988a, 1988b; Nowak et al., 1988), with the exception of 
Bichler et al. ( 1988), who have used a radioimmunobioassay (RIBA) to directly 
measure concentrations of natural hirudin in plasma. A specific ELISA method 
has been developed for the studies reported in this dissertation for the 
measurement of absolute concentrations of rHV2 in plasma samples from 
animal models. 
In addition, the in vitro and ex vivo pharmacodynamics of rHV2 have 
been studied using calcium-thrombin time (Ca+ 2TT), activated partial 
thromboplastin time (APTT) and a chromogenic anti-thrombin assay. In vivo 
pharmacodynamics of rHV2 has been profiled using a modified rabbit jugular 
vein stasis thrombosis model (Wessler et al., 1959; Fareed et al., 1985). The 
hemorrhagic effects of rHV2 have been studied using a modified rabbit ear 
bleeding model (Cade et al., 1984; Fareed et al., 1985). These studies 
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provide crucial information on the relationship between antithrombotic and 
hemorrhagic actions of this agent. Pharmacodynamic parameters, 
bioavailability profile and other pharmacokinetic parameters have been 
compared between the two routes of administration using appropriate 
statistical methods. 
New data on the status of renal function in rats after i.v. and s.c. 
administration of rHV2 have been provided in this dissertation. A multiple 
dosage study in dogs has been included to obtain more information on the ex 
vivo antithrombin properties of rHV2. Moreover, the hematological and blood 
chemistry profiles after repeated administration of rHV2 in dogs for a period 
of one week, are described. 
A systematic and integrated approach to study the pharmacokinetics 
and pharmacodynamics of rHV2 has not been made to date. A direct 
approach to study pharmacokinetics by using absolute concentration 
measurements from the ELISA method has helped to differentiate between 
true pharmacokinetics from previously used indirect pharmacodynamic 
methods. The results from these experiments validate the difference between 
functional and immunological methods to monitor rHV2 after various dosage 
regimens in the three animal species. 
The experimental methods used in this investigation represent optimized 
and pharmacologically valid experimental models to obtain much needed 
objective data on the pharmacokinetic and pharmacodynamic profile of this 
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recombinant antithrombotic agent. The data generated in this dissertation will 
be valuable in the design of newer clinical trials for i.v. and s.c. indications of 
this new anticoagulant drug. These studies will also serve as a model for 
obtaining valid pharmacological data on other recombinant antithrombotic 
drugs. 
CHAPTER Ill 
MATERIALS, METHODS AND EXPERIMENTAL PROTOCOLS 
Materials 
Recombinant Hirudin (rH) 
Recombinant hirudin (rH) used in all in vitro and in vivo experiments in 
this dissertation was kindly supplied by Sanofi Recherche, Toulouse, France. 
According to the supplier, this variant of rH was recombinant hirudin variant 
2 (rHV2) with a lysine residue in position 47 (rHV2-Lys47). This information 
was later reconfirmed by results from Ors. A. Patthy and S. Bajusz (Institute 
for Drug Research, Budapest, Hungary) (Appendix II). Henceforth, rH used in 
all experiments will be designated as "rHV2". A single batch of rHV2 was 
used in all studies i.e. ref no. SR 29010 and batch no. RHE 15, manufactured 
at Transgene, Strasbourg, France. As per the manufacturer's declaration 
(Appendix II), batch no. RHE 15 had been produced using an yeast expression 
vector. The specific activity and molecular weight of this batch have been 
specified by the manufacturer to be 14,495 ATU/mg and 6,906 daltons, 
respectively. Impurities, as determined by exclusion chromatography have 
been specified to be less than 0.8%. 
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Thrombin 
Human thrombin (no. a362) was kindly provided by Dr. John Fenton II 
(New York State Department of Health, Albany, NY). Henceforth, this 
thrombin will be referred to as "Fenton a362" or "a362" thrombin, which has 
a specific activity of 3007.22 NIH units/mg. a362 thrombin is composed 
primarily of a-thrombin (95. 72%), with trace amounts of 13-thrombin (2.37%) 
and v-thrombin ( 1.91 %) . a362 is free of contamination from HIV and hepatitis 
virus. 
Reagents and Kits 
0.025 M calcium chloride and 0.02 M calcium chloride solutions were 
obtained from Organon Teknika (Parsippany, NJ) and Baxter Health Corp., 
Dade Division (Miami, FL), respectively. Activated partial thromboplastin time 
(APTT) reagents were procured from Organon Teknika (Parsippany, NJ) and 
Baxter Health Corp., Dade Division (Miami, FL). Chromogenic substrate 
(Spectrozyme® TH) required for the amidolytic assay for thrombin was 
obtained from American Diagnostica (Greenwich, CT). Reagents required for 
Tris-EDTA buffer i.e. tris(hydroxymethyl)aminomethane (Trizma®), PEG 6000 
(polyethylene glycol 6000), Na2EDTA (Disodium ethylenediaminetetraacetic 
acid) and sodium chloride were all obtained from Sigma Chemical Co. (St. 
Louis, MO). Bovine aprotonin (6120 KIU/mg) was obtained from Pentapharm 
AG, Basel, Switzerland. 0.9% Sodium Chloride Irrigation Solution, USP, and 
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Sterile Water for Irrigation, USP, obtained from Baxter Healthcare Corp., 
Deerfield, IL, were used as normal saline and distilled water (free of metal 
contaminants), respectively. 
For thrombogenic challenge in the modified stasis thrombosis model in 
rabbits, Factor Eight Inhibitor Bypass Activator (FEIBA®) was obtained from 
Osterreichisches lnstitut fur Haemoderivate GES.M.B.H. (subsidiary of 
IMMUNO AG, Vienna, Austria). A competitive ELISA based kit (Asserachrom® 
Hirudin) for the quantitation of hirudin antigen was obtained from Serbio 
Research Laboratories, Gennevilliers, France. For clearance studies, 3H-lnulin 
was obtained from NEN/Dupont (Boston, MA) and liquid scintillation cocktail 
(Ecolite®) was obtained from ICN Biomedical, Inc. (Costa Mesa, CA). 
Xylazine (Rompun®, Miles, Inc., Shawnee Mission, KS) and ketamine 
hydrochloride (Ketaset®, Aveco Co., Inc., Fort Dodge, IA) were used to 
anesthetize rabbits. Sodium pentobarbital and phenytoin sodium solution 
(Beuthanasia®-D, Schering-Plough Animal Health Corp., Kenilworth, NJ) were 
used for rabbit euthanasia. Halothane (Burns Veterinary Supply, Glenview, IL) 
was used via a dispenser (Fluotec® Mark 2, Cyprane Ltd., Keighley, England) 
to induce light anesthesia in rats. Rats were restrained using Decapicones®, 
Braintree Scientific, Inc., Braintree, MA. 
Major Instruments 
Major instruments used in the experimental protocols reported in this 
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dissertation include Fibrometer®s (Becton Dickinson and Co., Rutherford, NJ) 
for determination of clotting times, Beckman DU®-7 spectrophotometer 
(Beckman Instruments, Inc., Fullerton, CA) and ACL ®300 Plus (Instrumentation 
Laboratory, Lexington, MA) for chromogenic substrate assays, Ultra Wash® 
microplate washer (Dynatech Laboratories, Inc., Chantilly, VA) and Dynatech 
MR 700® spectrophotometric reader (Dynatech Laboratories, Inc., Chantilly, 
VA) for the ELISA method, and a liquid scintillation counter (Minaxi Tri-Carb® 
4000 series, Packard Instrumental Company, Downer's Grove, IL) for 
clearance studies. Some of the later experimental protocols utilized a 
combined washer and reader in the ELISA method (Dynatech MR 7000®, 
Dynatech Laboratories, Inc., Chantilly, VA). Serum chemistry profile, 
urinalysis and hematological profile were performed at the Clinical Laboratory 
Division, Department of Pathology, Loyola University Chicago (Paramax® 
720ZX, Automated Chemistry Analyzer, Baxter Health Corp., Dade Div., 
Miami, FL; CX®3, Synchron Clinical System, Beckman Instruments, Inc., Brea, 
CA and Coulter® Stacker, Coulter Diagnostics, Hialeah, FL, respectively). 
IBM compatible personal computers linked to printers (LaserJet Ill or IV, 
Hewlett Packard, San Diego, CA) were available for word processing, 
pharmacokinetic analysis, statistical analysis and graphics. 
Animals 
All animals were allowed an acclimation period of at least four days after 
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arrival in the Animal Research Facility, Loyola University Chicago, before 
initiation of experiments. Male New Zealand White rabbits (2.5-3.0 kg; LSR 
Industries, Inc., Union Grove, WI) were used in the modified rabbit jugular vein 
stasis thrombosis model, modified rabbit ear bleeding model and 
pharmacokinetic/ pharmacodynamic studies. Adult, male mongrel dogs (25-30 
kg; Teays River Valley, Upland, IN) were used in pharmacokinetic and 
pharmacodynamic studies. Male Sprague-Dawley rats (250-300 g; Harlan, 
Indianapolis, IN) were used in pharmacokinetic and clearance studies. All 
animals used in the studies were used in accordance with the guidelines set 
forth by the Institutional Animal Care and Use Committee (IACUC)., Loyola 
University Chicago. 
Pooled Plasma, Serum and Whole Blood Preparations 
Blood bank plasma (BBP). BBP was obtained from the Blood Bank, 
Department of Pathology, Loyola University Chicago. This plasma was made 
from blood donated by human volunteers who were tested to be free of 
acquired immune-deficiency syndrome (AIDS) and hepatitis B virus. The fresh, 
frozen plasma packs, not more than 30 days old, were thawed at 37°C, 
pooled, aliquoted in volumes of 10 ml each and frozen at -70°C for a period 
of not more than two months. Pooled BBP was thawed at 37°C prior to use. 
Normal rabbit plasma (NRP), normal rat plasma (NRatP) and normal dog 
plasma (NDP). Guidelines of IACUC, Loyola University Chicago were followed 
55 
in the preparation of pooled plasma from dogs, rabbits and rats. NRP, NRatP 
and NDP were made from normal male rabbits, rats and dogs, respectively. 
Blood was collected from 10-12 conscious dogs via standard veni-
puncture of the forelimb vein using a Butterfly® (21 X 3/4, 12" tubing) infusion 
set (Abbott Hospitals, Inc., North Chicago, IL). Polypropylene syringes were 
used, with the initial 2-3 ml of blood being discarded. 4.5 ml of drawn blood 
were added to siliconized glass tubes (Vacutainer®, Becton Dickinson 
VACUTAINER Systems, Rutherford, NJ) containing 0.5 ml of 0.129 M (3.8%) 
sodium citrate solution. The collected blood was gently mixed with the 
anticoagulant and then centrifuged (Beckman GPR Centrifuge, Beckman 
Instruments, Inc., Fullerton, CA) at 2,500 rpm and 4°C for 20 minutes. The 
supernatant plasma was separated using polypropylene transfer pipettes and 
pooled to obtain a pooled, platelet-poor NDP. The NDP was stored in 1 ml 
aliquots at -70°C until use. 
Cardiac puncture under xylazine- and ketamine-induced anesthesia was 
used to draw blood from 10-12 rabbits. The plasma was separated, pooled 
to obtain NRP and stored as described above. 
Cardiac puncture under light halothane-induced anesthesia was used to 
draw blood from 8-10 rats. The blood was processed for plasma separation 
(NRatP) as described above. 
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Rat serum. For the measurement of creatinine and inulin clearances, 
blood (0.5 ml) was drawn from male Sprague-Dawley rats via tail bleeding 
using Bard-Parker® scalpel (no. 11, Becton-Dickinson AcuteCare, Franklin 
Lakes, NJ) into empty 1.5 ml microtubes (Sarstedt, Newton, NC). The blood 
was incubated at room temperature to activate clotting for at least an hour 
until serum separated. The clotted blood was centrifuged (Eppendorf® 
Microcentrifuge, Model 5415C, Brinkman Instruments, Inc., Westbury, NY) at 
2,500 rpm for 20 minutes and the supernatant serum was separated and 
stored at -70°C until ready for use. 
Dog and rat whole blood. Blood drawn from dogs (2 ml) or rats (0.5 ml) 
as described above was collected into Vacutainer® blood collection tubes or 
Microtainer® (with EDTA) obtained from Becton Dickinson V ACUTAINER 
Systems, Rutherford, NJ. The tubes were tilted gently for mixing and stored 
at 4°C for not more than 6 hours until use to obtain hematological profiles. 
Methods 
Global Clot-based Assays 
Activated Partial Thromboplastin Time (APTT) 
APTT is a screening test for the intrinsic pathway of coagulation, and is 
used in monitoring heparin therapy. It is based on the measurement of 
clotting time after plasma has been activated with a platelet substitute 
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(phosholipid), silica and calcium chloride. Two different types of APTT 
reagents were used - APTT (Dade) and APTT (OT) obtained from Baxter 
Healthcare Corp., Dade Division, and Organon Teknika, respectively. 100 µL 
of APTT reagent were added to 100 µL of plasma sample (prewarmed at 
37°C), and incubated at 37°C for 5 minutes (OT reagent) or 3 minutes (Dade 
reagent). The time taken for the sample to clot was determined using a 
Fibrometer® after addition of 100 µL of 0.025 M (GD/OT) or 0.02 M (Dade) 
CaCl2 solution, respectively. 
Thrombin Time (TT) 
TT measures the time taken by thrombin to convert fibrinogen to fibrin. 
200 µL of test plasma were warmed at 37°C for 3 minutes and 100 µL of 
thrombin (Fenton a362, reconstituted in normal saline to give 5, 10 or 20 NIH 
units depending on the test) were added to initiate clotting. As before, the 
clotting time was measured using a Fibrometer®. 
Calcium Thrombin Time (Ca+ 2TT) 
Both native hirudin as well as rH, being highly potent thrombin inhibitors, 
exhibit strong anti-Ila activity at very low concentrations. As a result, the 
clotting time, as monitored by TT, reaches beyond 300 seconds, which is the 
upper limit of sensitivity of the Fibrometer®. Hence, modified thrombin time 
tests were developed, where clotting was initiated by using a mixture of 
thrombin and 0.025 M CaCl2 solution. This test was optimized in the 
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Hemostasis Research Laboratories, Loyola University Chicago, and was 
designated as calcium-thrombin time (5, 10, 20, or 40 NIH units, depending 
on the potency of thrombin). In this assay, thrombin (a362) was reconstituted 
with 0.025 M CaCl2 solution to give 5, 10, 20 or 40 calcium-thrombin units. 
100 µL of calcium-thrombin reagent were added to 200 µL of prewarmed 
(37°C, 3 minutes) test sample and the clotting time was determined using a 
Fibrometer®. 
l1 215-225 Method for Protein Determination 
The l1 215-225 method (Chaykin, 1966) was used to determine total 
protein content in batch no. RHE 15 of rHV2 supplied by Sanofi Recherche. 
rHV2 solutions were made in Sterile Water for Irrigation, to obtain concen-
trations of 25, 50 and 100 µg/ml. The optical densities of this series of rHV2 
solutions were read at 215 and 225 nm, using a spectrophotometer (Beckman 
DU®7). The protein concentration in each sample was calculated by the 
formula (Chaykin, 1966): 
µg/ml protein = (11 215-225) x 144. 
The factor ( 144) has been previously determined and found to be identical on 
Beckman DU spectrophotometers (Waddell, 1956). Appropriate bovine serum 
albumin control was used. 
Chromogenic Anti-Ila Assay 
In this biochemical assay, the decrease in enzyme (thrombin or factor Ila) 
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activity produced by the inhibitor (rH) was determined by measuring the 
decrease in absorbance of the free chromophore (p-nitro aniline, pNA) per unit 
time at 405 nm. At excess substrate concentrations, the rate of decrease in 
absorbance was linearly related to the concentration of rH. The substrate 
used was Spectrozyme®TH (H-0-hexahydrotyrosyl-L-alanyl-L-arginine-p-
nitroanilide di acetate salt). An Automated Coagulation Laboratory system 
(ACL ® 300 Plus) or a spectrophotometer (DU®7, Beckman Instruments) were 
used to perform the chromogenic anti-Ila assay. 
The ACL ® 300 Plus system has a rotor capable of analyzing 16 samples 
at one time. 100 µL of a362 thrombin (5, 10 or 20 U/mL, depending on the 
test system, in tris-EDTA buffer, pH =8.4) were added to 10 µL of sample, 
incubated at 37°C for 1 minute followed by the addition of 40 µL of 
Spectrozyme®TH ( 1 µM/mL solution in Sterile Water for Irrigation, USP), in an 
automated fashion. Absorbances were read at 405 nm. The system was 
linked to an IBM compatible personal computer that was equipped with 
software to calculate the rate of change of absorbance with time. Control 
samples were analyzed using appropriate plasma with no rHV2. 
While using the DU®7 spectrophotometer, 400 µL of tris-buffer (pH= 8.4) 
were incubated with 25 µL of test sample in a cuvette at 37°C for 1 minute, 
followed by addition of 25 µL of 5, 10 or 20 NIH units/ml of a362 thrombin. 
After mixing and incubating at 37°C for an additional minute, 50 µL of 
Spectrozyme®TH (1 µM/mL) were added. The rate of change of absorbance 
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at 405 nm was noted. 
The composition of tris-EDTA buffer used in both methods was as 
specified below: 
Sodium Chloride ( 175 mM) 
Tris (50 mM) 
Na2EDTA (7.5 mM) 
Aprotonin ( 1 µg/ml) 
PEG 6000 (0.25%) 
Distilled Water 
10.227 g 
6.055 g 
2.792 g 
1.0 mg 
2.5 g 
1000.00 ml (q.s.) 
The above ingredients were dissolved in distilled water and pH adjusted to 
8.4. Tris buffer was stored at 4°C until use (within 7 days). 
Enzyme-Linked lmmunosorbent Assay (ELISA) 
Asserachrom® Hirudin ELISA kits (Serbia Research Laboratories, 
Gennevilliers, France) were used to measure rHV2 concentrations in this 
dissertation. "Sandwich" and "competitive" ELISA methods for the mea-
surement of rHV2 and other hirudin variants in biological fluids were 
developed and validated (Iyer et al., 1995) in collaboration with Serbia 
Research Laboratories, Gennevilliers, France. The assay employed in this 
dissertation was of the competitive type. In this method, microwells from a 
96-well micro plate were precoated with hirudin antigen (native hirudin). Fifty 
µL of standard or test sample containing competing hirudin were added to 
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each well followed by addition of 200 µL of anti-hirudin antibodies, specifically 
raised in rabbits against rHV2 and labelled with horseradish peroxidase (HRP) 
enzyme. The microplate was incubated with slow agitation at room 
temperature for 1 hour during which a competition ensued between the test 
hirudin and coated hirudin for the antibody. After five successful washings, 
color development was achieved by addition of 200 µL of ortho-phenylene 
diamine (OPD) substrate in the presence of 10 µL of hydrogen peroxide 
(H20 2). Reaction was stopped after 6 minutes with addition of 50 µL of 3M 
sulfuric acid. Absorbances were read at 405 nm after a stabilization period of 
10 minutes and were inversely proportional to concentration of rHV2 in test 
samples. 
The linear range for this assay was 25 to 1000 ng/ml with an intra- and 
inter-assay variation of 3.9% and 6.8%, respectively (Iyer et al., 1995). This 
required the dilution of test samples from pharmacokinetic experiments in 
animal models in assay dilution buffer (pH= 7.5) to bring final concentrations 
of rHV2 within the linear range. The standard curve was prepared from the 
same batch of rHV2, previously supplemented in vitro in the plasma system 
(NOP, NRP or NRatP) used, frozen at -70°C and thawed just prior to use. It is 
to be noted that the standard curves were subjected to the same dilution steps 
as the test samples in order to eliminate any matrix effect from surrounding 
plasma system (Iyer et al., 1995). Unknown concentrations of rHV2 in test 
samples were interpolated from a semilogarithmic plot of absorbances at 
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405 nm versus concentrations of standard. Figures 7 and 8 illustrate a 
schematic of the competitive ELISA method. It is most likely that this 
polyclonal antibody based ELISA method is capable of detecting metabolites 
of hirudin, which may or may not be active, and may be termed as "hirudin 
equivalents". 
Rabbit Jugular Vein Stasis Thrombosis Model 
A modified rabbit jugular vein stasis thrombosis model (Wessler et al., 
1959; Fareed et al., 1985) was used to study the in vivo antithrombotic 
properties of rHV2. In this model, male New Zealand White rabbits (2.5-3.0 
kg) were weighed and anesthetized with 20 mg/kg (i.m.) of xylazine 
(Rompun®) and 80 mg/kg (i.m.) of ketamine hydrochloride (Ketaset®). The 
rabbits were immobilized and prepared for surgery (neck area was shaved). 
Incisions were made from top of neck to bottom of sternum, and from the top 
and base of first incision toward each side to make flaps which would open 
and expose the underlying right and the left jugular veins. A fine-tip high 
temperature cautery (Accu-Temp®, Xomed-Treace, Jacksonville, FL) was used 
to cut the underlying, attached tissue and prevent any bleeding. Y-shaped 
segments of the two jugular veins were thus isolated, and the test dose of 
rHV2 was injected i.v. (via marginal ear vein) or s.c. (in the abdominal area) 
followed by a circulation time of 5 minutes or 2 hours, respectively. Figure 
9 illustrates the two isolated Y-shaped segments of jugular veins. Table 3 
(a) 
(b) 
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Figure 7. Scheme of competitive ELISA method (part I). Microplate (a) is 
pretreated with hirudin antigen (•) followed by addition (b) of competing 
hirudin ( o) in presence of horseradish peroxidase (HRP) labelled antibody (Y). 
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Figure 8. Scheme of competitive ELISA method (part II). A competition 
ensues between precoated hirudin antigen (•) and competing hirudin (o) 
during incubation (c) at room temperature. Absorbance is read at 492 nm 
after color development (d) due to addition of OPD/H20 2. 
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Figure 9. An illustration of the modified Wessler's rabbit jugular vein stasis 
thrombosis model. Y-shaped jugular vein segments are isolated and prepared 
for ligation. 
(Modified, by permission, from Walenga, "Factor Xa inhibition in mediating 
antithrombotic actions: application of a synthetic heparin pentasaccharide". 
Ph.D. diss., University of Paris, 1987, p82.) 
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lists the time schedule used in the modified rabbit jugular vein stasis 
thrombosis model. 
At the end of the specified circulation time of rHV2 or saline, FEIBA® 
(factor VIII inhibitor bypass activator-25 U/kg) was administered as a thrombo-
genic challenge (via marginal vein) and allowed to circulate for 20 seconds. 
The jugular vein segments were ligated using surgical silk and thereby a stasis 
of blood flow was produced. 
After 10 minutes, any clots formed in one segment (left side) were 
removed, placed in a dish (SIP® Brand diSPo® Petri Dish, Baxter Healthcare 
Corp., McGaw Park, IL) with normal saline, visually analyzed and graded to 
give a clot score (see below, Walenga, 1987). After another 10 minutes, any 
clots formed in the other segment (right side) were similarly evaluated. Blood 
samples were drawn via standard carotid artery catheterization at baseline, 
prior to the thrombogenic challenge ("post-drug"), and 6 minutes after the 
thrombogenic challenge ("post-FEIBA®"l. The samples were analyzed using 
different clot-based tests and chromogenic anti-Ila assay. Control experiments 
were performed using 0.9% saline instead of rHV2. The rabbits were 
sacrificed by i.v. injection of Beuthanasia®-D solution. In the time-course 
experiments, the drug was allowed to circulate for varying times after i. v. and 
s.c. administration before stasis was performed. 
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Clot-Score Grading System (Walenga, 1987) 
The clot-score grading system is illustrated in Figure 10. The clots 
obtained were graded on a scale from 0 to + 4, where 11 0 11 score indicated no 
clot formation with blood in a fluid state, 11 + 1 11 represented mostly fluid blood 
with a few minute clots, 11 + 2" was a larger amount of slightly bigger clots, 
11 + 3 11 indicated more definite clots (fully formed or broken to pieces forming 
a Y shape) with some fluid blood and 11 +4 11 clot represented a firm, large, 
solid Y-shaped clot with no surrounding blood. The grading of clots was 
always performed by an additional, independent observer. 
Rabbit Ear Bleeding Model 
The rabbit ear bleeding model (modified from Cade et al., 1986) was 
used to study the hemorrhagic effects of rHV2. Male New Zealand White 
rabbits (2.5-3.0 kg) were anesthetized by i.m. administration of 10 mg/kg of 
Rompun® and 80 mg/kg of Ketaset®. The test rHV2 dose was administered 
intravenously via the marginal ear vein (right ear), or subcutaneously in the 
abdominal area. One ear (usually left, opposite to the ear with site of i.v. 
injection) was immersed in a saline bath (one liter) at 37°C for 5-10 seconds, 
and using transillumination, an area between the central ear vein and the 
marginal ear vein was selected that was free from major blood vessels. The 
drug was allowed to circulate for 5 minutes and 1 hour after i.v. and s.c. 
administration, respectively. Using a Bard-Parker® surgical blade 
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Figure 10. Clot-score grading system used in the modified rabbit jugular vein 
stasis thrombosis model. Examples of "O" to "+4" clots. 
(Modified, by permission, from Walenga, "Factor Xa inhibition in mediating 
antithrombotic actions: application of a synthetic heparin pentasaccharide". 
Ph.D. diss., University of Paris, 1987, p83.) 
TABLE 3 
TIME SCHEDULE USED IN THE MODIFIED RABBIT JUGULAR VEIN 
STASIS THROMBOSIS MODEL 
Time (l.V.) Procedure Time (S.C.) 
Anesthetize rabbit, 
shave neck area, 
expose Y-shaped 
jugular vein 
segments 
0 min----> Baseline blood draw <----0 min 
Inject rHV2 
5 min ---- > Post-drug blood < ----120 min 
(Circulation draw. Inject FEIBA® (Circulation 
Time) Ligate vein segments Time) 
after 20 seconds 
11 min ---> Post-FEIBA® blood <----126 min 
draw 
15 min ---> Isolate one segment < ----130 min 
Grade clot 
25 min---> Isolate other <----140 min 
segment 
Grade other clot 
Euthanize rabbit 
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(Becton-Dickinson AcuteCare, Franklin Lakes, NJ), five uniform full thickness 
incisions were made in the selected area. An example of the incisions is 
illustrated in Figure 11. Immediately after making the incisions, the ear was 
immersed in the saline bath (stirred constantly) for 10 minutes. Five uniform 
incisions were similarly made in the other ear (right ear) at the end of 15 
minutes and 3 hours after i.v. and s.c. administration, respectively. Blood loss 
was measured for another 10 minutes in each case, in a fresh saline bath. 
The blood from each ear was thus collected in saline in one liter bottles and 
the total number of red blood cells per liter were counted using a Bright Line® 
hemacytometer (0.1 mm deep, American Optical, Buffalo, NY). Control 
experiments were performed using saline instead of rHV2. Table 4 illustrates 
the time-schedule used in the modified rabbit ear blood loss model. 
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Figure 11 . An illustration of the modified rabbit ear bleeding model. Five 
uniform incisions are made in an area free of blood vessels. 
(Modified, by permission, from Racanelli, "Biochemical and pharmacological 
studies on the interaction of protamine with heparins", Ph.D. diss., Loyola 
University Chicago, 1990, p332.) 
TABLE 4 
TIME SCHEDULE USED IN THE MODIFIED RABBIT EAR 
BLOOD LOSS MODEL 
Time (l.V.) Procedure Time (S.C.) 
Anesthetize rabbit, 
visually select area 
of both ears for 
potential sites of 
incisions 
0 min----> Inject rHV2 <----0 min 
5 min----> Make five uniform <----60 min 
incisions in one ear, 
immerse ear in sa-
line bath 
15 min----> <----70 min 
Remove ear and 
collect RBCs in sa-
line for counting 
15 min----> <----180 min 
Make five uniform 
incisions in other 
ear, 
immerse ear in sa-
25 min----> line bath <----190 min 
Remove other ear 
and collect RBCs in 
saline for counting 
Put rabbit back in 
cage after bleeding 
ceases 
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Experimental Protocols 
In Vitro Studies 
1. Construction of Concentration-Response Curves after In Vitro 
Supplementation of rHV2 in Plasma Systems 
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Calibration curves were constructed after in vitro supplementation of 
rHV2 in BBP, NDP, NRatP and NRP. The following tests were performed after 
supplementation of rHV2 in three individual replicates with each sample 
analyzed duplicate: 
1. APTT (OT and Dade) 
2.TT 
4. Chromogenic anti-Ila assay 
In case of NRatP, only the chromogenic anti-Ila assay was performed, due to 
the limitation of the amount of blood that can be obtained from rats. rHV2 
was supplemented in concentrations ranging from 0 to 10 µg/mL in the 
respective plasma systems, frozen at -70°C and thawed just prior to use. 
Appropriate dilutions were made in respective plasma, for each assay. The 
used for the standard curves were frozen for approximately the same period 
of time as the samples from the pharmacokinetic /pharmacodynamic studies. 
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2. Determination of Specific Activity of rHV2 using a Thrombin Titration 
Method 
Principle 
One antithrombin unit (ATU) of rH is the amount that inhibits 1 NIH unit 
of thrombin. 
Materials 
Assay working buffer (pH= 8.4). 
Triethanolamine HCI (M.W. = 185.65) - 0.1 M or 18.6 g 
NaCl (M.W. = 40) 0.2 M or 11. 7 g 
Distilled Water 1000 ml (q.s.) 
Triethanolamine and NaCl were dissolved in 800 ml of distilled water and pH 
was adjusted to 8.4 with 1 N NaOH. The volume was made up to 1000 ml. 
Thrombin dilution buffer (pH= 7 .9). 
Tris (M.W. = 121.1) 0.05 M or 6.06 g 
NaCl (M.W. = 40) 0.1 M or 5.84 g 
PEG 6000 0.1 % or 1 g 
Distilled Water 1000 ml (q.s.) 
All ingredients were dissolved in distilled water to make 1000 ml and pH was 
adjusted to 7 .9. 
Thrombin. 235 µl (23.5 U) of 100 U/ml thrombin (Fenton a362, 
2435.85 U/ml) were diluted with 765 µl of thrombin dilution buffer to make 
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1000 µl of 23.5 U/ml solution of thrombin in dilution buffer. 100 µl of this 
solution were used to give a final thrombin concentration of 1 U/ml in 2.35 
ml of total assay volume in each cuvette. 
Substrate. Spectrozyme® TH (H-D-hexahydrotyrosyl-l-alanyl-l-arginine-
p-nitroanilide-diacetate salt, 5 µM/vial, American Diagnostica, CT) was 
reconstituted with 3.33 ml of distilled water to give a 1.5 µM/ml solution. 
250 µl were used to give a final substrate concentration of 0. 160 µM/mL. 
Recombinant hirudin. Serial dilutions were made in normal saline from a 
1 mg/ml solution of rHV2 to yield final assay concentrations of 1.59 to 69.1 
ng/mL. 
Procedure 
In a polystyrene cuvette (path length= 1 cm), buffer and sample were 
preincubated at 37°C for two minutes and mixed. a-thrombin was added, 
mixed and incubated at 37°C for one minute followed by addition of substrate. 
The 0.D. variation per minute(~ O.D./min) at 37°C was measured at 405 nm 
during a time period of one minute using a spectrophotometer (DU-7®, 
Beckman). Given below are the individual volumes of each constituent: 
Buffer 
Sample 
- 1975 µl 
25 µl 
Mix and incubate at 37°C for two minutes. 
''" 
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Thrombin (2.35 U/ml) 100 µL 
Mix and incubate at 37°C for one minute. 
Spectrozyme® TH - 250 µL 
Total Volume - 2350 µL 
The antithrombin response using each concentration of rHV2 was 
measured as "% inhibition of thrombin" in duplicate when compared with 
saline controls. The "residual thrombin activity" in each sample was plotted 
against rHV2 concentrations and specific activity of rHV2 was determined 
using the rHV2 concentration corresponding to a residual thrombin activity of 
zero. The specific activity was thus determined three different times followed 
by calculation of mean specific activity. 
3. Determination of Protein Content of rHV2 by A 215-225 Method 
Appropriate dilutions of rHV2 were made in Sterile Water for Irrigation 
to give concentrations of 25, 50, and 100 µg/ml. The absorbances of each 
solution were read at 215 and 225 nm using a spectrophotometer. The 
protein content in each sample was determined as described in the 
"METHODS" section. 
In Vivo Studies 
1 . Assessment of Antithrombotic Profile of rHV2 using a Modified Jugular 
Vein Stasis Thrombosis Model in Rabbits - A Dose-Ranging Study 
Procedure. Male, New Zealand White rabbits (2.5-3.0 kg) were used in 
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a modified Wessler's jugular vein stasis thrombosis model to evaluate the in 
vivo antithrombotic effects of rHV2 as described under "METHODS" section. 
A circulation time of 5 and 120 minutes was allowed after i.v. and s.c. 
administration of rHV2, respectively. 
Sample size. A sample size of 5 rabbits was used for each dose 
including saline treated control rabbits. 
Dosage. 
1.V. - 0 (saline), 6.25, 12.5 and 25 µg/kg weight of each rabbit 
S.C. - 0 (saline), 125, 250 and 375 µg/kg weight of each rabbit. 
FEIBA® was used in a dose of 7.5 U/kg, i.v. 
Blood sampling times. 
Baseline, post-drug (5 minutes/i.v. and 120 minutes/s.c.) and post-
FEIBA® (11 minutes/i.v. and 126 minutes/s.c.). 
Ex vivo analysis. Clot scores were graded in a scale from 0 to + 4 as 
described under "METHODS". Plasma samples were analyzed for rHV2 
concentrations using competitive ELISA method. Coagulation tests, including 
APTT, TT, and Ca+ 2TT as well as chromogenic anti-Ila assay were performed. 
2.. Assessment of Hemorrhagic Activity of rHV2 using a Modified Rabbit Ear 
Blood Loss Model 
Procedure. A modified rabbit ear bleeding model was used to evaluate 
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the bleeding profile of rHV2 as described under "METHODS". Hemorrhagic 
responses were measured in experimentally determined therapeutic and 
supratherapeutic doses for a period of 10 minutes from each ear as described 
under "METHODS". No restriction on food and water was placed prior to 
anesthesia of rabbits. 
Sample size. A sample size of 5 rabbits was used for each i.v. or s.c. 
dose. 
Dosage. 
l.V. - 0 (saline), 0.025, 0.25, 0.5, 0. 75, 1.0 and 2.5 mg/kg. 
S.C. - 0 (saline), 0.375, 1.0, 2.5 and 5 mg/kg. 
Circulation times. 
l.V. - 5 minutes (one ear) and 15 minutes (other ear). 
S.C. - 60 minutes (one ear) and 180 minutes (other ear). 
3. Evaluation of Pharmacokinetics and Time Course of Antithrombotic 
Activity after rHV2 Administration in Rabbits 
Procedure. The purpose of this experiment was to relate the time course 
of in vivo antithrombotic activity of rHV2 with time course of plasma 
concentrations of rHV2. Male, New Zealand White rabbits (2.5-3.0 kg) were 
used in a modified stasis thrombosis model to obtain a profile of in vivo and 
ex vivo antithrombin activity. No restriction on food and water was placed 
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prior to anesthesia of rabbits. 
Sample size. Five rabbits were used for each circulation time after i.v. 
and s.c. administration of rHV2. 
Dosage. A dose of 25 µg/kg, i.v. and 375 µg/kg, s.c. were selected after 
reviewing the results from the dose-ranging study in rabbits. 
Circulation times. 
l.V. - 5, 15, 30, 45, 60, 90 and 120 minutes. 
S.C. - 30, 60, 120, 150, 180, 240 and 360 minutes. 
Blood sampling times. Additional blood samples (4.5 ml, two draws from 
each rabbit) were drawn to estimate rHV2 pharmacokinetics: 
l.V. - 3, 5, 9, 12, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90, 100 and 120 
minutes. 
s.c. - 5, 10, 20, 30, 45, 60, 75, 90, 110, 120, 135, 150, 180, 200, 220, 
240, 300, 320 and 360 minutes. 
Three post-drug blood draws were performed in each rabbit for every 
circulation time in the time course studies (composite grouping). 
Ex vivo analysis. Plasma samples from each time point were subjected 
to similar analysis methods as described before. 
4. Determination of Pharmacokinetic Characteristics and Ex Vivo 
Antithrombin Activity of rHV2 in Rats 
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Procedure. Male, Sprague-Dawley rats (250-300 g) were weighed and 
injected with increasing i.v. or s.c. doses of rHV2 via tail vein or in the 
abdominal area, respectively. 450 µL of blood were drawn into microtubes 
with 50 µL 3.8% sodium citrate solution, at specific time intervals via tail 
clipping method (Kraus, 1980, Luke et al., 1991). After each blood draw, the 
tail ends were cauterized using an Accu-Temp®, high temperature cautery. 
Halothane (1 % with oxygen, Kaczmarczyk and Reinhardt, 1975), used with 
a dispenser (Fluthane®) and maintained using a nose cone was utilized for 
induction of anesthesia during each blood draw. Rats were returned to their 
cages during periods between blood draws. No restriction on food and water 
was placed during study period. Microtubes with blood were centrifuged at 
2,500 rpm at 4°C for 20 minutes, plasma separated and stored at -70°C until 
further use. The rats were sacrificed by administration (intra-cardiac) of 0.2 
ml of Beuthanasia® solution. 
Sample size. Eight rats were used in each sub-treatment group (see 
below). 
Dosage. rHV2 dissolved in normal saline was administered in the 
following doses: 
1.V. - 0.1, 0.4 and 0.5 mg/kg. 
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S.C. - 0.1, 0.5 and 1.0 mg/kg. 
Blood sampling times. Three different time schedules (n = 8 rats, each) 
were used for each i.v. and s.c. dose (tota1=24 rats per i.v. or s.c. dose) to 
cover a broader range of time period. The following were the time schedules 
used for each dose: 
1.V.: 
Schedule 1 - baseline, 3, 12, 25, 40, 60, 120 and 360 minutes. 
Schedule 2 - baseline, 5, 15, 30, 45, 75, 180 and 480 minutes. 
Schedule 3 - baseline, 9, 20, 35, 50, 90, 240 and 1440 minutes. 
S.C.: 
Schedule 1 - baseline, 30, 90, 130, 160, 190, 220, 300 and 400 minutes. 
Schedule 2 - baseline, 60, 105, 140, 170, 200, 240, 320 and 480 minutes. 
Schedule 3 - baseline, 75, 120, 150, 180, 210, 270, 360 and 1440 minutes. 
A total of 144 rats were thus randomly assigned into the above 
composite groups. Equal volume ( = 0.5ml) of normal saline was injected i.p. 
for volume replenishment. 
Ex vivo analysis. Plasma samples were analyzed for rHV2 concentra-
tions using competitive ELISA method and antithrombin activity using 
chromogenic anti-Ila assay. 
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5. Evaluation of Renal Function after rHV2 Administration in Rats 
Procedure. Male Sprague-Dawley rats (250-300g) were housed in 
individual metabolic cages and allowed an acclimation period of at least two 
days. Complete urine voiding was ensured using a halothane nose cone prior 
to drug administration. The test dose of rHV2 was injected via the tail vein 
(i.v.) or in the abdominal area (s.c.). An equal number of normal saline-treated 
control rats were used for each route of administration. Blood samples were 
drawn via tail bleed at baseline and at 24 hours for obtaining serum chemistry 
and hematological data. No restriction on food and water was placed during 
entire study period. 
24 hours after drug (or saline) administration, a single dose 3H-inulin 
clearance was performed. The rats were transferred from metabolic cages to 
individual, disposable bins and anesthetized with halothane nose cone. A 
bolus dose of 3H-inulin ( 10 µCi) was administered via tail vein. Blood samples 
(200 µL) were drawn at regular intervals, serum separated, and stored at -
70°C. Prior to analysis, the serum samples were thawed, and the 3H 
disintegrations per minute (dpm) were read after addition of 5 ml of Ecolite® 
to 10 µL of each sample using a counter (Minaxi®4000 series) for a period of 
2.5 minutes/sample. At the end of the study, the rats were sacrificed with an 
intra-cardiac administration of Beuthanasia® solution. 
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Sample size. Eight rats were used in each treatment group (i.v. or s.c. 
dose with saline controls). 
Dosage. 
1.V. rHV2 - 0.5 mg/kg. 
S.C. rHV2 - 1.0 mg/kg. 
The above doses were selected from the results from pharmacokinetic 
experiments in rats, described above. 
Blood sampling times. Blood samples were collected at baseline and 24 
hours (1 ml) for preparation of whole blood and serum. After administration 
of 3H-inulin, 200 µL of blood were collected at the following times: 
Baseline, 5, 10, 20, 30, 45, 60, 75 and 90 minutes. 
Ex vivo analysis. Serum samples were analyzed for 3H disintegrations 
per minute using a scintillation counter. In addition, serum chemistry and 
hematological profiles were obtained. 
6. Investigation of Pharmacokinetics and Pharmacodynamics of rHV2 after 
Single Dose Administration in Dogs 
Procedure. Conscious, adult, male mongrel dogs (25 to 30 kg) were 
weighed and randomly treated with increasing doses of rHV2 dissolved in 
normal saline. The test dose (see below) was administered via the superficial 
saphenous vein (i.v.) or in the lower abdominal area (s.c.). Blood samples (9 
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ml) were obtained via standard venipuncture in the forelimb using Butterfly® 
(21 x 3/4, 12"tubing) infusion set (Abbott Hospitals, Inc., North Chicago, IL) 
at various time intervals as specified below. Blood samples collected in 
Vacutainers® were centrifuged at 2500 rpm at 4°C for 20 minutes and plasma 
samples from individual blood draws were separated and stored at -70°C until 
further analysis. No restriction on food and water was placed during the 
entire study period. 
Sample size. A sample size of 6 dogs was used for each treatment 
(dose). The dogs were randomly assigned with treatment sequences. 
Dosage. rHV2 was used in i.v. and s.c. doses as given below: 
l.V. - 0.25, 0.5 and 1.0 mg/kg. 
S.C. - 0.25, 0.5 and 1.0 mg/kg. 
Blood sampling times. The following blood sampling times were used: 
l.V. - baseline, 3, 6, 12, 18, 30, 60, 120, 360 and 1440 minutes. 
S.C. - baseline, 15, 30, 45, 60, 90, 120, 150, 180, 240, 360 and 1440 
minutes. 
Ex vivo analysis. Plasma concentrations of rHV2 were determined using 
the competitive ELISA method. Ex vivo antithrombin activity was screened 
using chromogenic anti-Ila assay as well coagulation tests such as APTT 
(Dade), APTT (OT), TT (20 U/mL), and Ca+ 2TT ( 10 and 20 U/mL). 
7. Investigation of Pharmacodynamics of rHV2 after Repeated 
Administration in Dogs 
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Procedure. Conscious, adult, male mongrel dogs (25-30 kg) were 
administered with multiple i.v. or s.c. doses of rHV2 for one week at a dosing 
interval of every 24 hours. Blood samples were drawn at various time 
intervals and processed as described above. 
Sample size. A sample size of 6 dogs was used for each treatment (i.v. 
dose or s.c. dose). 
Dosage. A 1 mg/kg (i.v. and s.c.) dose was selected from the single 
dose studies described above. 
Blood sampling times. The following time schedule was used for blood 
draws after the first dose: 
l.V. - baseline, 3, 6, 12, 18, 30, 60, 120, 360 and 1440 minutes. 
S.C. - baseline, 15, 30, 45, 60, 90, 120, 150, 180, 240, 360 and 1440 
minutes. 
The following time schedule was used for blood draws after adminis-
tration of the second to the last dose: 
1.V. - baseline, 5, 30 and 60 minutes. 
S.C. - baseline, 120, 180 and 240 minutes. 
Additional blood samples (2 ml) were obtained after each dose at 
baseline and 30 minutes (i.v.) or 120 minutes (s.c.) to obtain serum chemistry 
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and hematological profiles. 
Ex vivo analysis. The plasma samples were subjected to the same tests 
to determine plasma concentrations and antithrombin activity of rHV2 as 
described in the single dose studies in dogs. In addition, serum samples and 
whole blood samples at specific time intervals were analyzed for chemistry 
and hematological profiles. 
Data Analysis 
Plasma concentrations of rHV2 were plotted against corresponding times 
using a graphics software (SigmaPlot®, Version 5.01, Jandel Corporation, 
Sausalito, CA). Various pharmacokinetic parameters were calculated using 
standard non-compartmental methods (Gibaldi and Perrier, 1982; Gibaldi, 
1984; Rowland and Tozer, 1989) as shown below: 
The maximum concentration of rHV2 reached in plasma (Cmax) and time 
to reach Cmax (tmax) were determined by visual examination of the 
graphs. 
Elimination rate constant (ke) of rHV2 was determined from the slope of 
the terminal portion of the plasma concentration-time curve. 
Terminal half-life (t 112) of rHV2 was determined using the equation, 
t 112 = 0.693/ke. 
Area under the concentration-time curve up to the last blood sampling 
time (AUC0_t) was estimated using the trapezoid rule and extrapolated 
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to infinity (AUC0_00 ) using the formula, 
* AUC0_00 = AUCo-t + C /k8 
* * where C was the concentration of rHV2 at the last sampling time (t ) . 
Area under the (first) moment curve up to the last sampling time 
(AUMC0_t) was calculated from a plot of the product of drug concen-
tration and time versus time. AUMC0_00 was calculated from the 
formula, 
* * * 2 AUMC0_00 =AUMCo-t + C .t /k8 + C /(k8 ) . 
After single dose administration, mean residence time (MRT) of rHV2 or 
the time required to eliminate 63.2% of dose, was calculated as follows: 
MRT = AUMC0_00 /AUC0_00 • 
Bioavailability (F) of rHV2 after s.c. administration was determined from 
the following equation: 
F=AUC0_001 s.cJAUC0_001 i.v. X Dosei.vJDose5 .c.· 
Systemic (total) clearance (Cltotl of rHV2 was calculated using the 
formula, Cltot = Dose/AUC0_00 after i.v., and F X Dose/AUC0_00 , after 
s.c. administration. 
Apparent volume of distribution (V d) of rHV2 was determined using the 
formula, 
To determine the inulin clearance parameter, the disintegrations per 
minute per minute (dpm) of 3H of each blood sample were plotted (semilogar-
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ithmic) versus time and the elimination rate constant of 3H-inulin was 
determined from slope of terminal portion after linear regression. AUCo-t was 
determined by trapezoidal rule and extrapolated to infinity (AUC0_00 ) by the 
sum of AUCo-t and AUCt-oo (as described previously). lnulin clearance (Clin) 
was calculated from dose/AUC0_00 • This method has been previously 
validated and found to closely estimate the true glomerular filtration rate in 
rats (Luke et al., 1991). 
In the pharmacodynamic studies, each response was expressed as mean 
± standard deviation (SD) and/or standard error of the mean (SEM). 
Responses were also plotted against time. Relationship between pharmaco-
kinetics and pharmacodynamics were determined by correlation of time course 
of each response with time course of concentration in plasma. 
Statistical Analysis 
Appropriate statistical analytical tests were used to determine signifi-
cance in differences between the various treatment groups (Zar, 1984). One-
way analysis of variance (ANOV A) was performed to test for differences 
between two or more treatment groups on different animals, followed by 
multiple comparison tests such as Tukey test. One-way and two-way 
repeated measures ANOV A tests were performed in the multiple dose 
experiments in dogs (Wilkinson, 1990). For non-parametric analysis, Kruskal-
Wallis one-way ANOV A was performed, followed by multiple comparison 
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using Mann-Whitney test. 
In the case of treatments on the same animal (eg.: pre- and post-test), 
a paired t-test was performed. Independent t-tests were performed to test for 
differences between treatments on two different groups of animals. Wilcoxon 
test was used as the non-parametric analog of the paired t-test (Zar, 1984). 
Correlation analysis were used to establish a relationship between pharma-
cokinetics and pharmacodynamics in each species at different doses after i. v. 
and s.c. administration. Statistical packages such as Systat® (Wilkinson, 
1990) and Primer of Biostatistics (Glantz, 1992) were used for statistical 
analysis. 
Approval of Protocols 
All animal protocols were reviewed and approved by the following 
committees: 
1 . Institutional Animal Care and Use Committee (IACUC), Loyola 
University Chicago. 
The IACUC approval numbers for the individual protocols are listed 
below: 
i) In vivo antithrombotic activity, hemorrhagic and pharmacokinetic/ 
pharmacodynamic studies in rabbits after single i.v. and s.c. 
administration of rHV2: # 92-015. 
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ii) Pharmacokinetic/ pharmacodynamic, urinary excretion and renal 
function studies in rats after single i.v. and s.c. administration of 
rHV2: # 93-020-1 a. 
iii) Pharmacokinetic and pharmacodynamic studies in dogs after 
single and multiple i.v. and s.c. administration of rHV2: 
# 93-060. 
2. Radiation Control Committee, Loyola University Chicago. 
CHAPTER IV 
RESULTS 
In Vitro Studies 
1. Construction of Concentration-Response Curves after In Vitro 
Supplementation of rHV2 in Plasma Systems 
rHV2 was supplemented in normal rabbit plasma (NRP), normal rat 
plasma (NRatP), normal dog plasma (NOP) and blood bank plasma (88P) to 
obtain plasma concentrations of 0 to 10 µg/ml. The supplemented plasma 
samples were screened for various coagulation tests and amidolytic anti-Ila 
activity, as described under the "Materials, Methods and Experimental 
Protocols" section. The supplementation of rHV2 and construction of 
concentration-response curves were performed on three different replicates 
using three separate pooled plasma preparations (sample size of at least six, 
each). Hence, each observation in the figures in this section represents the 
mean from three separate experiments ± SEM, and each individual experiment 
was performed in duplicate. The results from these assays are expressed in 
terms of adjusted concentration of rHV2 in the final assay system. 
Concentration-response curves after rHV2 supplementation in NRP. The 
rHV2 supplemented NRP samples were initially analyzed using coagulation 
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tests: TT ( 10 U/ml), Ca+ 2TT ( 1 OU/ml), Ca+ 2TT (20 U/ml) and Ca+ 2TT (30 
U/ml). The results from this experiment are depicted in Figure 12. The 
baseline values for TT ( 10 U/ml), Ca+ 2TT ( 10 U/ml), Ca+ 2TT (20 U/ml) and 
Ca+ 2TT (30 U/ml) were 26.9 ± 3.1, 20.46 ± 2.45, 10.47 ± 1.02 and 6.5 
± 0.25 seconds (mean ± SEM), respectively. As the thrombin strength in the 
reagent was increased, the concentration-response curves shifted to the right, 
as indicated in Figure 12. The clotting time, as measured by TT ( 10 U/ml), 
exhibited a steep increase reaching ~ 300 seconds at a low concentration of 
0.9 pM/ml. However, when the thrombin reagent ( 10 U/ml) was 
reconstituted in CaCl2 solution, a sigmoidal curve was obtained with at least 
6 points in the linear portion of the curve. The clotting time, as measured by 
this assay {ca+ 2TT (10 U/ml)}, reached ~ 300 seconds at rHV2 
concentration of approximately 8 pM/ml. 
On the other hand, when the calcium thrombin reagent was modified 
to 20 U/ml, a higher rHV2 concentration was required to exhibit measurable 
increases from baseline values, as compared to Ca+ 2TT ( 10 U/ml). There 
were only 2 to 3 points in the linear portion with a sharp increase in Ca+ 2TT 
(20 U/ml) to ~ 300 seconds at rHV2 concentration of 10 pM/ml, as shown 
in Figure 12. An additional modification in the thrombin reagent to 30 U/ml 
exhibited very little concentration dependency, with almost no change in 
clotting times compared to baseline value (6.5 seconds) up to a concentration 
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Figure 12. In vitro calibration curves using thrombin time and calcium 
thrombin time after supplementation of rHV2 in normal rabbit f-lasma. 
Symbols represent TT (10 U/ml):+, ca+ 2TT (10 U/ml): /l, ca+ TT (20 
U/ml): • and Ca+ 2TT (30 U/ml): D. The concentrations of rHV2 represent 
the final concentration of rHV2 corrected for volume in each assay system. 
All data represent the mean value from three individual experiments ± SEM, 
each performed in duplicate. 
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of 10 pM/mL. The results from this set of experiments led to the conclusion 
that Ca+ 2TT ( 10 U/mL) would be the most optimal thrombin time, or more 
appropriately, modified thrombin time, that can used to monitor in vitro 
anticoagulant activity of rHV2. 
The observed results with Ca+ 2TT ( 10 U/mL) were compared with 
other in vitro assays, as illustrated in Figure 13. In this experiment, rHV2 
supplemented NRP samples were analyzed using Ca+ 2TT ( 10 U/mL), APTT 
(OT), APTT (Dade) and amidolytic anti-Ila assay. The baseline clotting times 
using Ca+ 2TT (10 U/mL), APTT (OT) and APTT (Dade) were 20.46 ± 2.45, 
57.05 ± 1.56 and 14.7 ± 4.2 (mean ± SEM), respectively, in NRP. Figure 
13 illustrates a shift to the right in the concentration-response curves from 
Ca+ 2TT ( 10 U/mL) to APTT (OT) and then to APTT (Dade). The thrombin 
inhibition curve using amidolytic anti-Ila assay was aligned between Ca+ 2TT 
( 10 U/mL) and APTT (OT). APTT (OT) was linear in the rHV2 concentration 
range between 10 and 150 pM/mL, beyond which the response was > 300 
seconds. APTT (Dade) exhibited very little dose dependency until about 150 
pM/mL. The linear range for the chromogenic anti-Ila assay was between 1 
and 10 pM/mL. 
Because of the wide differences in the biochemical conditions, marked 
variations in the shape of concentration-response curves have been noted. 
The initiation of the observed anticoagulant/antithrombin effects was 
dependent on the type of assay used. It is clear from this comparison that the 
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Figure 13. In vitro antithrombin profile of rHV2 supplemented in normal rabbit 
plasma (NRP). Symbols represent Ca +2n (10 U/ml): • , APTT (OT): ~, 
APTT (Dade): •, and chromogenic anti-Ila assay: D. The concentrations of 
rHV2 represent the final concentration of rHV2 corrected for volume in each 
assay system. All data are mean observations from three individual 
experiments, each performed in duplicate ± SEM. 
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relative sensitivity range of each of these assays for rH differs significantly. 
To better express these results, the slopes of the concentration-response 
curves were calculated in the selected linear range of each of the assays. The 
slopes were calculated using a least square regression analysis of the points 
in the linear portion of each curve (Miller and Freund, 1977). The slopes for 
the linear portions of the concentration-response curves in NRP, as well as in 
the other plasma preparations, are listed in Table 5. 
In the clotting assays, a wide variation in the values of calculated slopes 
was observed in NRP samples (Table 5). When the Ca+ 2TT ( 10 U/ml) slope 
was compared with APTT (OT) and APTT (Dade), marked differences were 
noted (p < 0.05, one-way ANOVA followed by Tu key's multiple comparison 
test). Even within the two APTT reagents, an almost 6-fold difference 
(p < 0.05) was observed in the slopes {0.65 seconds/pM/mL with APTT (OT) 
versus 0.1 second/pM/mL with APTT (Dade)}. 
The correlation coefficients for the linear portion of concentration-
response curves were found to be 0.99, 0.95, 0.86 and 0.98 for the Ca+ 2TT 
( 10 U/ml), APTT (OT), APTT (Dade) and chromogenic anti-Ila assay, 
respectively. 
Concentration-response curves after rHV2 supplementation in NDP. 
rHV2 was supplemented in NDP in concentration ranges similar to that 
described above. Figure 14 shows the results from rHV2 supplemented NDP 
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samples that were analyzed using Ca+ 2TT ( 10 U/ml), APTT (OT), APTT 
(Dade), and the anti-Ila assay. The baseline values for Ca+ 2TT ( 10 U/ml), 
APTT (OT) and APTT (Dade) in NOP were 16.4 ± 2.05, 18.6 ± 3.2 and 13.5 
± 1.2 (mean ± SEM), respectively. The alignment of the concentration-
response curves was similar to that found with NRP samples. The response 
curves for Ca+ 2TT ( 10 U/ml), anti-Ila assay and APTT (OT) were almost 
parallel to each other with a shift to the right. The linear ranges of the three 
coagulation assays and the anti-Ila assay were similar to that obtained with 
NRP. 
The correlation coefficients for the linear portions of the response 
curves with Ca+ 2TT ( 10 U/ml), APTT (OT), APTT (Dade) and chromogenic 
anti-Ila assay in NOP were 0.92, 0.98, 0.99 and 0.96, respectively. The 
analysis of slopes obtained from the concentration-response curves revealed 
similar results to those obtained in the rabbit plasma studies. The results from 
the coagulation assays in NOP showed similar trends as in NRP, where major 
differences were noted between slopes of ca+ 2TT (10 U/ml) {40.31 
seconds/pM/mL}, APTT (OT) {1. 74 seconds/pM/mL) and APTT (Dade) {0.26 
seconds/pM/mL}. The slope of the amidolytic anti-Ila assay response in NOP 
was nearly identical to that obtained in the rabbit plasma (4.53 % thrombin 
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Figure 14. In vitro antithrombin profile of rHV2 supplemented in normal dog 
plasma (NDP). Symbols represent Ca +2TT (10 U/ml): • , APTT (OT): l1, 
APTT (Dade): "", and chromogenic anti-Ila assay: D . The concentrations of 
rHV2 represent the final concentration of rHV2 corrected for volume in each 
assay system. All data are mean observations from three individual 
experiments, each performed in duplicate ± SEM. 
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inhibition/pM/mL-NRP vs. 3.97 % thrombin inhibition/pM/mL-NDP, Table 5). 
Concentration-Response curves after rHV2 supplementation in BBP. 
Figure 15 illustrates the concentration-response curves obtained after 
supplementation of rHV2 in BBP. The curves obtained with the three 
coagulation tests and amidolytic assay were similar to those obtained with 
NRP and NDP samples. The baseline values for Ca+ 2TT ( 10 U/ml), APTT 
(OT) and APTT (Dade) were 18.9 ± 1.2, 27.56 ± 3.9 and 18.3 ± 2.6 (mean 
± SEM), respectively. The corresponding correlation coefficients for the linear 
portions of the response curves were 0.94, 0.95, and 0.98, respectively. The 
correlation coefficient for the amidolytic anti-Ila assay was 0.97. 
The results from the slope analysis of the concentration-response 
curves in blood bank plasma were similar to those obtained in rabbit and dog 
plasma (Table 5). The slope of ca+ 2rr (10 U/ml) was lower in BBP (20.74 
seconds/pM/mL) compared with that in NRP (37.43 seconds/pM/mL) and NDP 
(40.31 seconds/pM/mL). However, this difference was not significant. The 
linear range for all of the assays in BBP was approximately the same as that 
found in NRP and NDP. The slope of APTT (Dade) in BBP (0.45 
seconds/pM/mL) was significantly higher (p < 0.05) than that found in NRP 
(0.1 second/pM/mL). However, it did not differ significantly from that 
obtained in NDP. Interestingly, the slope of the anti-Ila assay response in BBP 
was similar to those found with dog and rabbit plasma (Table 5). 
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Figure 15. In vitro antithrombin profile of rHV2 supplemented in blood bank 
plasma (BBP). Symbols represent ca+ 2TT (10 U/ml): e, APTT (OT):~, 
APTT (Dade): •, and chromogenic anti-Ila assay: D . The concentrations of 
rHV2 represent the final concentration of rHV2 corrected for volume in each 
assay system. All data are mean observations from three individual 
experiments, each performed in duplicate ± SEM. 
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Concentration-response curve after rHV2 supplementation in NRatP. 
Due to the limited amount of blood that can be drawn from rats, only 
the amidolytic anti-Ila assay was performed in rHV2 supplemented NRatP. 
The in vitro antithrombin activity measured by amidolytic anti-Ila assay after 
rHV2 supplementation in NRatP is shown in Figure 16. A higher rHV2 
concentration was required to produce equivalent inhibition of thrombin 
compared with that observed in NRP, NDP and BBP. The linear range for this 
assay in NRatP was 10 to 100 pM/mL compared with 1 to 10 pM/mL in the 
other plasma preparations. A much lower value of slope (0.65 % thrombin 
inhibition/pM/mL) was obtained with rat plasma (Table 5). 
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Figure 16. In vitro standard curve for chromogenic anti-Ila assay after 
supplementation of rHV2 in normal rat plasma (NRatP). The concentrations 
of rHV2 represent the final concentration of rHV2 corrected for volume in each 
assay system. All data represent the mean value from three individual 
experiments ± SEM, each performed in duplicate. 
Plasma 
System 
NRP 
NDP 
BBP 
NRatP 
Units 
TABLE 5 
SLOPES FROM CONCENTRATION-RESPONSE CURVES 
AFTER IN VITRO SUPPLEMENTATION OF rHV2 IN 
VARIOUS PLASMA SYSTEMS 
Slope from Concentration-Response Curve (Mean ± SEM) 
ca+ 2n APTT APTT Anti-Ila 
(10U/mL) (OT) (Dade) 
37.43* 0.65** 0.10@ 4.53 
± 4.37 ± 0.11 ± 0.07 ± 0.60 
40.31 * 1.74 0.26 3.97 
± 11.82 ± 0.07 ± 0.08 ± 0.53 
20.74* 1.73 0.45 4.79 
± 4.40 ± 0.46 ± 0.09 ± 0.84 
--- --- ---
0.65# 
± 0.06 
sec/pM/mL sec/pM/mL sec/pM/mL %1nh/pM/mL 
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* p<0.05, Ca + 2TT (10 U/mL) versus APTT (OT) and APTT (Dade) 
in NRP, NDP and BBP 
* * p < 0.05, APTT (OT) versus APTT (Dade) in NRP 
@ p < 0.05, APTT (Dade), NRP versus BBP 
# p < 0.05, Anti-Ila assay, NRatP versus NRP, NDP and BBP 
(one-way ANOVA followed by Tukey test). 
2. Determination of Specific Activity of rHV2 using a Thrombin Titration 
Method 
Figure 17 illustrates the residual thrombin activity obtained after 
addition of increasing concentrations of rHV2, supplemented in normal saline. 
Thrombin activity was expressed as a percentage of the activity obtained in 
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control (saline) samples. The amidolytic activity of thrombin on its substrate 
(Spectrozyme® TH) decreased progressively in the presence of increasing 
amounts of inhibitor (rHV2) until it reached a steady level of 5 to 10% residual 
thrombin activity. Figure 17 indicates that approximately 63.5 ng/ml final 
concentration of rHV2 completely neutralized one NIH unit of a-thrombin. This 
meant that the specific activity of this batch of rHV2, as measured by 
thrombin titration method, was 15,873.02 ATU/mg protein. Table 6 lists the 
specific activities of rHV2 calculated by above method from three separate 
determinations (each performed in duplicate). The average specific activities 
of rHV2 obtained from the three individual experiments was 15,877.67 
ATU/mg protein, which closely matched the calculated potency from the 
average thrombin titration curve depicted in Figure 17. This specific activity 
was approximately the same as the manufacturer's assigned potency of rHV2 
( 14,495 A TU/mg). 
TABLE 6 
DETERMINATION OF SPECIFIC ACTIVITY (ATU/mg) of rHV2 
USING THROMBIN TITRATION METHOD 
Experiment No. 
1 
2 
3 
Mean specific activity ± S.D. 
Specific activity from average curve 
Specific Activity 
16,260.16 
15,748.00 
15,625.00 
15,877.67 ± 336. 77 
15,873.02 
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Figure 17. Thrombin titration curve for determination of specific activity of 
rHV2. Each data point represents the mean of three individual experiments, 
each determined in duplicate ± SEM. 
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3. Determination of Protein Content of rHV2 using /1 215-225 Method 
The difference in mean optical densities (n = 3) at 215 and 225 nm 
(A 215-225 nm) of rHV2 solutions at concentrations of 25, 50 and 100 µg/ml 
was found to be 0.19 ± 0.06, 0.39 ± 0.03 and 0. 71 ± 0.1 (mean ± SEM), 
respectively. This translated to a protein content of 27.4, 56.2 and 102.2 
µg/ml of protein in these solutions, respectively. 
In Vivo Studies 
1. Assessment of Antithrombotic Profile of rHV2 using a Modified Jugular 
Vein Stasis Thrombosis Model in Rabbits - A Dose-Ranging Study 
The antithrombotic properties of rHV2 were evaluated using a modified 
rabbit jugular vein stasis thrombosis model, as described in the chapter on 
"Materials, Methods and Experimental Protocols". rHV2 was used in i.v. 
doses of 6.25, 12.5 and 25 µg/kg and s.c. doses of 125, 250 and 375 µg/kg. 
Appropriate saline treated control groups (n = 5) were included for each route 
of administration. The results obtained from these studies are described in the 
following sections. 
1.V. administration. 1.V. administration of rHV2 exhibited a dose 
dependent antithrombotic activity with increasing doses, as illustrated in 
Figure 18. Saline treated, control rabbits exhibited clot scores of + 3 and + 4 
after 10 minute and 20 minute stasis times, respectively. With rHV2 
administration, the antithrombotic activity increased progressively until clot 
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Figure 18. In vivo antithrombotic activity of rHV2 after i.v. administration in 
rabbits. Increasing doses of 0 (saline), 6.25, 12.5 and 25 µg/kg were 
administered in male, New Zealand White rabbits (n = 5 per dose), in the 
modified jugular vein stasis thrombosis model. rHV2 circulation time was 5 
minutes followed by a 10 and 20 minute stasis in the left and right sides, 
respectively. All data represent a mean of 5 clot scores ± SEM. 
* - significant variation (p < 0.05) in clot scores between all doses 
including saline control after 10 minute stasis time, and * * - significant 
difference (p < 0.05) in clot scores between 12.5 and 25 µg/kg rHV2 
treatments with corresponding saline and 6.25 µg/kg rHV2 treatment after 20 
minute stasis time (Kruskal-Wallis one-way ANOVA followed by Mann-Whitney 
test). @ - significant increase in clot scores after specific doses of rHV2 at 
20 minutes versus 10 minutes (Wilcoxon test). 
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scores of 0 and + 1 were obtained at 10 minute and 20 minute stasis times, 
respectively, at a dose of 25 µg/kg of rHV2. At the 10 minute stasis time, 
clot scores obtained after all rHV2 doses and saline treatment were 
significantly different from each other (p < 0.05, Kruskal-Wallis non-parametric 
one-way ANOVA, followed by multiple comparison using Mann-Whitney test). 
At the 20 minute stasis time, however, there was no significant variation in 
the antithrombotic responses obtained after saline treatment and the lowest 
dose i.e. 6.25 µg/kg of rHV2. Significant increases in antithrombotic activity 
(p < 0.05) were seen at the higher doses, i.e. 12.5 and 25 µg/kg of rHV2, 
when clot scores were compared to those obtained after saline and 6.25 µg/kg 
rHV2 treatment (Figure 18). 
Increasing the stasis time to 20 minutes on one jugular vein segment 
significantly decreased the antithrombotic activity of rHV2 when compared to 
corresponding results after 10 minute stasis. This was observed after 
treatment with all doses of rHV2 except 12.5 µg/kg (p < 0.05, Wilcoxon test). 
Complete antithrombotic activity was observed with a dose of 25 µg/kg, i.v., 
indicated by a clot score of 0 after a stasis time of 10 minutes. 
The results from global coagulation assays after i.v. administration of 
rHV2 in rabbits are depicted in Figures 19 to 22. In the case of APTT (OT), 
there was no variation in responses between the three doses of rHV2 and 
saline treatment both at 5 (post-drug) and 11 minutes (post-FEIBA®) after 
rHV2 administration, as shown in Figure 19. As expected, the APTT (OT) 
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Figure 19. Ex vivo antithrombin activity of rHV2 using APTT (OT), after i.v. 
administration in rabbits. rHV2 was used in doses of 0, 6.25, 12.5 and 25.0 
µg/kg in male, New Zealand White rabbits (n = 5). All data represent a mean 
of 5 responses each determined in duplicate ± SEM. 
No significant difference between different treatment groups in APTT 
(OT) values in post-drug and post-FEIBA® samples (one-way ANOVA). @and 
@@- significant difference (p < 0.05 and 0.1, respectively) in APTT (OT) 
values between post-drug and post-FEIBA® samples after administration of 
specific doses of rHV2 (paired t-test). 
110 
values after FEIBA® administration were significantly lower than post-drug 
APTT (OT) values after rHV2 administration at different doses (p < 0.1 after 
saline and 12.5 µg/kg rHV2 and p < 0.05 after 6.25 and 25 µg/kg rHV2, paired 
t-test). 
In the case of APTT (Dade), significant increases (p < 0.05) in clotting 
times were seen after the administration of 12.5 and 25 µg/kg rHV2 doses 
when compared with saline and 6.25 µg/kg rHV2 treatment, in both the post-
drug and post-FEIBA® samples, as indicated in Figure 20. There was a 
significant decrease in APTT (Dade) after FEIBA® administration in the 25 
µg/kg rHV2 treatment group (paired t-test). 
The results obtained with TT ( 10 U/ml) are illustrated in Figure 21 . TT 
( 10 U/ml) showed a marked increase in clotting times ( ~ 300 seconds) after 
administration of 12.5 and 25 µg/kg of rHV2 (p < 0.05 compared with 
corresponding saline and 6.25 µg/kg rHV2 treatment, one-way ANOVA 
followed by Tu key test). Administration of FEIBA® did not decrease the TT 
( 10 U/ml) values significantly after administration of all doses of rHV2 (paired 
t-test, Figure 21). On the other hand, Ca+ 2TT ( 10 U/ml) showed a more 
linear increase in response with increasing i.v. doses of rHV2, as shown in 
Figure 22. A significant increase (p < 0.05, one-way ANOVA) was seen in 
Ca+ 2TT ( 10 U/ml) in post-drug and post-FEIBA® samples when compared 
with corresponding saline and 6.25 µg/kg rHV2 treatment. There were 
significant decreases (p < 0.05, paired t-test) in clotting times using this assay 
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Figure 20. Ex vivo antithrombin activity of rHV2 using APTT (Dade) after i. v. 
administration in rabbits. rHV2 was used in doses of 0, 6.25, 12.5 and 25.0 
µg/kg in male, New Zealand White rabbits (n = 5). All data represent a mean 
of 5 responses each determined in duplicate ± SEM. 
* - significant difference (p < 0.05) in APTT (Dade) values from saline 
and 6.25 µg/kg rHV2 treated groups in post-drug samples, + - significant 
difference (p < 0.05) from 12.5 µg/kg rHV2 treated group in post-drug 
samples and * * - significant difference (p < 0.05) from saline and 6.25 µg/kg 
treated groups in post-FEIBA® samples (one-way ANOVA followed by Tukey 
test). @ - significant difference (p < 0.05) in APTT (Dade) between post-drug 
and post-FEIBA® samples after administration of 25 µg/kg of rHV2 (paired t-
test). 
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Figure 21 . Ex vivo antithrombin activity of rHV2 using TT ( 10 U/ml), after i. v. 
administration in rabbits. rHV2 was used in doses of 0, 6.25, 12.5 and 25.0 
µg/kg in male, New Zealand White rabbits (n = 5). All data represent a mean 
of 5 responses each determined in duplicate ± SEM. 
* - significant difference (p < 0.05) in TT ( 10 U/ml) values compared to 
saline and 6.25 µg/kg rHV2 treated groups in post-drug samples and * * -
significant difference (p < 0.05) from saline and 6.25 µg/kg treated groups in 
post-FE I BA® samples (one-way ANOVA followed by Tu key test). 
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Figure 22. Ex vivo antithrombin activity of rHV2 using Ca + 2TT (10 U/ml), 
after i.v. administration in rabbits. rHV2 was used in doses of 0, 6.25, 12.5 
and 25.0 µg/kg in male, New Zealand White rabbits (n = 5). All data represent 
a mean of 5 responses each determined in duplicate ± SEM. 
* - significant difference (p < 0.05) in Ca+ 2TT ( 10 U/ml) values from 
saline and 6.25 µg/kg rHV2 treated groups in post-drug samples, + -
significant difference (p < 0.05) from 12.5 µg/kg rHV2 treated group in post-
drug samples and * * - significant difference (p < 0.05) from saline, 6.25 and 
12.5 µg/kg treated groups in post-FEIBA® samples (one-way ANOVA followed 
by Tu key test). @ - significant difference (p < 0.05) in Ca+ 2TT ( 10 U/ml) 
between post-drug and post-FEIBA® samples at specific doses of rHV2 (paired 
t-test). 
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after FEIBA® administration in the samples from the higher dose treatments 
(12.5 and 25µg/kg). rHV2 administration at 25µg/kg showed ca+ 2n (10 
U/ml) values greater than or equal to 300 seconds (Figure 22). 
Ex vivo antithrombin activity measured using the chromogenic 
antithrombin assay was expressed as "percent inhibition of thrombin" when 
compared with the thrombin inhibition produced by baseline samples from 
each corresponding rabbit, as illustrated in Figure 23. A dose dependent, 
linear increase in thrombin inhibition was observed with increasing i.v. doses 
of rHV2. A significant prolongation (p < 0.05, one-way ANOVA followed by 
Tukey test) of the thrombin inhibitory activity was seen after administration 
of increasing doses of rHV2. FEIBA® administration produced a significant 
decrease (p < 0.05, paired t-test) in anti-Ila activity in groups administered with 
the higher two doses of rHV2, as shown in Figure 23. The 25 µg/kg dose 
produced a thrombin inhibitory activity of almost 76 ± 6 %. 
Selection of appropriate i. v. dose for time course study. From the in 
vivo clot score results and ex vivo clotting and anti-Ila results illustrated 
above, an i.v. dose of 25 µg/kg was chosen for further time course studies in 
rabbits using stasis thrombosis model. These results are described in the 
following sections. 
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Figure 23. Ex vivo antithrombin activity of rHV2 using chromogenic anti-Ila 
assay, after i.v. administration in rabbits. rHV2 was used in doses of 0, 6.25, 
12.5 and 25.0 µg/kg in male, New Zealand White rabbits (n = 5). All data 
represent a mean of 5 responses each determined in duplicate ± SEM. 
* - significant difference (p < 0.05) in anti-Ila activity from saline and 
6.25 µg/kg rHV2 treated groups in post-drug samples, + - significant 
difference (p < 0.05) from 12.5 µg/kg rHV2 treated group in post-drug 
samples and * * - significant difference (p < 0.05) from saline, 6.25 and 12.5 
µg/kg treated groups in post-FEIBA® samples (one-way ANOVA followed by 
Tu key test). @ - significant difference (p < 0.05) in antithrombin activity 
between post-drug and post-FEIBA® samples at specific doses of rHV2 (paired 
t-test). 
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S.C. administration. A dose dependent increase in antithrombotic 
activity was seen after s.c. administration of rHV2 using the modified jugular 
vein stasis thrombosis model. These results are in Figure 24. Saline treated 
groups exhibited clot scores of + 3 and + 4 after 10 minute and 20 minute 
stasis, respectively. Significantly stronger antithrombotic responses were 
obtained after administration of 250 and 375 µg/kg doses of rHV2 at 10 
minute stasis time (clot scores= 0, p < 0.05, Kruskal-Wallis one-way ANOVA 
followed by Mann-Whitney test). 
After 20 minute stasis, clot scores obtained with all doses of rHV2, 
including saline treatment, showed significant differences from each other 
(p < 0.05, Kruskal-Wallis one-way ANOVA followed by Mann-Whitney test). 
Using the Wilcoxon test, a significant decrease (p < 0.05) in antithrombotic 
activity was seen at 20 minutes when compared to that observed at 10 
minute stasis time after s.c. administration of specific doses of rHV2 (Figure 
24). A strong antithrombotic effect was observed after s.c. administration of 
rHV2 at a dose of 375 µg/kg as shown by mean clot scores of 0 and < 1 at 
10 minute and 20 minute stasis, respectively. 
The results from the global coagulation assays after s.c. administration 
of rHV2 are shown in Figures 25 to 28. All three doses of rHV2, and FEIBA® 
administration showed a significant increase (p < 0.05, one-way ANOVA 
followed by Tukey test) in APTT (OT) values compared with corresponding 
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Figure 24. In vivo antithrombotic activity of rHV2 after s.c. administration in 
rabbits. rHV2 was used in increasing doses of 0 (saline), 125, 250 and 375 
µg/kg in male, New Zealand White rabbits (n = 5 per dose), in the modified 
jugular vein stasis thrombosis model. rHV2 circulation time was 120 minutes 
followed by a 10 and 20 minute stasis in the left and right sides, respectively. 
All data represent a mean of 5 clot scores ± SEM. 
* - significant difference (p < 0.05) in clot scores between 250 and 375 
µg/kg rHV2 treatments and corresponding saline and 125 µg/kg treatments 
after 10 minute stasis time, + - significant difference in clot scores between 
saline and 125 µg/kg rHV2 treatment after 10 minute stasis time, and * * -
significant variation (p < 0.05) in clot scores between all doses including saline 
control after 20 minute stasis time (Kruskal-Wallis one-way ANOVA followed 
by Mann-Whitney test). @ - significant increase in clot scores after specific 
doses of rHV2 (Wilcoxon test). 
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values after saline treatment, as shown in Figure 25. There was a significant 
decrease (p < 0.05, paired t-test) in APTT (OT) values after administration of 
FEIBA® following the three rHV2 doses. On the other hand, there were no 
significant changes in clotting times, as measured by APTT (Dade), between 
the three s.c. doses of rHV2 and saline treatment, as illustrated in Figure 26 
(one-way ANOVA followed by Tu key test). A weaker, yet significant, increase 
in APTT (Dade) was found only after administration of FEIBA® following 375 
µg/kg rHV2 treatment, when compared with corresponding saline control. 
TT ( 10 U/ml) showed a major increase in clotting times after 
administration of all three doses of rHV2, as indicated in Figure 27. 
Significant prolongation in TT ( 10 U/ml) was found after administration of all 
three s.c. doses of rHV2 and FEIBA® compared to corresponding saline 
treatment (one-way ANOVA followed by Tukey test). In contrast to i.v. 
administration, a linear response was not seen with increasing s.c. doses, as 
monitored by Ca+ 2TT ( 10 U/ml) and indicated in Figure 28. A stronger 
increase was seen in clotting times after administration of rHV2 in all doses 
and FEIBA® compared with saline controls (one-way ANOVA followed by 
Tu key test). 
The amidolytic antithrombin assay results showed a dose dependent 
linear increase in ex vivo activity after increasing s.c. administration of rHV2, 
as depicted in Figure 29. Significant increases in thrombin inhibitory response 
was seen after rHV2 administration and saline treatments as well as between 
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Figure 25. Ex vivo antithrombin activity of rHV2 using APTT (OT), after s.c. 
administration in rabbits. rHV2 was used in doses of 0, 125, 250 and 375 
µg/kg in male, New Zealand White rabbits (n = 5). All data represent a mean 
of 5 responses each determined in duplicate ± SEM. 
*, * *- significant difference (p < 0.05) in APTT (OT) values compared 
to saline in post-drug and post-FEIBA® samples, respectively (one-way ANOVA 
followed by Tu key test). @-significant difference (p < 0.05) in APTT (OT) 
between post-drug and post-FEIBA® samples after administration of specific 
doses of rHV2 (paired t-test). 
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Figure 26. Ex vivo antithrombin activity of rHV2 using APTT (Dade), after s.c. 
administration in rabbits. rHV2 was used in doses of 0, 125, 250 and 375 
µg/kg in male, New Zealand White rabbits (n = 5). All data represent a mean 
of 5 responses each determined in duplicate ± SEM. 
**-significant difference (p < 0.05) in APTT (Dade) values compared to 
saline in post-FE I BA® samples (one-way ANOVA followed by Tu key test). 
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Figure 27. Ex vivo antithrombin activity of rHV2 using TT ( 10 U/ml), after 
s.c. administration in rabbits. rHV2 was used in doses of 0, 125, 250 and 
375 µg/kg in male, New Zealand White rabbits (n = 5). All data represent a 
mean of 5 responses each determined in duplicate ± SEM. 
*, **-significant difference (p < 0.05) in TT ( 10 U/ml) values compared 
to saline in post-drug and post-FEIBA® samples, respectively (one-way ANOVA 
followed by Tukey test). @-significant difference (p<0.05) in TT (10 U/ml) 
between post-drug and post-FEIBA® samples after saline treatment (paired t-
test). 
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Figure 28. Ex vivo antithrombin activity of rHV2 using Ca+ 2TT ( 10 U/mL), 
after s.c. administration in rabbits. rHV2 was used in doses of 0, 125, 250 
and 375 µg/kg in male, New Zealand White rabbits (n = 5). All data represent 
a mean of 5 responses each determined in duplicate ± SEM. 
*, **-significant difference (p < 0.05) in Ca+ 2TT ( 10 U/ml) values compared 
to saline in post-drug and post-FEIBA® samples, respectively (one-way 
ANOVA followed by Tu key test). 
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Figure 29. Ex vivo antithrombin activity of rHV2 using chromogenic anti-Ila 
assay, after s.c. administration in rabbits. rHV2 was used in doses of 0, 125, 
250 and 375 µg/kg in male, New Zealand White rabbits (n = 5). All data 
represent a mean of 5 responses each determined in duplicate ± SEM. 
* - significant difference (p < 0.05) in thrombin inhibitory activity 
compared to saline, 125 and 250 µg/kg rHV2 treated groups, * * - significant 
difference (p < 0.05) from saline and 125 µg/kg rHV2 groups and * * * -
significant difference (p < 0.05) from saline in post-drug samples; + -
significant difference (p < 0.05) from saline and 125 µg/kg rHV2 treated 
groups and + + - significant difference (p < 0.05) from saline treated group in 
post-FE I BA® samples (one-way ANOVA followed by Tu key test). 
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the three doses in post-drug and post-FEIBA® samples (one-way ANOVA 
followed by Tu key test). Progressively increasing, dose dependent 
antithrombin activity was observed at 125, 250 and 375 µg/kg of rHV2. A 
thrombin inhibitory activity of approximately 92 ± 4% was seen after s.c. 
administration of 375 µg/kg of rHV2 (Figure 29). 
Selection of appropriate s.c. dose for time course study. From the 
above results on in vivo clot scores and ex vivo coagulation testing and anti-
Ila assay, a dose of 375 µg/kg was chosen for time course studies in rabbits 
after s.c. administration of rHV2 using the stasis thrombosis model. The 
results from these studies are described in the following sections. 
2. Assessment of Hemorrhagic Activity of rHV2 using a Modified Rabbit 
Ear Blood Loss Model 
The hemorrhagic activity of rHV2 was studied in a modified rabbit ear 
blood loss model as described in the "Materials, Methods and Experimental 
Protocols" chapter. 
1.V. administration. A dose dependent increase in hemorrhagic activity 
was observed after i. v. administration of rHV2 in male, New Zealand White 
rabbits, as shown in Figure 30. A more linear increase in RBC loss was found 
with increasing doses after 5 minutes (r = 0.97) when compared to that after 
15 minutes (r = 0. 80). An apparent maximal bleeding response was obtained 
after administration of 1 mg/kg of rHV2 at both 5 and 15 minutes. No 
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Figure 30. Hemorrhagic effects of rHV2 in a rabbit modified ear blood loss 
model after i.v. administration. Male, New Zealand White rabbits (n = 5) were 
administered with increasing i.v. doses of 0, 0.025, 0.25, 0.5, 0. 75 1.0 and 
2.5 mg/kg and blood loss was measured at 5 and 15 minutes. All data 
represent a mean of 5 responses each determined in duplicate ± SEM. 
* - significant difference (p < 0.05) in RBC loss compared to saline, 
0.025, 0.25 and 0.5 mg/kg rHV2 treated groups at 5 minutes, * * - significant 
difference (p < 0.05) from saline, 0.025, 0.25, 0.5 and 0. 75 mg/kg rHV2 
treated groups at 15 minutes (one-way ANOVA followed by Tu key test). @ -
significant difference (p < 0.05) between RBC loss at 5 and 15 minutes at 
specific doses of rHV2 (paired t-test). 
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significant variations were found in blood loss with the administration of rHV2 
doses of up to 0.5 mg/kg, i.v., when compared with saline treated group, after 
both circulation times. It is noteworthy that there was no difference in blood 
loss between saline treatment and antithrombotic i.v. dose (0.025 mg/kg) of 
rHV2, as determined from the studies using the modified stasis thrombosis 
model, after 5 and 15 minutes. 
Significant differences (p < 0.05) were found in blood loss after 
administration of much higher doses of rHV2 (0.75, 1 and 2.5 mg/kg, i.v.) 
when compared to the responses after saline and lower rHV2 doses, using a 
one-way ANOVA followed by multiple comparison using Tukey test, as 
illustrated in Figure 30. In the linear portion of the dose response curve, 
significant decreases (p < 0.05) were found in blood loss at 15 minutes when 
compared to that at 5 minutes (0.25, 0.5 and 0. 75 mg/kg) using paired t-test. 
S.C. administration. Figure 31 depicts a similar dose dependent 
hemorrhagic activity after administration of increasing s.c. doses of rHV2. 
Linear increases in bleeding responses were obtained with increasing rHV2 
doses at time periods of 1 hour (r = 0.98) and 3 hours (r = 0.90) after 
administration. As seen in the i.v. studies, there was no variation in the 
bleeding response between saline treatment and antithrombotic s.c. dose 
(0.375 mg/kg) of rHV2, as determined from the experiments using stasis 
thrombosis model, at both 1 and 3 hours. Significant increases in RBC loss 
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Figure 31 . Hemorrhagic effects of rHV2 in a rabbit modified ear blood loss 
model after s.c. administration. Male, New Zealand White rabbits (n = 5) were 
administered with increasing s.c. doses of 0, 0.375, 1, 2.5 and 5 mg/kg and 
blood loss was measured at 1 and 3 hours. All data represent a mean of 5 
responses each determined in duplicate ± SEM. 
* - significant difference (p < 0.05) in RBC loss compared to saline, 
0.375, 1 and 2.5 mg/kg rHV2 treated groups at 1 hr, * * - significant 
difference (p < 0.05) from saline and 0.375 rHV2 treated groups at 1 hr, * * * -
significant difference (p < 0.05) from 0.375 mg/kg treated group at 1 hr, + -
significant difference (p < 0.05) from 0, 0.375 and 1 mg/kg rHV2 at 3 hrs and 
+ + - significant difference (p < 0.05) from 0 and 0.375 mg/kg doses at 3 hrs 
(one-way ANOVA followed by Tu key test). @ - significant difference 
(p < 0.05) between RBC loss at 5 and 15 minutes at specific doses of rHV2 
(paired t-test). 
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were seen after administration of 1 to 5 mg/kg doses of rHV2, when 
compared with corresponding saline- and 0.375 mg/kg dose of rHV2 treated 
groups, at 1 and 3 hours using a one-way ANOVA followed by Tukey test 
(Figure 31). 
The bleeding response at 3 hours was approximately equivalent to, or 
higher than that observed at 1 hour after administration of all s.c. doses 
except 5 mg/kg after which there was a significant decrease in RBC loss at 3 
hours (paired t-test). 
It is important to emphasize that there was no significant variation in 
blood loss after administration with experimentally determined antithrombotic 
i.v. (0.025 mg/kg) and s.c. (0.375 mg/kg) doses of rHV2 when compared with 
blood loss from saline treated control rabbits using this rabbit model for ear 
blood loss. 
3. Evaluation of Pharmacokinetics and Time Course of Antithrombotic 
Activity after rHV2 Administration in Rabbits 
After the determination of a suitable antithrombotic i.v. (25 µg/kg) and 
s.c. (375 µg/kg) dose of rHV2, a time course study of antithrombotic activity 
was performed in rabbits. The results from these experiments are described 
below. 
I. V. Administration. The time course of in vivo antithrombotic activity 
of rHV2 after i.v. administration is depicted in Figure 32. At the 10 minute 
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stasis interval, rHV2 exhibited a total, sustained antithrombotic activity up to 
almost 30 minutes, as indicated by clot scores of 0 at 5 and 15 minutes, and 
approximately 0.2 at 30 minutes. After a period of 30 minutes, the 
antithrombotic activity decreased gradually until clot scores of + 3 and + 4 
were reached at 2 and 3 hours, respectively. However, at the 20 minute 
stasis time, the antithrombotic activity decreased markedly after the first 5 
minutes. At this stasis time of 20 minutes, clot scores dropped from + 1 at 
5 minutes to + 3.6 at 15 minutes, after which a constant response of almost 
equivalent to + 4 was obtained, until 3 hours after administration of rHV2 
(Figure 32). 
In addition to in vivo antithrombotic responses, time course of ex vivo 
coagulation tests and amidolytic anti-Ila assay was also performed. The 
variations in APTT (OT) and APTT (Dade) values, with respect to time, are 
shown in Figure 33. APTT (OT) exhibited a mean peak increase from 
corresponding baseline values of a 118.67% at 3 minutes followed by a rapid 
decline to 34.07% at 5 minutes. After 5 minutes, APTT (OT) values 
fluctuated between 20% and 60% increases from baseline values until about 
1. 7 hours, after which there was no change from baseline values. APTT 
(Dade), on the other hand, showed a mean peak increase in clotting times of 
only 31.4% from baseline at 5 minutes, also shown in Figure 33. APTT 
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Figure 32. Time course of in vivo antithrombotic activity of rHV2 after i.v. 
administration (25 µg/kg). Male, New Zealand White rabbits (n = 5) were used 
in the modified jugular vein stasis thrombosis model. n = 5 rabbits were used 
for each circulation time. Clot scores were graded after a stasis time of 10 ( 
+ ) and 20 ( • ) minutes in the left and right jugular vein segments, 
respectively. All data represent the mean of 5 determinations ± SEM. 
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Figure 33. Time course of ex vivo antithrombin activity using coagulation 
tests, APTT (OT) { • } and APTT (Dade) { • }. Male, New Zealand White 
rabbits (n = 5) were administered with an i.v. dose of 25 µg/kg of rHV2. All 
data represent the mean of 5 responses ± SEM, each determined in duplicate. 
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(Dade) values varied between 0 and 20% increases from baseline for the rest 
of the time period up to 3 hours. 
The time course of Ca+ 2TT ( 10 U/ml) after i. v. administration is 
depicted in Figure 34. The decline in clotting times was rapid with a peak at 
3 minutes (9-fold increase from baseline). Almost no anticoagulant effect of 
rHV2 was observed at about 1 hour, using this assay method. 
Figure 35 depicts the time course of ex vivo thrombin inhibitory activity 
(chromogenic anti-Ila assay) after i.v. administration of rHV2. Peak thrombin 
inhibitory activity of about 85 % was obtained 3 minutes after rHV2 
administration followed by an anti-Ila activity of 75% at 5 minutes. 
Thereafter, a rapid decline in thrombin inhibitory activity was observed until 
only 10% of activity remained at 30 minutes, with almost no anti-Ila activity 
remaining after 1 hour (Figure 35). 
The pharmacokinetics of rHV2 after administration of an i. v. dose of 25 
µg/kg is illustrated in Figure 36. A maximum plasma rHV2 concentration 
(Cmax) of 0. 75 µg/ml was achieved at 3 minutes (tmaxL as measured by the 
competitive ELISA method. The rHV2 concentrations decreased rapidly after 
that, until a level of ::::::: 0.2 µg/ml was reached at 12 minutes. Thereafter, 
rHV2 concentrations remained steady between 0 and 0.2µg/ml up to 3 hours 
(Figure 36). 
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Figure 34. Time course of ex vivo antithrombin activity using Ca+ 2TT ( 10 
U/ml) assay, after i. v. administration of rHV2 (25 µg/kg). n = 5 male, New 
Zealand White rabbits were used and blood samples drawn at regular intervals. 
All data represent mean of five responses each determined in duplicate ± 
SEM. 
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Figure 35. Time course of ex vivo antithrombin activity using the chromogenic 
anti-Ila assay, after i. v. administration of rHV2 (25 µg/kg). n = 5 male, New 
Zealand White rabbits were used and blood samples drawn at regular intervals. 
All data represent mean of five responses each determined in duplicate ± 
SEM. 
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Figure 36. Pharmacokinetics of rHV2 after i.v. administration (25 µg/kg) in 
male, New Zealand White rabbits. Plasma concentrations were determined 
using competitive ELISA method. All data represent mean concentration from 
5 rabbits, each determined in duplicate ± SEM. 
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Table 7 lists the pharmacokinetic parameters obtained by non-
compartmental analysis after single dose i.v. administration and s.c. 
administration of rHV2 in rabbits. In the terminal phase after i.v. 
administration, the elimination rate constant (k8 ) and the terminal elimination 
half-life (t 112) were 0. 76 hr-1 and 0.91 hr (55 minutes), respectively. The area 
under the plasma concentration-time curve up to 3 hours (AUC0_3) was found 
to be 0.24 µg-hr/ml. This value for the AUC0_00 did not change when 
extrapolated to infinity. The area under the first moment curve up to 3 hours 
(AUMC0_3) was 0.16 µg-hr2/ml, which also remained unchanged when 
extrapolated to ex>. 
The mean residence time of rHV2 (MRT) after i.v. administration was 
0.66 hr (40 minutes), as indicated in Table 7. The total clearance rate (Cltot) 
of rHV2 in rabbits was found to be 104 ml/hr/kg. The volume of distribution 
(V d) was 137 ml/kg (Table 7). 
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TABLE 7 
PHARMACOKINETIC PARAMETERS OBTAINED AFTER SINGLE DOSE 1.V. 
(25 µg/kg) AND S.C. (375 µg/kg) ADMINISTRATION OF rHV2 IN RABBITS 
Parameter 1.V.Dosing S.C.Dosing 
Cmax (µg/mL) 0.75 0.38 
tmax (min) 3.00 220.00 
k
8 
(hr-1) 0.76 1.78 
t 112 (hr) 0.91 0.39 
AUC0_00 (µg-hr/mL) 0.24 1.61 
AUMC0_00 (µg-hr2/mL) 0.16 5.49 
MRT (hr) 0.66 3.41 
Cltot (ml/hr/kg) 104.17 104.16 
V d (ml/kg) 137.07 58.52 
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Integration of pharmacokinetics with pharmacodynamics of rHV2 after 
i.v. administration. A correlation analysis was performed between plasma 
rHV2 concentrations determined by the ELISA method and ex vivo 
antithrombotic activity. Figure 37 describes this relationship in the form of a 
sigmoidal curve. Clot scores obtained at the 10 minute stasis interval were 
plotted against plasma rHV2 concentrations obtained at the corresponding 
circulation time of rHV2. At very low rHV2 concentrations, little or no 
antithrombotic activity was obtained (clot scores of + 3 and 3.4 at 2 and 3 
hours, respectively). As the rHV2 concentrations increased in plasma, 
stronger antithrombotic activity was obtained, until total prevention of 
thrombosis occurred at 0.25 µg/ml (Figure 37). In the linear portion of the 
curve, a significant negative correlation was obtained between available 
plasma concentrations and antithrombotic activity (Pearson correlation 
coefficient, r =-0.93). 
Figure 38 depicts the relationship between plasma concentrations 
obtained after i. v. administration of rHV2 and corresponding ex vivo 
antithrombin activity determined from coagulation tests and chromogenic 
substrate assay. The most significant correlation between indirect 
pharmacodynamics and direct pharmacokinetics of rHV2 was obtained with 
the chromogenic substrate assay (r = 0.94). The results from APTT (OT) and 
APTT (Dade) coagulation tests correlated poorly with corresponding plasma 
concentrations with r = 0.81 and r = 0. 77, respectively. A significant 
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Figure 37. Correlation between plasma concentrations of rHV2 and in vivo 
antithrombotic activity of rHV2 after i.v. administration in rabbits. rHV2 was 
administered in a dose of 25 µg/kg in male, New Zealand White rabbits and 
clot scores were graded. Numbers in parentheses indicate circulation time of 
rHV2 in hours (h) or minutes (m). All data represent a mean of 5 
determinations ± SEM. 
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Figure 38. Relationship between plasma concentrations of rHV2 and ex vivo 
antithrombin activity, after i.v. administration in rabbits. Male, New Zealand 
White rabbits (n = 5) were administered with an i.v. dose 25 µg/kg of rHV2. 
The tests performed include APTT (OT) { • }, APTT (Dade) { • } and 
chromogenic substrate assay { • }. All data represent the mean of 5 
determinations ± SEM, each determined in duplicate. 
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correlation (r = 0.87) was obtained between Ca+ 2TT ( 10 U/ml) and 
corresponding plasma rHV2 concentrations (Figure 39). 
S.C. Administration. rHV2 was used at a dose of 375 µg/kg to 
determine the time course of antithrombotic activity after s.c. administration. 
The changes in in vivo antithrombotic activity with respect to time after s.c. 
administration of rHV2 are illustrated in Figure 40. At the 10 minute stasis 
time, a complete inhibition of clot formation was obtained almost throughout 
the time period up to 6 hours, as illustrated by clot scores of 0 to + 0.5. A 
mean clot score of about + 2.5 was obtained at 9 hours. On the other hand, 
when stasis was performed for 20 minutes, a "U" shaped curve was obtained 
exhibiting peak antithrombotic activity at 2 hours (clot score of almost 0). 
There was a steady progressive increase in antithrombotic activity of rHV2 up 
to 2 hours, after which the activity dropped markedly to clot score of + 2.8 
at 2.5 hours. Thereafter, the clot scores gradually increased to approximately 
+3.5 (Figure 40). 
Figure 41 illustrates the time course of results from ex vivo coagulation 
tests, APTT (OT) and APTT (Dade). A 50% increase in clotting time was seen 
using APTT (Dade) about 30 minutes after drug administration, after which the 
responses fluctuated between 0 and 40% increases from baseline without 
exhibiting any time dependency. On the other hand, APTT (OT) showed a 
distinct peak in clotting time at 4 hours after rHV2 administration. Initially, 
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Figure 39. Correlation between ~lasma concentrations of rHV2 and ex vivo 
antithrombin activity using Ca+ TT ( 10 U/ml), after i. v. administration in 
rabbits. Male, New Zealand White rabbits (n = 5) were administered with an 
i.v. dose 25 µg/kg of rHV2. All data represent the mean of 5 determinations 
± SEM, each determined in duplicate. 
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Figure 40. Time course of in vivo antithrombotic activity of rHV2 after s.c. 
administration in rabbits. rHV2 was administered in a s.c. dose of 375 µg/kg 
in male, New Zealand White rabbits (n = 5 per circulation time). Clot scores 
were graded after stasis for 10 and 20 minutes in the left and right jugular 
vein segments, respectively. All data are mean responses from 5 rabbits, each 
determined in duplicate ± SEM. 
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Figure 41. Time course of ex vivo antithrombin activity of rHV2 after s.c. 
administration in rabbits. Figure depicts results from coagulation tests: APTT 
(OT) { D } and APTT (Dade) { 0 }. All data represent mean response from 
5 rabbits, each determined in duplicate ± SEM. 
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APTT (OT) values fluctuated between 0 and 70% increases from 
corresponding baseline values up to 3 hours, after which the responses 
increased progressively until a peak was reached at 4 hours, as shown in 
Figure 41 . After 4 hours, APTT (OT) values declined rapidly until steady state 
levels were reached. 
The time course of ex vivo clotting time using Ca+ 2TT ( 1 O U/ml) is 
depicted in Figure 42. Thirty minutes after rHV2 administration, Ca+ 2TT 
values increased progressively up to about a 21-fold increase from 
corresponding baseline values. During the period between 30 minutes and 4 
hours, the Ca+ 2TT values fluctuated between 10- and 21-fold increases from 
baseline values. After 4 hours, the responses dropped steadily to baseline 
values. 
The changes in ex vivo antithrombin activity measured using 
chromogenic substrate assay, with respect to time is shown in Figure 43. 
After s.c. administration of rHV2, the thrombin inhibitory activity of this agent 
increased steadily with increases in circulation time of rHV2 until an anti-Ila 
activity of about 82% was reached at 1 hour. The anti-Ila activity remained 
constant between 80 and 90% between the time period of 1 to 4 hours. 
Thereafter, the responses decreased rapidly until no anti-Ila activity remained 
at 7.5 hours (Figure 43). 
The pharmacokinetics of rHV2 after s.c. administration of 375 µg/kg of 
rHV2 is described in Figure 44. Plasma concentrations of rHV2 were 
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Figure 42. Time course of ex vivo antithrombin activity of rHV2 using 
ca+ 2TT (10 U/mL), after s.c. administration in rabbits. Male, New Zealand 
White rabbits (n = 5) were subcutaneously administered with 375 µg/kg of 
rHV2. All data represent the mean response from 5 rabbits, each determined 
in duplicate, ± SEM. 
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Figure 43. Time course of ex vivo antithrombin activity of rHV2 using 
chromogenic anti-Ila assay, after s.c. administration in rabbits. Male, New 
Zealand White rabbits (n = 5) were subcutaneously administered with 375 
µg/kg of rHV2. All data represent the mean response from 5 rabbits, each 
determined in duplicate, ± SEM. 
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Figure 44. Pharmacokinetics of rHV2 after s.c. administration in rabbits. 
Male, New Zealand White rabbits (n = 5) were administered with 375 µg/kg of 
rHV2. Plasma rHV2 concentrations were determined using a competitive 
ELISA method. All data represent the mean of concentrations from five 
rabbits, each determined in duplicate ± SEM. 
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determined by the competitive ELISA method, as described previously. An 
absorption phase, a peak and an apparent terminal elimination phase were 
observed in the plasma rHV2 concentration-time curve. A peak rHV2 
concentration (Cmax) of = 0.38 µg/ml was obtained at 220 minutes (tmax) 
after rHV2 administration. After the peak, rHV2 concentrations decreased 
steadily until a very low concentration ( = 0.05 µg/ml) was found at 7.5 
hours. 
The pharmacokinetic parameters obtained after s.c. administration of 
375 µg/kg of rHV2 are listed in Table 7. The Cmax obtained (0.38 µg-hr/ml) 
was only about half of that obtained after i.v. administration. Once the peak 
was reached, the elimination rate (ke) of rHV2 was fast at 1. 78 hr-1. The 
terminal elimination half-life (t112) was found to be 0.39 hr (23.40 minutes) 
which was less than half of that obtained after i.v. administration. The areas 
under the plasma concentration-time curve (AUC0_00 ) and first moment curve 
(AUMC0_00 ) were found to be 1.61 µg-hr/ml and 5.49 µg-hr2/ml, 
respectively. 
After s.c. administration, the mean residence time (MRT) of rHV2 was 
3.4 hours which was about 5 times that obtained after i.v. administration, as 
shown in Table 7. The total clearance rate (Cltot) after s.c. administration was 
almost identical to that obtained after i.v. administration, i.e. 104 ml/hr/kg. 
The apparent volume of distribution (V d) was about half of that obtained after 
i.v. administration i.e. 58 ml/kg. The relative bioavailability (F) after s.c. 
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administration was found be 44. 72%, when compared to i.v. administration. 
Integration of pharmacokinetics with pharmacodynamics of rHV2 after 
s.c. administration. A correlation analysis of plasma rHV2 concentrations 
determined from the ELISA method and results from in vivo and ex vivo 
assay methods was performed. After s.c. administration, the clot scores 
obtained using the jugular vein stasis thrombosis model were plotted against 
plasma rHV2 concentrations obtained at specific circulation times of rHV2. 
This relationship is illustrated in Figure 45, with arrow heads pointing toward 
the direction of increasing circulation times of rHV2. At 0.5 hr (and rHV2 
concentration of 0.24 µg/ml) the clot score was + 2.4 which decreased to 
+ 1.2 and + 0.2 at 1 hour (rHV2 level of 0.27 µg/ml) and 2 hours (rHV2 level 
of 0.3 µg/ml) after rHV2 administration, respectively. Hence, peak 
antithrombotic activity was obtained at 2 hours at a plasma concentration of 
0.3 µg/ml of rHV2, as shown in Figure 45. After 2 hours, the antithrombotic 
activity decreased markedly to a clot score of + 2.8 at 2.5 and 3 hours (rHV2 
level of 0.26 µg/ml). It was interesting to note that at 4 hours, a clot score 
of + 3.2 was obtained even though the plasma concentration was at its 
apparent peak, i.e. 3.8 µg/ml. After 4 hours, the antithrombotic activity 
decreased progressively with clot scores of + 3.4 and + 3.6 at 6 and 9 hours, 
respectively. 
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Figure 45. Relationship between plasma concentrations of rHV2 and in vivo 
anti-thrombotic activity using modified jugular vein stasis thrombosis model. 
Male, New Zealand White rabbits (n = 5) were subcutaneously administered 
with 375 µg/kg of rHV2. Numbers in parentheses indicate circulation time of 
rHV2 in hours (h). Arrow heads point toward direction of increasing 
circulation times of rHV2. 
All data represent the mean response from 5 rabbits, each determined 
in duplicate, ± SEM. 
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The relationship between the results from coagulation tests, APTT(OT) 
and APTT (Dade) with plasma rHV2 concentrations is shown in Figure 46. 
Relatively poor correlations were obtained between APTT (OT) and APTT 
(Dade) values and corresponding plasma concentrations, as shown by 
correlation coefficient values of 0.60 and 0.19, respectively. On the other 
hand, the results from Ca + 2n (10 U/ml) correlated better with ex vivo 
plasma rHV2 concentrations (r = 0. 73), though not as significant as that 
obtained after i. v. administration (Figure 4 7). Figure 48 illustrates the 
relationship between the results from the ex vivo chromogenic anti-Ila assay 
and those from the ELISA method. The most significant correlation after s.c. 
administration of rHV2 was obtained with this assay (r = 0.89). 
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Figure 46. Relationship between plasma concentrations of rHV2 and 
coagulation tests, APTT (OT) { D } and APTT (Dade) { 0 } after s.c. 
administration. Male, New Zealand White rabbits (n = 5) were administered 
with 375 µg/kg of rHV2. All data represent the mean response from 5 rabbits, 
each determined in duplicate, ± SEM. 
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Figure 47. Correlation between plasma concentrations of rHV2 and coagula-
tion test, Ca +2rr (10 U/ml) after s.c. administration. Male, New Zealand 
White rabbits (n = 5) were administered with 375 µg/kg of rHV2. All data 
represent the mean response from 5 rabbits, each determined in duplicate, ± 
SEM. 
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Figure 48. Correlation between plasma concentrations of rHV2 and ex vivo 
anti-thrombin activity using chromogenic anti-Ila assay, after s.c. administra-
tion of rHV2. Male, New Zealand White rabbits (n = 5) were subcutaneously 
administered with 375 µg/kg of rHV2. All data represent the mean response 
from 5 rabbits, each determined in duplicate, ± SEM. 
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4. Determination of Pharmacokinetic Characteristics and Ex Vivo 
Antithrombin Activity of rHV2 in Rats 
The pharmacokinetics of rHV2 was studied in rats after administration 
of increasing i.v. and s.c. doses, as described in the chapter on "Materials, 
Methods and Experimental Protocols". 
l.V. Administration. rHV2 was administered in i.v. doses of 0.1, 0.4 
and 0.5 mg/kg in male, Sprague-Dawley rats (n = 8 per treatment group and 
per time schedule, composite data) via the tail vein. Plasma concentrations 
of rHV2 at specified time points were determined using the competitive ELISA 
method. Figure 49 depicts the composite plasma concentration-time curve 
after i. v. administration of rHV2 in rats. A dose dependent increase in plasma 
rHV2 concentrations was observed with increasing rHV2 doses. After 
administration of each dose, rHV2 distributed quickly, after which there was 
a more gradual decline in plasma concentrations reaching almost zero within 
the first 45 minutes. 
Table 8 lists the pharmacokinetic parameters after administration of 
each dose, as determined by non-compartmental analysis. The time (tmax) 
to reach maximum plasma concentration (Cmax) was 3 minutes after each 
dose. The Cm ax values were ::::: 187, 579 and 821 ng/ml after administration 
of 0.1, 0.4 and 0.5 mg/kg doses, respectively (Table 8, Figure 49). A dose 
dependent increase in area under the plasma concentration-time curve values 
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Figure 49. Pharmacokinetics of rHV2 after i.v. administration of increasing 
doses in rats. Male, Sprague-Dawley rats were administered with i.v. doses 
of 0.1 ( + ), 0.4 ( D ) and 0.5 ( • ) mg/kg of rHV2 via tail vein. n = 8 rats 
were used in each treatment group. Plasma rHV2 concentrations were 
determined by competitive ELISA method. All data represent mean 
concentration from 8 rats ± SEM, each determined in duplicate. 
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(AUC0_00 ) was observed, i.e. = 47, 134, and 165 ng-hr/ml, with increasing 
rHV2 doses. The areas under the first moment curves (AUMC0_00 ) were 
approximately 36, 78 and 162 ng-hr2/ml, respectively. 
The mean residence times (MRT) were approximately 0. 78, 0.59 and 
0.98 hr after i.v. administration of 0.1, 0.4 and 0.5 mg/kg doses of rHV2, 
respectively, as listed in Table 8. No major variations were found in the 
terminal elimination rate constant (ke) values between the three doses (2.28, 
1.8 and 1.7 hr.-1, respectively). Similarly, no major differences were found 
in the terminal elimination half-lives (t 112) after increasing doses. The t 112 
values obtained were approximately 0.3, 0.39 and 0.42 hr, translating to 18, 
23 and 25 minutes, respectively, after increasing i.v. doses of rHV2. 
Both total clearance (Cltot) rates, as well as volume of distribution (V d) 
values did not vary with increasing i.v. doses of rHV2. Cltot rates of 2.15, 
3.0 and 3.0 L/hr/kg were obtained after administration of 0.1, 0.4 and 0.5 
mg/kg, respectively. The volume of distribution (V d) values were 0.941, 1. 7 
and 1.8 L/kg, respectively, with corresponding escalating doses of rHV2 
(Table 8). 
A time course analysis of ex vivo antithrombin activity using the 
amidolytic anti-Ila activity was also performed in conjunction with 
pharmacokinetics of rHV2 in rats. Figure 50 shows the time course of 
thrombin inhibitory activity of rHV2 in rats after i.v. administration of 0.1, 0.4 
and 0.5 mg/kg. Peak thrombin inhibitory activities were obtained at 3 min. 
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TABLE 8 
PHARMACOKINETIC PARAMETERS OBTAINED AFTER SINGLE DOSE 
l.V. (0.1, 0.4 and 0.5 mg/kg) ADMINISTRATION OF rHV2 IN RATS 
Parameter 0.1 mg/kg 0.4 mg/kg 0.5 mg/kg 
Cm ax 187.03 578.88 820.56 (ng/mL) 
tmax 3.00 3.00 3.00 (min) 
ke ( h r- 1 ) 2.28 1.79 1.66 
t1/2 0.30 0.39 0.42 (hr) 
AUC0_00 46.60 133.83 164.70 (ng-hr/mL) 
AUMC 00 (ng-hr2}~nL) 36.35 78.32 162.26 
MRT 0.78 0.59 0.98 (hr) 
Cl tot 2145.80 2988.00 3030.00 (ml/hr/kg) 
vd 941.00 1669.00 1825.00 {ml/kg) 
160 
after administration of all three rHV2 doses. The maximum antithrombin 
effect observed was approximately 52, 81 and 97% after i. v. injection of 0.1, 
0.4 and 0.5 mg/kg of rHV2. Hence, the antithrombin activity increased 
proportionally with increases in i.v. dose of rHV2. 
The time course of ex vivo antithrombin activity closely followed the 
pharmacokinetics of rHV2 in rats. After each dose, the thrombin inhibitory 
activity declined quickly with very little residual activity after = 45 minutes 
(Figure 50). The progression of antithrombin activity with time was related 
to the plasma concentrations of rHV2 obtained using the competitive ELISA 
method, after each i.v. dose of rHV2. The correlation coefficients were 
significant: 0.96, 0.96 and 0.90 for 0.1, 0.4 and 0.5 mg/kg dosages of rHV2, 
respectively. 
S.C. Administration. rHV2 was administered in s.c. doses of 0.1, 0.5 
and 1 .0 mg/kg in the abdominal area of male, Sprague-Dawley rats, as 
described in the chapter on "Materials, Methods and Experimental protocols". 
n = 8 rats were used per treatment group and time schedule (composite data). 
Figure 51 illustrates the plasma concentration-time curve after s.c. 
administration of rHV2 in rats. rHV2 was absorbed within the first 1 to 1.25 
hours after administration of each dose. After the peak, rHV2 concentrations 
declined progressively as shown in Figure 51 . Plasma concentrations 
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Figure 50. Time course of ex vivo antithrombin activity (chromogenic anti-Ila 
assay) of rHV2 in rats after i.v. administration. Male, Sprague-Dawley rats 
were administered with i.v. doses of 0.1 ( + ), 0.4 ( D ) and 0.5 ( • ) 
mg/kg of rHV2 via tail vein. n =8 rats were used in each treatment group. 
All data represent mean concentration from 8 rats ± SEM, each determined 
in duplicate. 
obtained after each dose were proportional to the magnitude of the 
administered dose. 
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Table 9 lists the pharmacokinetic parameters after s.c. administration 
of rHV2 in rats. A tmax value of 1.25 hrs was obtained after administration 
of 0.1 and 0.5 mg/kg rHV2 doses, and that of 1 hr was obtained after 
administration of 1.0 mg/kg of rHV2. The peak plasma concentrations (Cmax) 
increased linearly with increasing doses. The Cmax values obtained were 
approximated to be 43, 272 and 547 ng/mL after administration of 0.1, 0.5 
and 1 .0 mg/kg, respectively. Similarly, dose dependent increases were 
observed in AUC0_00 and AUMC0_00 values. AUC0_00 values obtained were = 
79, 581 and 1146 ng-hr/mL after administration of 0.1, 0.5 and 1.0 mg/kg 
rHV2 doses, respectively, as shown in Table 9. AUMC0_00 values obtained 
were 112, 989 and 1947 ng-hr2/ ml, for the corresponding doses. 
The MRTs were calculated to be equal to 1.43, 1. 70 and 1. 70 hrs for 
the 0.1, 0.5 and 1.0 mg/kg doses, respectively (Table 9). There were no 
major differences between the three doses in k8 or t 112 values. The k8 values 
were 0.98, 1.02 and 1.15 hr-1 which corresponded to t 112 values of 
approximately 0. 71, 0.68 and 0.60 hr (or 42, 41 and 36 minutes), 
respectively. 
As depicted in Table 9, there were no major fluctuations in both Cltot 
rates as well as apparent V d' after administration of increasing s.c. doses of 
rHV2. The Cltot rates were = 255, 298 and 320 ml/kg/hr after 
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Figure 51. Pharmacokinetics of rHV2 after s.c. administration of increasing 
doses in rats. Male, Sprague-Dawley rats were administered with s.c .. doses 
of 0.1 ( + ), 0.5 ( D ) and 1.0 ( • ) mg/kg of rHV2 in the abdominal area. 
n = 8 rats were used in each treatment group. Plasma rHV2 concentrations 
were determined by competitive ELISA method. All data represent mean 
concentration from 8 rats ± SEM, each determined in duplicate. 
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TABLE 9 
PHARMACOKINETIC PARAMETERS OBTAINED AFTER SINGLE DOSE 
S.C. (0.1, 0.5 and 1.0 mg/kg) ADMINISTRATION OF rHV2 IN RATS 
Parameter 0.1 mg/kg 0.5 mg/kg 1.0 mg/kg 
Cm ax 43.41 272.51 546.77 (ng/mL) 
tmax 1.25 1.25 1.00 (hr) 
ke (hr-1) 0.98 1.02 1.15 
t1/2 0.71 0.68 0.60 (hr) 
AUC0_00 79.18 581.18 1146.54 (ng-hr/mL) 
AUMC 00 (ng-hrl}~L) 112.84 989.21 1947.17 
MRT 1.43 1.70 1.70 (hr) 
Cl tot 255.11 298.54 320.09 (ml/kg/hr) 
vd 111.89 162.19 167.67 (ml/kg) 
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administration of 0.1, 0.5 and 1.0 mg/kg doses of rHV2. The corresponding 
apparent V d values obtained were 112, 162 and 168 ml/kg, respectively. 
The time course of ex vivo antithrombin activity was also studied after 
s.c. administration of rHV2, using the chromogenic anti-Ila assay. This 
progression after administration of all three s.c. doses of rHV2 is depicted in 
Figure 52. A dose dependent increase in thrombin inhibitory activity was 
observed after administration of each increasing dose of rHV2. Peak anti-Ila 
activity of approximately 16, 41 and 85% was observed at 1.5, 0.5 and 0.5 
hrs after administration of 0.1, 0.5 and 1.0 mg/kg of rHV2, respectively. 
The curves for the time course of ex vivo anti-Ila activity after s.c. 
administration (Figure 52), and the pharmacokinetic curves after s.c. 
administration (Figure 51) were similar. This was reflected by the significant 
correlation coefficients of 0.90 and 0.97 using the higher two dosages of 
rHV2, when the antithrombin activity was correlated with corresponding 
plasma rHV2 concentrations. In comparison, the correlation after the lowest 
dose, i.e. 0.1 mg/kg, s.c., was poor (r = 0. 78). 
5. Evaluation of Renal Function after rHV2 Administration in Rats 
A single dose 3H-inulin clearance study was performed to evaluate 
renal function after i.v. and s.c. administration of rHV2 in rats. rHV2 was 
used in an i.v. dose of 0.5 mg/kg and s.c. dose of 1.0 mg/kg. 24 hours after 
rHV2 administration, 3H-inulin was injected intravenously at a dose of 10 µCi 
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Figure 52. Time course of ex vivo antithrombin activity (chromogenic anti-Ila 
assay) of rHV2 in rats after s.c. administration. Male, Sprague-Dawley rats 
were administered with s.c .. doses of 0.1 ( + ), 0.5 ( D ) and 1.0 ( • ) 
mg/kg of rHV2 in the abdominal area. n = 8 rats were used in each treatment 
group. All data represent mean concentration from 8 rats ± SEM, each 
determined in duplicate. 
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per rat. 
Figure 53 illustrates the disposition of 3H-inulin in rats after i. v. and 
s.c. administration of rHV2, along with appropriate saline treated controls. 
The dpm/ml obtained in each sample using a liquid scintillation counter were 
converted to µCi/ml and plotted on a log scale vs. circulation time of 3H-
inulin. Table 10 lists the corresponding dispositional parameters of 3H-inulin, 
using non-compartmental methods. The dispositional curves of 3H-inulin after 
rHV2 and corresponding saline treatment (i.v. or s.c.) were closely parallel to 
one other, as shown in Figure 53. 
The rate of 3H-inulin clearance (Clin) was calculated in each rHV2 
treated group and compared with corresponding saline treated group. Clin 
was calculated using the formula, Dose/AUC0_00 • Clin was equal to 1.30 ± 
0.11 ml/min/1 OOg body weight (saline) vs. 1.10 ± 0.13 ml/min/1 OOg body 
weight (rHV2) after i. v. administration, and 1 .46 ± 0.12 ml/min/1 OOg body 
weight (saline) vs. 1.36 ± 0.14 ml/min/1 OOg body weight (rHV2) after s.c. 
administration (Table 10). There were no significant differences in Clin values 
between all four treatments (p = 0.132, one-way ANOVA). The calculated 
Clin values closely matched the reported value for glomerular filtration rate 
(GFR) of 1.02 ml/min/1 OOg body weight in rats (Ringler and Dabich, 1979). 
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TIME (post 3 H-INULIN, minutes) 
Figure 53. Plasma concentration-time curve of 3H-inulin in rats pretreated 
with rHV2 compared with saline treated controls. Male, Sprague-Dawley rats 
were pretreated with i.v. bolus (0.5 mg/kg) or s.c. (1.0 mg/kg) of rHV2 along 
with saline treated controls. At 24 hours, a single dose 3H-inulin ( 10 µCi) 
clearance study was performed. 
Symbols indicate i.v. saline ( 0), i.v. rHV2 ( •), s.c. saline ( V) and 
s.c. rHV2 ( T ) administration. All data represent the mean concentration in 
8 rats, each determined in triplicate, ± SEM. 
TABLE 10 
DISPOSITIONAL PARAMETERS OBTAINED IN 3H-INULIN 
CLEARANCE STUDIES IN RATS 
Parameter Saline, rHV2, Saline, rHV2, 
i.v. i.v. s.c. s.c. 
Clin 1.30 1.10 1.46 1.36 
(ml/min/1 OOg) ± 0.11 ± 0.13 ± 0.12 ± 0.14 
No significant differences in Clin between treatment groups (one-way 
ANOV A). All data represent the mean of individual parameters from 8 
rats ± SEM. 
5a. Serum Chemistry Profile in Rats after Administration of rHV2 
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Male, Sprague-Dawley rats (n = 8 per treatment group) were 
administered with 0.5 mg/kg and 1.0 mg/kg of rHV2 via i.v. and s.c. routes, 
respectively. Serum chemistry parameters were determined prior to (baseline) 
and 24 hours after treatment with rHV2, and compared with saline treated 
control groups. 
1.V. Administration. The results from serum chemistry tests after i.v. 
administration of rHV2 are listed in Tables 11 and 12. rHV2 treatment led to 
a significant decrease in triglyceride level at 24 hours (66 ± 8 mg/dL) from 
corresponding baseline value ( 116 ± 18 mg/dL) {p < 0.05, paired t-test, Table 
11 }. In the saline treated groups, a significant decrease was found in 
170 
TABLE 11 
SERUM CHEMISTRY PROFILE IN RATS AFTER l.V. 
ADMINISTRATION (0.5 mg/kg) OF rHV2 (part I) 
Test Saline Treatment (iv) rHV2 Treatment (iv) Baseline 24 hours Baseline 24 hours 
ALB 2.5 2.4 2.6 2.4 
(g/dL) ± 0.1 ± 0.1 ± 0.1 ± 0.1 
T PROT 6.3 6.1 6.3 6.2 
(g/dL) ± 0.2 ± 0.1 ± 0.1 ± 0.0 
T BIL 0.2 0.3 0.3 0.2 
(mg/dL) ± 0.0 ± 0.0 ± 0.1 ± 0.0 
ALP 178 161 199 194 
(IU/L) ± 8 ± 9 ± 14 ± 13 
AST 142 125 120 99 
(IU/L) ± 16 ± 11 ± 9 ± 8 
ALT 57 50 58 60 
(IU/L) ± 3 ± 3 ± 3 ± 3 
y-GT 1.4 ** 0.5 1.0 0.3 
(IU/L) ± 0.8 ± 0.2 ± 0.5 ± 0.3 
CHOL 87 86 95 95 
(mg/dL) ± 5 ± 6 ±4 ± 3 
* * TRIG 130 75 116 66 
(mg/dL) ± 10 ± 7 ± 18 ± 8 
GLU 137 127 138 125 
(mg/dL) ± 15 ± 7 ± 8 ± 7 
*-p < 0.05, * *-p < 0.10 - significant difference from corresponding 
baseline (paired t-test). All data represent the mean observation from 
6 to 8 rats ± SEM. See List of Abbreviations for explanation of 
terms. 
Test 
LDH 
(IU/L) 
BUN 
(mg/dL) 
CREAT 
(mg/dL) 
U ACID 
(mg/dL) 
Na+ 
(mmol/L) 
K+ 
(mmol/L) 
er 
(mmol/L) 
C02 (mmol/L) 
ca+ 2 
(mg/dL) 
PHOS 
(mg/dL) 
TABLE 12 
SERUM CHEMISTRY PROFILE IN RATS AFTER 1.V. 
ADMINISTRATION (0.5 mg/kg) OF rHV2 (part II) 
Saline Treatment (iv) rHV2 Treatment (iv) 
Baseline 24 hours Baseline 24 hours 
2363 
± 531 
21 
± 2 
0.7 
± 0.1 
1.6 
± 0.2 
145 
± 1 
6.4 
± 0.3 
102 
± 1 
22 
± 2 
10.5 
± 0.2 
9.3 
± 0.9 
* * 1925 
± 259 
20 
± 1 
0.6 
± 0.1 
1.4 
± 0.1 
147 
± 1 
6.0 
± 0.1 
103 
± 1 
24 
± 1 
10.4 
± 0.1 
9.0 
± 0.3 
1501 
± 269 
21 
± 1 
0.6 
± 0.0 
1.4 
± 0.1 
146 
± 11 
5.3 
± 0.3 
94 
±4 
22 
± 1 
10.4 
± 0.1 
8.3 
± 0.3 
1693 
± 445 
20 
± 1 
0.5 
± 0.1 
1.3 
± 0.1 
134 
± 8 
5.3 
± 0.4 
92 
± 6 
10.4 
± 0.1 
8.5 
± 0.2 
*-p < 0.05, * *-p < 0.10 - significant difference from corresponding 
baseline (paired t-test). All data represent the mean observation from 
6 to 8 rats ± SEM. See List of Abbreviations for explanation of 
terms. 
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triglyceride (TRIG), lactic dehydrogenase (LDH) and gamma-glutamyl 
transferase (y-GT) levels at 24 hours when compared with baseline levels 
(Tables 11 and 12) {paired t-test}. There was a significant increase in total 
carbon dioxide (C02) levels in rHV2 treated groups at 24 hours (27 ± 1 
mmol/L) when compared with corresponding baseline value (22 ± 1 mmol/L) 
{p < 0.05, paired t-test, Table 12}. However, there was no significant change 
in co2 level between saline treatment and rHV2 treatment (independent t-
test) at baseline and 24 hours. 
It is interesting to note that no significant differences were seen in 
most serum chemistry parameters between saline and rHV2 treated groups 
both at baseline and 24 hours (independent t-test) after i.v. administration of 
rHV2. 
S.C. Administration. The serum chemistry parameters obtained before 
and after s.c. administration (1.0 mg/kg) of rHV2 are listed in Tables 13 and 
14. As observed with the i. v. administration, there was a significant 
decrease in triglyceride level at 24 hours (74 ± 8 mg/dl) after rHV2 
administration, when compared with corresponding baseline (126 ± 11 
mg/dl) {p < 0.05, paired t-test, Table 13}. A significant decrease in LDH level 
was observed at 24 hours ( 1546 ± 251 IU/L) after rHV2 administration when 
compared with corresponding baseline (2279 ± 350 IU/L) {p<0.05, paired 
t-test, Table 14}. 
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TABLE 13 
SERUM CHEMISTRY PROFILE IN RATS AFTER S.C. 
ADMINISTRATION (1.0 mg/kg) OF rHV2 (part I) 
Test Saline Treatment (sc) rHV2 Treatment (sc) 
Baseline 24 hours Baseline 24 hours 
ALB 2.4 *2.6 2.4 2.4 
{g/dL) ± 0.1 ± 0.1 ± 0.1 ± 0.1 
T PROT 6.0 6.3 6.1 6.0 
{g/dL) ± 0.1 ± 0.2 ± 0.2 ± 0.1 
T BIL 0.3 0.2 0.3 0.2 
(mg/dL) ± 0.0 ± 0.0 ± 0.0 ± 0.1 
ALP 200 181 205 187 
(IU/L) ± 11 ± 7 ± 14 ± 12 
AST 107 146 127 117 
(IU/L) ± 13 ± 32 ± 9 ± 9 
ALT 53 58 53 50 
(IU/L) ± 8 ± 14 ± 2 ± 3 
y-GT 1.8 1.3 1.4 1 .1 
(IU/L) ± 0.7 ± 0.5 ± 0.5 ± 0.5 
CHOL 93 97 91 97 
(mg/dL) ± 7 ± 7 ± 6 ± 8 
TRIG 114 92 126 *74 
(mg/dL) ± 11 ± 9 ± 11 ± 8 
GLU 154 146 131 132 
(mg/dL) ± 6 ± 8 ±4 ± 13 
*-p < 0.05 - significant difference from corresponding baseline (paired 
t-test). All data represent the mean observation from 6 to 8 rats ± 
SEM. See List of Abbreviations for explanation of terms. 
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TABLE 14 
SERUM CHEMISTRY PROFILE IN RATS AFTER S.C. 
ADMINISTRATION ( 1 .0 mg/kg) OF rHV2 (part II) 
Test Saline Treatment (sc) rHV2 Treatment (sc) 
Baseline 24 hours Baseline 24 hours 
LOH 1281 1680 2279 *1546 
(IU/L) ± 209 ± 415 ~ 350 ± 251 
BUN 19 22 21 22 
(mg/dL) ± 2 ± 2 ± 1 ± 1 
CREAT 0.6 0.6 0.7 0.6 
(mg/dL) ± 0.1 ± 0.0 ± 0.1 ± 0.0 
U ACID 1.3 1.4 1.6 1.3 
(mg/dL) ± 0.1 ± 0.1 ± 0.1 ± 0.1 
Na+ 144 151 146 142 
(mmol/L) ± 1 ± 5 ±0 ±4 
K+ 6.0 5.9 5.9 5.4 
(mmol/L) ± 0.3 ± 0.3 ± 0.2 ± 0.2 
er 102 106 101 99 
(mmol/L) ± 1 ± 3 ±0 ± 3 
C02 20 22 24 23 (mmol/L) ± 2 ± 2 ± 1 ± 1 
ca+ 2 10.0 10.7 10.4 10.3 
(mg/dL) ± 0.6 ± 0.3 ± 0.2 ± 0.1 
PHOS 8.2 8.7 8.7 8.6 
(mg/dL) ± 0.6 ± 0.1 ± 0.3 ± 0.2 
*-p < 0.05 - significant difference from corresponding baseline (paired 
t-test). All data represent the mean observation from 6 to 8 rats ± 
SEM. See List of Abbreviations for explanation of terms. 
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No significant differences were found in most serum chemistry 
parameters between saline and rHV2 treatments both at baseline and 24 
hours (independent t-test). 
5b. Hematological Profile in Rats after Administration of rHV2 
l.V. Administration. Table 15 lists the hematological parameters prior 
to, and after (24 hours) i.v. dosing (0.5 mg/kg) of rHV2 in rats when 
compared with saline treatment. A slight, yet significant (p < 0.1, paired t-
test) decrease in RBC count, hemoglobin (HGB) level and hematocrit (HCT) 
was observed at 24 hours after saline treatment, when compared with 
corresponding baseline. A significant decrease was also noted in the above 
parameters at 24 hours after rHV2 treatment, when compared to 
corresponding baseline (Table 15). In the rHV2 treated group, a significant 
decrease was seen at 24 hours in platelet count (818 ± 34 x 1 o3 /µL) 
compared to baseline (925 ± 27 x 103/µL) {p<0.05, paired t-test}. No 
significant changes were seen in most hematological markers between saline 
and rHV2 treatments at both baseline and 24 hours, as shown in Table 15 
(independent t-test). 
S.C. Administration. The hematological profile after s.c. rHV2 
treatment (1.0 mg/kg) in rats is listed in Table 16. A significant decrease 
(p < 0.05, paired t-test) was noted in RBC count, HGB level and HCT value at 
24 hours after rHV2 treatment compared to baseline values. A slight 
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decrease in HCT was also seen 24 hours after saline treatment (p < 0.1, 
paired t-test) as shown in Table 16. No significant differences were found in 
most hematological parameters between saline and rHV2 treatments at 
baseline and 24 hours (independent t-test). 
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TABLE 15 
HEMATOLOGICAL PROFILE IN RATS AFTER 1.V. ADMINISTRATION 
(0.5 mg/kg) OF rHV2 
Test Saline Treatment (iv) rHV2 Treatment (iv) 
Baseline 24 hours Baseline 24 hours 
WBC 15.6 15.6 13.8 14.1 
(x 103/µL) ± 1.3 ± 0.9 ± 0.6 ± 1.3 
RBC 8.1 **7.4 7.7 **7.3 
(x 106/µL) ± 0.2 ± 0.1 ± 0.2 ± 0.2 
HGB 16.6 **15.6 15.8 *14.9 
(g/dl) ± 0.4 ± 0.2 ± 0.3 ± 0.3 
HCT 47.6 **43.0 44.1 *41.6 
(%) ± 1.5 ± 0.8 ± 0.8 ± 0.8 
MCV 58.4 57.9 57.0 57.1 
(fl) ± 0.5 ± 0.4 ± 0.6 ± 0.5 
MCH 20.4 20.9 20.4 20.4 
(pg) ± 0.3 ± 0.2 ± 0.3 ± 0.3 
MCHC 35.0 36.2 35.8 35.8 
(g/dl) ± 0.7 ± 0.3 ± 0.6 ± 0.4 
RDW 11. 7 11.5 11.5 11.3 
(%) ± 0.2 ± 0.1 ± 0.2 ± 0.2 
Platelet 944 944 926 *818 
(x 103/µL) ± 55 ± 97 ± 27 ± 34 
MPV 6.0 5.7 5.6 5.7 
(fl) ± 0.2 ± 0.1 ± 0.1 ± 0.1 
*-p < 0.05, * *-p < 0.10 - significant difference from corresponding 
baseline. All data represent the mean observation from 6 to 8 rats 
± SEM. See List of Abbreviations for explanation of terms. 
TABLE 16 
HEMATOLOGICAL PROFILE IN RATS AFTER S.C. ADMINISTRATION 
(1.0 mg/kg) OF rHV2 
Test 
WBC 
(x 103/µL) 
RBC 
(x 106 /µL) 
HGB 
{g/dl) 
HCT 
(%) 
MCV 
(fl) 
MCH 
(pg) 
MCHC 
{g/dl) 
RDW 
(%) 
Platelet 
(x 103 /µL) 
MPV 
(fl) 
Saline Treatment (sc) rHV2 Treatment (sc) 
Baseline 24 hours Baseline 24 hours 
12.4 
± 0.9 
7.7 
± 0.2 
15.3 
± 0.8 
44.1 
± 1.0 
57.5 
± 0.2 
20.0 
± 0.8 
34.6 
± 1.3 
11.2 
± 0.2 
1027 
± 51 
5.9 
± 0.2 
13.5 
± 1.1 
7.2 
± 0.2 
15.0 
± 0.4 
* *41.5 
± 1.0 
57.4 
± 0.4 
20.7 
± 0.1 
36.1 
± 0.2 
11.4 
± 0.1 
1049 
± 44 
5.8 
± 0.2 
13.8 
± 0.4 
7.6 
± 0.2 
15.8 
± 0.3 
43.6 
± 1.0 
57.6 
± 0.9 
20.8 
± 0.3 
36.2 
± 0.2 
11.6 
± 0.1 
1011 
± 38 
5.8 
± 0.2 
14.4 
± 0.6 
*7.0 
± 0.2 
*14.6 
± 0.3 
*40.2 
± 0.7 
57.6 
± 1.0 
20.9 
± 0.3 
36.4 
± 0.4 
11.6 
± 0.1 
904 
± 41 
5.8 
± 0.2 
*-p < 0.05, * *-p < 0.10 - significant difference from corresponding 
baseline. All data represent the mean observation from 6 to 8 rats ± 
SEM. See List of Abbreviations for explanation of terms. 
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6. Investigation of Pharmacokinetics and Pharmacodynamics of rHV2 after 
Single Dose Administration in Dogs 
Male, mongrel dogs (25-30 kg) were administered with increasing i.v. 
and s.c. doses of rHV2 in a parallel fashion, as described in the chapter on 
"Materials, Methods and Experimental Protocols". rHV2 was used in i.v. and 
s.c. doses of 0.25, 0.5 and 1.0 mg/kg. 
l.V. Administration. The plasma samples obtained after rHV2 
administration in dogs at various time periods were analyzed using coagulation 
tests, such as APTT (OT), APTT (Dade), TT (20 U/ml), Ca+ 2TT ( 10 U/ml) 
and Ca + 2TT (20 U/ml), as well as the amidolytic anti-Ila assay. 
The pharmacokinetics after i.v. administration of rHV2 is depicted in 
Figure 54. As observed in the rat and the rabbit studies, peak plasma 
concentrations were obtained at 3 minutes (tmax), followed by a rapid decline, 
reaching = 1 to 2 µg/ml at 60 to 120 minutes after drug administration. The 
pharmacokinetic parameters obtained after single dose administration of rHV2 
in all three doses, are shown in Table 17. Peak plasma rHV2 concentrations 
were 3.51, 5.40 and 7.16 µg/ml after administration of 0.25, 0.5 and 1.0 
mg/ml, respectively. The corresponding AUC0_00 values were 1.49, 3.17 and 
6.34 µg-hr/ml, respectively. Dose dependent, though non-linear, increases 
were found between the three doses in the Cmax , AUC0_00 and AUMC0_00 
values. 
The ke values after escalating i.v. doses of rHV2 in dogs were 0.65, 
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Figure 54. Pharmacokinetics of rHV2 in dogs after escalating i.v. bolus 
administration. Plasma concentrations were determined using competitive 
ELISA method. rHV2 was administered in i.v. doses of 0.25 ( • ), 0.5 
( 0 ) and 1.0 ( + ) mg/kg. All data represent the mean concentration from 
6 dogs ± SEM, each determined in duplicate. 
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0.85 and 0.74 hr-1, respectively. The corresponding t 112 values obtained 
were 1.07, 0.80 and 0.94 hr (translating to 64, 48 and 56 minutes), 
respectively (Table 17). The MRTs after escalating i. v. doses of rHV2 were 
1.03, 1.14 and 1.46 hrs., respectively. The Cltot rates and V d were 167, 158 
and 156 ml/hr/kg, and 256, 194 and 212 ml/kg, after i. v. administration of 
0.25, 0.50 and 1.0 mg/kg, respectively. No major differences were found in 
the t 112, ke, Cltot' and Vd values between the three doses of rHV2, after i.v. 
administration in dogs (Table 17). 
The results from ex vivo coagulation tests, obtained after i. v. administr-
ation of rHV2 are described in Figures 55 to 59. The time course of ex vivo 
APTT (OT) response after administration of all three doses of rHV2 is 
represented in Figure 55. The response is expressed as a mean percent 
increase from corresponding baseline value from six dogs. The baseline APTT 
(OT) obtained was about 16 seconds. A dose dependent peak increase in 
APTT (OT) was obtained at 3 minutes after rHV2 administration in all three 
dosing groups. Thereafter, the responses decreased steadily to baseline 
values between 60 and 120 minutes. Similarly, a dose dependent peak 
increase in clotting time was observed in the case of APTT (Dade), as shown 
in Figure 56. The baseline APTT (Dade) was about 12 seconds. Again, there 
was a sharp decline in response with time, reaching close to baseline values 
at about 120 minutes. 
The time course of TT (20 U/ml) after step-wise augmentation of rHV2 
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TABLE 17 
PHARMACOKINETIC PARAMETERS OBTAINED AFTER SINGLE DOSE 
1.V. (0.25, 0.50 and 1.0 mg/kg) ADMINISTRATION OF rHV2 IN DOGS 
Parameter 0.25 mg/kg 0.50 mg/kg 1.0 mg/kg 
Cm ax 3.51 5.40 7.16 (µg/mL) 
tmax 3.00 3.00 3.00 (min) 
ke ( hr-1) 0.65 0.85 0.74 
t1/2 1.07 0.80 0.94 (hr) 
AUC0_00 1.49 3.17 6.34 (µg-hr/mL) 
AUMC 00 (µg-hrl}~L) 1.53 3.60 9.36 
MRT 1.03 1.14 1.46 (hr) 
Cl tot 167.00 158.00 156.00 (ml/hr/kg) 
vd 256.00 194.00 212.39 (ml/kg) 
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doses is depicted in Figure 57. The baseline TT (20 U/ml) was about 8 
seconds. Three minutes after rHV2 administration, the clotting times, 
measured by TT (20 U/ml) increased to > 300 seconds ( > 40-fold increase 
from corresponding baseline values) in each treatment group. This increase 
remained sustained up to 45 minutes after doses of 0.25 and 0.5 mg/kg, and 
up to 60 minutes after a dose of 1 .0 mg/kg, respectively. The responses 
returned to baseline values at about 120 minutes in all three treatment groups. 
The changes in Ca+ 2TT (10 U/ml) and Ca+ 2TT (20 U/ml) after rHV2 
administration in escalating doses are depicted in Figures 58 and 59, 
respectively. The baseline Ca+ 2TT { 10 U/ml) and Ca+ 2TT (20 U/ml) were 
about 11 and 6 seconds, respectively. In the case of Ca+ 2TT { 10 U/ml), 
there was a sustained, maximum 30- to 40-fold increase in clotting times at 
3 minutes {x 300 seconds in measured clotting time) after rHV2 administration 
in the range of doses employed. The Ca + 2rr (10 U/ml) values remained 
steady at the maximal response for up to 18, 30 and 60 minutes after 
administration of 0.25, 0.5 and 1.0 mg/kg, respectively. It was interesting to 
note that at the higher two treatment doses, a 10-fold (0.5 mg/kg) and 25-fold 
increase (1.0 mg/kg) in response persisted even at 120 minutes. 
Similarly, Ca + 2rr (20 U/ml) responses increased in a dose dependent 
fashion, as described in Figure 59. At 3 minutes, there was almost a 50-fold 
increase in Ca+ 2TT (20 U/ml) with the lowest dose, and a 60-fold increase 
in response with the higher two doses of rHV2. In the 0.25 mg/kg treatment 
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group, the response remained at the maximum level for about 6 minutes, after 
which it decreased progressively until it reached baseline values at 60 
minutes. The higher two treatment groups exhibited maximal responses for 
up to 18 minutes, after which the intensity of responses decreased steadily 
in a dose dependent manner. In comparison with Ca+ 2TT ( 10 U/ml), the 
clotting response using Ca+ 2TT (20 U/ml) decreased to almost zero at 120 
minutes after rHV2 administration of 0.5 mg/kg. 
The ex vivo antithrombin activity as measured by the amidolytic anti-Ila 
assay is illustrated in Figure 60. The highest ex vivo antithrombin activity was 
observed at 3 minutes with about 90% thrombin inhibition for the 0.25 mg/kg 
treatment group, and an almost 100% thrombin inhibition for the higher two 
doses of rHV2. The thrombin inhibitory activity after the lower two doses 
decreased more rapidly, in a parallel fashion. After administration of 1.0 
mg/kg, the activity remained at x 90% for up to 18 minutes followed by a 
slower progression toward baseline. It is interesting to note that a 40% and 
20% thrombin inhibitory activity persisted with the highest dose at 60 and 
1 20 minutes, respectively (Figure 60). 
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Figure 55. Time-course of ex vivo antithrombin activity [APTT (OT)] of rHV2, 
after administration increasing i.v. doses in dogs. rHV2 was used in doses of 
0.25 ( • ), 0.5 ( 0 ) and 1.0 ( + ) mg/kg. All data represent the mean 
concentration from 6 dogs ± SEM, each determined in duplicate. 
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Figure 56. Time-course of ex vivo antithrombin activity [APTT (Dade)] of 
rHV2 after administration increasing i.v. doses in dogs. rHV2 was used in 
doses of 0.25 ( • ), 0.5 ( 0 ) and 1.0 ( + ) mg/kg. All data represent the 
mean concentration from 6 dogs ± SEM, each determined in duplicate. 
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Figure 57. Time-course of ex vivo antithrombin activity TT (20 U/ml) of rHV2 
after administration increasing i.v. doses in dogs. rHV2 was used in doses of 
0.25 ( • ), 0.5 ( 0 ) and 1.0 ( + ) mg/kg. All data represent the mean 
concentration from 6 dogs ± SEM, each determined in duplicate. 
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Figure 58. Time-course of ex vivo antithrombin activity Ca +2n (10 U/ml) 
of rHV2 after administration increasing i.v. doses in dogs. rHV2 was used in 
doses of 0.25 ( • ), 0.5 ( 0 ) and 1.0 ( + ) mg/kg. All data represent the 
mean concentration from 6 dogs ± SEM, each determined in duplicate. 
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Figure 59. Time-course of ex vivo antithrombin activity Ca +2n (20 U/ml) 
of rHV2 after administration increasing i.v. doses in dogs. rHV2 was used in 
doses of 0.25 ( • ), 0.5 ( 0 ) and 1.0 ( + ) mg/kg. All data represent the 
mean concentration from 6 dogs ± SEM, each determined in duplicate. 
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Figure 60. Time-course of ex vivo antithrombin activity of rHV2 after 
administration increasing i. v. doses in dogs (chromogenic anti-Ila assay). 
rHV2 was used in doses of 0.25 ( • ), 0.5 ( 0 ) and 1.0 ( + ) mg/kg. All 
data represent the mean concentration from 6 dogs ± SEM, each determined 
in duplicate. 
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S.C. Administration. The plasma samples obtained after rHV2 
administration were screened for ex vivo antithrombin activity using 
coagulation tests, ELISA and amidolytic anti-Ila assay. 
Figure 61 illustrates the pharmacokinetics after single dose s.c. 
administration of rHV2 in doses of 0.25, 0.50 and 1.0 mg/kg. Table 18 lists 
the pharmacokinetic parameters of rHV2 after escalating s.c. doses. As seen 
in the i.v. studies, there was a dose dependent increase in peak plasma 
concentrations. The Cmax values obtained were 0.43, 0.80 and 1.07 µg/ml, 
after administration of 0.25, 0.5 and 1.0 mg/kg, respectively. The 
corresponding tmax values were 90, 120 and 90 minutes, respectively. There 
were dose dependent increases in AUC0_00 , AUMC0_00 and Cmax values 
between the three doses (Table 18). 
As observed in the i.v. studies in dogs, no major differences were 
obtained in Cltot' apparent V d' t 112 and ke values between the three doses. 
The t 112 values were 1.05, 1.1 and 1.03 hr (i.e., 63, 66 and 61 minutes, 
respectively) after increasing s.c. administration of rHV2. The MRT values 
were 3.8, 3.28 and 3.01 hrs., after administration of 0.25, 0.5 and 1.0 
mg/kg, respectively. The Cltot and apparent V d parameters were 167, 156 
and 156 ml/hr/kg, and 228, 248 and 233 ml/kg, after escalating s.c. doses 
of rHV2. The average F value after s.c. administration of three doses of rHV2 
was almost equal to 98%. 
The results from coagulation tests after s.c. administration are depicted 
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Figure 61. Pharmacokinetics of rHV2 in dogs after single s.c. bolus 
administration. Plasma concentrations were determined using competitive 
ELISA method. rHV2 was administered in s.c. doses of 0.25 ( • ), 0.5 
( 0 ) and 1.0 ( + ) mg/kg. All data represent the mean concentration from 
6 dogs ± SEM, each determined in duplicate. 
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TABLE 18 
PHARMACOKINETIC PARAMETERS OBTAINED AFTER SINGLE DOSE 
S.C. (0.25, 0.50 and 1.0 mg/kg) ADMINISTRATION OF rHV2 IN DOGS 
Parameter 0.25 mg/kg 0.50 mg/kg 1.0 mg/kg 
Cm ax 0.43 0.80 1.07 (µg/mL) 
tmax 90.00 120.00 90.00 (min) 
ke ( h r- 1) 0.73 0.63 0.67 
t1/2 1.05 1.10 1.03 (hr) 
AUC0_00 1.75 3.04 5.95 (µg-hr/mL) 
AUMC 00 (µg-hrl}~L) 6.67 9.97 17.90 
MRT 3.80 3.28 3.01 (hr) 
Cl tot 167.00 156.19 156.00 (ml/hr/kg) 
vd 228.00 247.93 232.59 (ml/kg) 
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in Figures 62 to 66. In the case of APTT (OT), there was a 16 to 20% 
increase from baseline at 75 and 180 minutes in the treatment group with the 
lowest dose of rHV2 (Figure 62). The baseline clotting time using APTT (OT) 
was about 16 seconds. The time course of APTT (OT) after the higher two 
doses was almost superimposable with a peak response of about 38% at 75 
minutes. 
Figure 63 shows the time course of APTT (Dade) after rHV2 administra-
tion. The baseline APTT (Dade) was about 12 seconds. A peak increase in 
activity ( 15 % increase from baseline) was seen at 120 minutes after 
administration of the lowest dose. As seen with APTT (OT), the peak 
responses after the higher two doses were almost superimposable (22% 
increase at 75 minutes). After the peak response, APTT (Dade) values 
decreased dose dependently in these two groups (0.5 and 1 mg/kg doses). 
The time course of TT (20 U/ml) is depicted in Figure 64. The baseline 
TT (20 U/ml) was about 7.5 seconds. Figure 64 shows that there was a dose 
dependent increase in TT (20 U/ml) with increasing doses of rHV2. There 
was almost no change in response with time with the lowest dose. With the 
administration of 0.5 mg/kg, there was plateau in the maximal response 
between 60 and 180 minutes ( ~ 300 seconds in clotting time). The peak 
response with 1.0 mg/kg was almost double as that obtained with 0.5 mg/kg. 
The time course of TT (20 U/ml) after 1 mg/kg also exhibited a plateau phase 
between 120 and 180 minutes. 
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The time dependent progression of results from ex vivo coagulation 
tests using Ca+ 2TT ( 10 U/ml) and Ca+ 2TT (20 U/ml) are shown in Figures 
65 and 66, respectively. The baseline Ca+ 2TT ( 10 U/ml) was about 10 
seconds. After rHV2 administration, there was a maximal increase in Ca + 2rr 
(10 U/ml) at 120, 150 and 120 minutes using doses of 0.25, 0.5 and 1.0 
mg/kg, respectively. The corresponding responses were about 8-, 28-, and 
45-fold increases from baseline Ca+ 2TT ( 10 U/ml), respectively (Figure 65). 
The baseline Ca + 2TT (20 U/ml) was about 6 seconds. Figure 66 shows that 
there was almost no difference in Ca+ 2TT (20 U/ml) from baseline at all 
blood sampling times after administration of the lowest dose. Maximal 
Ca+ 2TT (20 U/ml) responses were obtained at 75 and 120 minutes after 
rHV2 administration of 0.5 and 1.0 mg/kg, respectively. 
The variations in ex vivo antithrombin activity (anti-Ila assay) with time 
are depicted in Figure 67. There was a linear increase in thrombin inhibitory 
response with increasing doses of rHV2. However, the maximal responses 
obtained with the s.c. doses were lesser than that obtained with correspond-
ing i. v. doses of rHV2 (see Figure 60). The peak thrombin inhibitory activities 
were about 18% (between 75 and 150 minutes), 34% (at 75 minutes) and 
50% (at 120 minutes) after rHV2 administration of 0.25, 0.5 and 1.0 mg/kg, 
respectively. 
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Figure 62. Time-course of ex vivo antithrombin activity [APTT (OT)] of rHV2 
after administration increasing s.c doses in dogs. rHV2 was used in doses of 
0.25 ( • ), 0.5 ( 0 ) and 1.0 ( + ) mg/kg. All data represent the mean 
concentration from 6 dogs ± SEM, each determined in duplicate. 
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Figure 63. Time-course of ex vivo antithrombin activity [APTT (Dade)] of 
rHV2 after administration increasing s.c. doses in dogs. rHV2 was used in 
doses of 0.25 ( • ), 0.5 ( 0 ) and 1.0 ( + ) mg/kg. All data represent the 
mean concentration from 6 dogs ± SEM, each determined in duplicate. 
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Figure 64. Time-course of ex vivo antithrombin activity TT (20 U/ml) of rHV2 
after administration increasing s.c. doses in dogs. rHV2 was used in doses 
of 0.25 ( • ), 0.5 ( 0 ) and 1.0 ( + ) mg/kg. All data represent the mean 
concentration from 6 dogs ± SEM, each determined in duplicate. 
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Figure 65. Time-course of ex vivo antithrombin activity Ca+ 2TT ( 10 U/ml) 
of rHV2 after administration increasing s.c. doses in dogs. rHV2 was used in 
doses of 0.25 ( • ), 0.5 ( 0 ) and 1.0 ( + ) mg/kg. All data represent the 
mean concentration from 6 dogs ± SEM, each determined in duplicate. 
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Figure 66. Time-course of ex vivo antithrombin activity Ca+ 2TT (20 U/ml) 
of rHV2 after administration increasing s.c. doses in dogs. rHV2 was used in 
doses of 0.25 ( • ), 0.5 ( 0 ) and 1.0 ( + ) mg/kg. All data represent the 
mean concentration from 6 dogs ± SEM, each determined in duplicate. 
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Figure 67. Time-course of ex vivo antithrombin activity of rHV2 after 
administration increasing s.c. doses in dogs (chromogenic anti-Ila assay). 
rHV2 was used in doses of 0.25 ( • ), 0.5 ( 0 ) and 1.0 ( + ) mg/kg. 
Antithrombin activity was determined using chromogenic anti-Ila assay. All 
data represent the mean concentration from 6 dogs ± SEM, each determined 
in duplicate. 
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7. Investigation of Pharmacodynamics of rHV2 after Repeated 
Administration in Dogs 
rHV2 was administered at a repeated, daily dose of 1 mg/kg for a period 
of seven days using i.v. and s.c. routes (n =6 dogs, per route). Plasma 
samples obtained after specified time intervals were subjected to the 
competitive ELISA, chromogenic anti-Ila assay and coagulation tests, as 
described in the chapter on "Materials, Methods and Experimental Protocols". 
1.V. Administration. The time course of plasma concentration of rHV2 
after multiple dose administration in dogs, is depicted in Figure 68. The 
symbols: d, a, b, and c, indicate the plasma level of rHV2 at baseline, 6, 30 
and 60 minutes after administration of each dose. After administration of the 
first dose (I), approximately 7.4µg/ml of rHV2 was detected in the plasma by 
the ELISA method at 6 minutes. As observed with the single dose i.v. 
experiments, there was a rapid decline in the plasma concentrations after 6 
minutes, decreasing to approximately 2 and 1 µg/ml at 30 and 60 minutes, 
respectively. After administration of doses II and Ill, the plasma rHV2 levels 
at 6 minutes increased to = 11 and 10.8 µg/ml, respectively. However, 
there was no significant difference between the rHV2 levels between all seven 
doses at 6 minutes after drug administration (p = 0.301, one-way repeated 
measures ANOV A). The plasma concentrations of rHV2 at 30 and 60 minutes 
after each dose were also not significantly different from each other (one-way 
repeated measures ANOV A). 
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The area under the plasma concentration-time curve and clearance 
values were calculated from baseline to 24 hours after each dose. These 
values are listed in Table 19. 
TABLE 19 
AREA UNDER THE CURVE AND CLEARANCE VALUES AFTER 
REPEATED ADMINISTRATION ( 1 mg/kg) OF rHV2 IN DOGS 
l.V. Dosing S.C. Dosing 
Dose AUC Cltot AUC Cltot (µg-hr/ml) (ml/hr/kg) (µg-hr/ml) (ml/hr/kg) 
I 11.84 85.08 5.37* 120.45* 
± 0.50 ± 3.47 ± 1.46 ± 29.44 
II 17.00 66.52 7.75 137.78* 
± 3.21 ± 9.30 ± 0.93 ± 28.01 
Ill 19.42 65.75 9.21 49.48 
± 4.95 ± 12.71 ± 0.68 ± 3.04 
IV 15.16 88.55 8.17 65.04 
± 4.46 ± 19.09 ± 0.92 ± 9.2 
v 17.18 71.32 7.44 68.38 
± 4.07 ± 13.34 ± 1.13 ± 11.07 
VI 13.36 75.26 9.46 51.24 
± 0.46 ± 2.67 ± 1.57 ± 4.63 
VII 15.44 77.99 9.49 50.67 
± 3.74 ± 13.15 ± 1.19 ± 5.35 
* - p < 0.05, one-way repeated measures ANOVA 
All data represent mean observation from six dogs ± SEM 
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After i.v. dosing, there were no significant differences in the AUC as 
well as clearance values with repeated administration (p = 0.597 /AUC and 
0. 530/Cltot' one-way repeated measures ANOV A). 
A similar progression in ex vivo antithrombin activity was obtained with 
the APTT (Dade). The results with APTT (Dade) are illustrated in Figure 69. 
There was a sharp increase in APTT (Dade) at 6 minutes after each dose of 
rHV2, followed by a rapid decrease in activity at 30 minutes and 60 minutes. 
The step-wise decrease observed in the progression of plasma rHV2 
concentrations and APTT (Dade) was not as clearly evident with the Ca+ 2TT 
( 10 U/ml) assay. The time course of Ca+ 2TT ( 10 U/ml) after repeated rHV2 
administration is shown in Figure 70. At each blood sampling time, there was 
no significant difference in APTT (Dade) as well as Ca+ 2TT ( 10 U/ml) 
between all seven doses (one-way repeated measures ANOVA). 
Figure 71 illustrates the time course of ex vivo antithrombin activity of 
rHV2 after repeated i.v. administration in dogs, using the amidolytic anti-Ila 
assay. An 82 % inhibition of thrombin was obtained at 6 minutes after 
administration of dose I. After administration of the subsequent doses, the 
thrombin inhibitory activity increased to approximately 96-98%. No significant 
differences were found in the thrombin inhibitory activity at 6, 30 and 60 
minutes after each dose (one-way repeated measures ANOVA). 
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Figure 68. Time-course of plasma concentration of rHV2 after repeated i.v. administration in dogs. rHV2 
was administered in daily doses of 1 mg/kg for one week. Plasma concentrations were determined using 
the competitive ELISA method. Each observation represents the mean concentration from six dogs ± 
SEM. 
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Figure 69. Time-course of ex vivo antithrombin activity (APTT-Dade) of rHV2 after repeated i.v. 
administration in dogs. rHV2 was administered in daily doses of 1 mg/kg for one week. Each observation 
represents the mean observation from six dogs ± SEM, each determined in duplicate. 
d, a, b, and c - baseline, 6, 30, 60 minutes after each dose, respectively. 
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Figure 70. Time-course of ex vivo antithrombin activity (Ca+ 2TT-10 U/ml) of rHV2 after repeated i.v. 
administration in dogs. rHV2 was administered in daily doses of 1 mg/kg for one week. Each observation 
represents the mean observation from six dogs ± SEM, each determined in duplicate. 
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Figure 71. Time-course of ex vivo antithrombin activity (chromogenic anti-Ila assay) of rHV2 after 
repeated i.v. administration in dogs. rHV2 was administered in daily doses of 1 mg/kg for one week. 
Each observation represents the mean observation from six dogs ± SEM, each determined in duplicate. 
d, a, b, and c - baseline, 6, 30, 60 minutes after each dose, respectively. 
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S.C. Administration. Blood samples were drawn at baseline and at 120, 
180 and 240 minutes after each s.c. dose of rHV2. Figure 72 describes the 
time course of plasma concentrations of rHV2 after repeated s.c. 
administration. The symbols: s, p, q, and r, represent plasma levels of rHV2 
at baseline, 120, 180, and 240 minutes after each dose. A comparison of 
rHV2 levels at 240 minutes indicated no difference between the seven doses 
(p = 0.239, one-way repeated measures ANOVA). There were no significant 
differences in measured plasma concentrations of rHV2 between the seven, 
repeated administrations at 120 and 180 minutes, as well (one-way repeated 
measures ANOV A). 
The AUC and Cltot values were calculated after each s.c. dose, the 
values of which are listed in Table 19. There was a significant increase in 
AUC values after the second dose (p = 0.023, one-way repeated measures 
ANOV A). In addition, there was a significant decrease in Cltot after the third 
dose (p = 0.000, one-way repeated measures ANOVA). 
The progression of APTT (Dade) and Ca+ 2TT ( 10 U/ml) after repeated 
s.c. administration of rHV2 is shown in Figures 73 and 74, respectively. 
Using both tests, there was no significant variation in the ex vivo antithrombin 
activity at each blood sampling time, after each dose of rHV2 (one-way 
repeated measures ANOV A). 
The anti-Ila assay exhibited a more step-wise progression of thrombin 
inhibitory activity than the APTT (Dade) and Ca+ 2TT ( 10 U/ml) assay (Figure 
210 
75). Similar to previous results, no significant differences were observed in 
the responses between doses, at various blood sampling times (one-way 
repeated measures ANOVA). As seen in the single dose s.c. studies, only a 
50 to 55% maximum inhibition of thrombin was observed at 120 minutes. 
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Figure 72. Time-course of plasma concentration of rHV2 after repeated s.c. administration in dogs. 
rHV2 was administered in daily doses of 1 mg/kg for one week. Plasma concentrations were determined 
using the competitive ELISA method. Each observation represents the mean concentration from six dogs 
± SEM. 
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Figure 73. Time-course of ex vivo antithrombin activity {APTT-Dade) of rHV2 after repeated s.c. 
administration in dogs. rHV2 was administered in daily doses of 1 mg/kg for one week. Each observation 
represents the mean observation from six dogs ± SEM, each determined in duplicate. 
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Figure 74. Time-course of ex vivo antithrombin activity (Ca +2TT-10 U/ml) of rHV2 after repeated s.c. 
administration in dogs. rHV2 was administered in daily doses of 1 mg/kg for one week. Each observation 
represents the mean observation from six dogs ± SEM, each determined in duplicate. 
baseline, p, q, and r - 120, 180 and 240 minutes, after each dose, respectively. 
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Figure 75. Time-course of ex vivo antithrombin activity (chromogenic anti-Ila assay) of rHV2 after 
repeated s.c. administration in dogs. rHV2 was administered in daily doses of 1 mg/kg for one week. 
Each observation represents the mean observation from six dogs ± SEM, each determined in duplicate. 
baseline, p, q, and r - 120, 180 and 240 minutes, after each dose, respectively. 
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7a. Serum Chemistry Profile in Dogs after Repeated rHV2 Administration 
I. V. Administration. Male, mongrel dogs were treated with repeated i. v. 
administration of rHV2 ( 1 mg/kg, every 24 hours) for seven days, as described 
under "Materials, Methods and Experimental Protocols". Figures 76 to 80 
illustrate the variations in different serum chemistry parameters at baseline 
("pre-rHV2") and 30 minutes ("post-rHV2") after rHV2 administration over this 
period. For each parameter, a two-way repeated analysis of variance was 
performed, to study the effect of day (rHV2 dose on each day) of treatment 
("day effect"), the difference between "pre-rHV2" and "post-rHV2" on each 
day ("pre-post effect") as well as that of any interaction between the two 
effects. 
Figure 76 depicts changes in phosphorous, albumin, uric acid and total 
bilirubin levels at baseline and 30 minutes after each dose of rHV2. No 
significant differences were found in any of the above parameters between the 
various days, and between baseline and 30 minutes after rHV2 administration, 
on each day. Figure 77 shows the variations in electrolytes after repeated 
rHV2 administration in dogs. No significant differences were found in sodium, 
chloride, calcium and potassium levels between different days, and pre- and 
post-rHV2 times of blood draw on each day. 
Figure 78 illustrates the changes in hepatic enzymes, alkaline 
phosphatase (ALP), alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) as well as blood urea nitrogen (BUN) and creatinine 
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after repeated rHV2 administration. Once again, no significant variations were 
observed in these parameters, using the two-way ANOV A test. 
The variations in total co2, total protein and y-glutamyl transferase (y-
GT) after repeated rHV2 administration are shown in Figure 79. No significant 
difference was observed in total protein values between the seven days, and 
pre- and post-rHV2 times. However, there was a significant day-to-day 
variation in total co2 levels at the 90% confidence level (p = 0.076). There 
was a trend toward an initial increase in total co2 levels at pre- and post-drug 
times on the first two days, followed by a gradual decrease on the remaining 
days. Within each day, there was no significant difference between pre- and 
post-rHV2 total co2 values. Furthermore, there was no significant interaction 
between the day and pre-post effects on total co2 levels. Similarly, there 
was a significant day-to-day variation in y-GT levels (p = 0.085) with an initial 
decrease in pre- and post-rHV2 levels up to day 3, followed by an increase to 
levels equal to initial values, by the sixth day (Figure 79). 
Figure 80 depicts the variations in lactic dehydrogenase (LDH), 
cholesterol, glucose and triglyceride levels after repeated i.v. administration 
of rHV2 in dogs. As observed with most other serum chemistry parameters, 
there were no significant variations between all the above parameters (two-
way repeated measures ANOV A). It was interesting to note that there was 
a gradual decrease in LDH levels up to day 3 and gradual increase thereafter 
to initial levels. However, this progression was not significant (p =0.297, 
217 
0.520 and 0.284 for the day effect, pre-post effect and the interaction, 
respectively). A similar trend was observed with triglyceride levels, where a 
slight decrease, though insignificant, was observed on the third day of the 
study (Figure 80). 
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Figure 76. Serum chemistry profile after repeated i.v. administration of rHV2 
in dogs (part I). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in 
phosphorous, albumin, uric acid and total bilirubin levels at baseline and 30 
minutes after each administration. All data represent the mean determination 
from 6 dogs ± SEM. 
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Figure 77. Serum chemistry profile after repeated i. v. administration of rHV2 
in dogs (part II). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in sodium, 
chloride, calcium and potassium levels at baseline and 30 minutes after each 
administration. All data represent the mean determination from 6 dogs ± 
SEM. 
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Figure 78. Serum chemistry profile after repeated i.v. administration of rHV2 
in dogs (part Ill). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in alkaline 
phosphatase (ALP), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), blood urea nitrogen (BUN) and creatinine at baseline 
and 30 minutes after each administration. All data represent the mean 
determination from 6 dogs ± SEM. 
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Figure 79. Serum chemistry profile after repeated i.v. administration of rHV2 
in dogs (part IV). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in total co2, 
total protein and y-glutamyltransaminase (y-GT) at baseline and 30 minutes 
after each administration. All data represent the mean determination from 6 
dogs ± SEM. 
*-day-to-day variation, p < 0. 10 (two-way repeated measures ANOV A). 
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Figure 80. Serum chemistry profile after repeated i.v. administration of rHV2 
in dogs (part V). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in lactate 
dehydrogenase (LDH), cholesterol, glucose and triglyceride levels at baseline 
and 30 minutes after each administration. All data represent the mean 
determination from 6 dogs ± SEM. 
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S.C. Administration. The serum chemistry profile of dogs after repeated 
administration of rHV2 (1 mg/kg, s.c.) is illustrated in Figures 81 to 85. Blood 
samples were drawn at baseline (pre-rHV2) and 120 minutes (post-rHV2) after 
each dose, and the sera were analyzed for chemistry parameters. A two-way 
repeated measures ANOVA was performed, to study the "day" effect and 
"pre-post" effect, and their interaction, as explained before. 
Figure 81 depicts the variations in inorganic phosphorous, albumin, uric 
acid and total bilirubin at baseline and 120 minutes after each rHV2 
administration. No significant differences were seen in all four parameters 
(two-way repeated measures ANOVA). Similarly, there were no significant 
fluctuations in serum sodium, chloride, calcium and potassium values, as 
shown in Figure 82. 
There were no significant variations in hepatic enzymes, ALP, ALT and 
AST, as well as BUN and creatinine after multiple rHV2 administration, as 
shown in Figure 83. Similarly, Figure 84 illustrates that no significant 
variations were seen in total co2, total protein and y-GT after daily 
administration of rHV2 (two-way repeated measures ANOV A). 
Figure 85 depicts the changes in LDH, cholesterol, glucose and 
triglyceride levels with time. There were fluctuations in LDH levels, exhibiting 
a step-wise decrease at 120 minutes after drug administration on all days, 
except day 0. No significant day-to-day variations were observed in LDH 
levels at baseline and 120 minutes (p = 0.194). However, there was a 
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significant "pre-post" effect (p = 0.06), as well as a significant interaction 
(p = 0.07). The day-to-day variations in the differences between pre- and post-
rHV2 LDH levels were analyzed using a method of contrasts (Wilkinson, 1990; 
J.Corliss-personal communication). The LOH levels at 120 minutes after rHV2 
administration on days 2, 3, 4 and 6 were significantly lower than 
corresponding baseline values (Figure 85). No significant variations were 
observed in the other parameters, illustrated in the same Figure (85), i.e. 
cholesterol, glucose and triglyceride, after multiple, s.c. rHV2 administration. 
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Figure 81. Serum chemistry profile after repeated s.c. administration of rHV2 
in dogs (part I). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in 
phosphorous, albumin, uric acid and total bilirubin levels at baseline and 30 
minutes after each administration. All data represent the mean determination 
from 6 dogs ± SEM. 
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Figure 82. Serum chemistry profile after repeated s.c. administration of rHV2 
in dogs (part II). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in sodium, 
chloride, calcium and potassium levels at baseline and 30 minutes after each 
administration. All data represent the mean determination from 6 dogs ± 
SEM. 
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Figure 83. Serum chemistry profile after repeated s.c. administration of rHV2 
in dogs (part Ill). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in alkaline 
phosphatase (ALP), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), blood urea nitrogen (BUN) and creatinine at baseline 
and 30 minutes after each administration. All data represent the mean 
determination from 6 dogs ± SEM. 
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Figure 84. Serum chemistry profile after repeated s.c. administration of rHV2 
in dogs (part IV). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in total co2, 
total protein and y-glutamyltransaminase (y-GT) at baseline and 30 minutes 
after each administration. All data represent the mean determination from 6 
dogs ± SEM. 
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Figure 85. Serum chemistry profile after repeated s.c. administration of rHV2 
in dogs (part V). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in lactate 
dehydrogenase (LOH), cholesterol, glucose and triglyceride levels at baseline 
and 30 minutes after each administration. All data represent the mean 
determination from 6 dogs ± SEM. 
* -p < 0. 1 (pre and post-rHV2 variation, two-way repeated measures 
ANOVA). 
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7b. Hematological Profile after Repeated rHV2 Administration in Dogs 
I. V. Administration. Figures 86 to 87 depict the changes in various 
hematological parameters after i.v. administration of rHV2. Each figure shows 
the periodic change in different hematological parameters at baseline and 30 
minutes after each i.v. dose, up to seven days. Statistical analysis was 
performed using two-way ANOV A, as discussed before. 
The variations in mean cell volume (MCV), hematocrit (HCT), mean cell 
hemoglobin concentration (MCHC) and mean cell hemoglobin (MCH) levels are 
shown in Figure 86. No significant differences were seen in MCV, MCHC and 
MCH values between the times of blood sampling after repeated rHV2 
administration. There was a significant decrease in HCT after daily 
administration of rHV2 (p = 0.000, for day effect). Also, there was a 
significant decrease in HCT at 30 minutes after rHV2 administration, compared 
to corresponding baseline (p = 0.002 for pre-post effect). The difference 
between pre- and post-rHV2 HCT levels was not significant, from day to day 
(p = 0. 163, for the interaction). 
Figure 87 illustrates the variations in red cell distribution width (RDW), 
hemoglobin (HGB) and mean platelet volume (MPV) at different times after 
multiple rHV2 administration. There were no significant changes in RDW and 
MPV levels after multiple rHV2 administration. There was a significant 
decrease in HGB between the various days, as well as between baseline and 
post-rHV2 HGB levels on each day (p < 0.05, two-way repeated measures 
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ANOV A; p = 0 .129 for the interaction). 
There were no significant alterations in cell count of platelets, WBCs 
and RBCs, after repeated i.v. administration of rHV2 in dogs, as illustrated in 
Figure 88. 
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Figure 86. Hematological profile after repeated i.v. administration of rHV2 in 
dogs (part I). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in mean cell 
volume (MCV), hematocrit (HCT), mean cell hemoglobin concentration (MCHC) 
and mean cell hemoglobin (MCH) at baseline and 30 minutes after each 
administration. All data represent the mean determination from 6 dogs ± 
SEM. 
*-p < 0.05 (significant day-to-day and pre- & post-rHV2 variation, two-
way repeated measures ANOV A). 
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Figure 87. Hematological profile after repeated i. v. administration of rHV2 in 
dogs (part II). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in red cell 
distribution width (RDW), hemoglobin (HGB) and mean platelet volume (MPV) 
at baseline and 30 minutes after each administration. All data represent the 
mean determination from 6 dogs ± SEM. 
*-p < 0.05 (significant day-to-day and pre- & post-rHV2 variation, two-
way repeated measures ANOV A). 
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Figure 88. Hematological profile after repeated i.v. administration of rHV2 in 
dogs (part Ill). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in platelet, 
RBC and WBC count at baseline and 30 minutes after each administration. All 
data represent the mean determination from 6 dogs ± SEM. 
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S.C. Administration. Blood samples were drawn at baseline and 120 
minutes after repeated rHV2 administration (1 mg/kg, s.c.) in dogs. The 
fluctuations in various hematological parameters are described in Figures 89 
to 91. Figure 89 exhibits the changes in MCV, HCT, MCHC and MCH after 
repeated administration. As observed in the i.v. studies, HCT values 
decreased progressively with time, displaying significant day-to-day variation, 
as well as significant variation between pre- and post-rHV2 HCT levels on 
each day (p<0.05, two-way ANOVA; p =0.154 for the interaction term). No 
significant variations were seen in MCV, MCHC or MCH after multiple rHV2 
administration (Figure 89). 
The variations in ROW, HGB and MPV are shown in Figure 90. No 
significant variations were observed in ROW and MPV. However, there was 
a significant progressive, step-wise decrease in hemoglobin levels (p < 0.05, 
two-way ANOVA; p = 0.130 for the interaction). Figure 91 shows that there 
were no significant variations in blood cell count (RBCs, WBCs and platelets) 
after repeated s.c. administration of rHV2. 
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Figure 89. Hematological profile after repeated s.c. administration of rHV2 in 
dogs (part I). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in mean cell 
volume (MCV), hematocrit (HCT), mean cell hemoglobin concentration (MCHC) 
and mean cell hemoglobin (MCH) at baseline and 30 minutes after each 
administration. All data represent the mean determination from 6 dogs ± 
SEM. 
*-p < 0.05 (significant day-to-day and pre- & post-rHV2 variation, two-
way repeated measures ANOV A). 
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Figure 90. Hematological profile after repeated s.c. administration of rHV2 in 
dogs (part II). Male, mongrel dogs (n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in red cell 
distribution width (RDW), hemoglobin (HGB) and mean platelet volume (MPV) 
at baseline and 30 minutes after each administration. All data represent the 
mean determination from 6 dogs ± SEM. 
*-p < 0.05 (significant day-to-day and pre- & post-rHV2 variation, two-
way repeated measures ANOV A). 
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Figure 91. Hematological profile after repeated s.c. administration of rHV2 in 
dogs {part Ill). Male, mongrel dogs {n = 6) were injected with 1 mg/kg rHV2 
every 24 hours, for a period of one week. Figure shows changes in platelet, 
RBC and WBC count at baseline and 30 minutes after each administration. All 
data represent the mean determination from 6 dogs ± SEM. 
CHAPTER V 
DISCUSSION 
In Vitro Studies 
Hirudin is a 65 or 66 amino acid polypeptide that was isolated from the 
salivary glands of medicinal leeches. Recombinant forms of the native protein 
isoforms are currently available. Hirudin and rH variants are highly potent 
inhibitors of thrombin (Ki = 50 pM). rHs are undergoing investigation for use 
as a prophylactic and therapeutic antithrombotic agent after deep venous 
thrombosis and unstable angina, during coronary bypass surgery, and to 
prevent restenosis after percutaneous transluminal coronary angioplasty. 
In this dissertation, the pharmacology of recombinant hirudin variant 2 
(rHV2) has been studied, using pharmacokinetic and pharmacodynamic 
methods. Specific experimental designs have been developed and executed 
to characterize the pharmacokinetic and pharmacodynamic properties of rHV2 
in different animal species, such as dogs, rabbits and rats. 
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1. Construction of Concentration-Response Curves after In Vitro 
Supplementation of rHV2 in Plasma Systems 
Assay dependent variations in the responses of antithrombotic drugs in 
laboratory monitoring methods have been known for some time. Besides the 
mechanisms of activation in individual assays, the dilution of recombinant 
hirudin in samples due to the addition of assay reagents may contribute 
significantly to differences in observed end points. Thus, the current assay 
methods used are not equivalent and provide results that are distinct from one 
another. In this dissertation, a systematic study on the direct comparison of 
various assays in reference to the assay matrix effect and adjustment of final 
assay concentration of rHV2, has been carried out. The purpose of 
concentration-response studies reported in this dissertation is to provide an 
objective assessment of the relative effects of hirudin in different assays with 
special reference to assay conditions and final concentrations. 
A profile of in vitro anticoagulant and antithrombin activities of rHV2 
was obtained in pooled animal plasma preparations in parallel with ex vivo 
coagulation and anti-Ila assays from in vivo experiments in rats, rabbits and 
dogs. In addition, the in vitro anticoagulant and antithrombin activity was 
investigated after supplementation of rHV2 in blood bank plasma (BBP) in an 
effort to relate the results from animal studies with human studies. 
Selection of coagulation and anti-Ila assays. The coagulation tests used 
to evaluate the in vitro anticoagulant activity of rHV2 included activated partial 
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thromboplastin time (APTT- OT and Dade), thrombin time (TT), and calcium 
thrombin time (Ca+ 2TT). 
APTT is used to evaluate abnormalities in the intrinsic pathway of blood 
coagulation. It has been the conventional clotting method used to monitor 
heparin therapy (Racanelli, 1990; Camici and Evangelisti, 1993) and has been 
used to evaluate hirudin anticoagulant activity, as well (Chesebro et al., 
1991 a; 1991 b). Heparin exhibits multiple sites of action on coagulation 
enzymes (11 8 , X8 and Xll 8 ) and its anticoagulant action is mediated by 
antithrombin-111 (AT-Ill) and heparin cofactor-II (HC-11) (Of usu et al., 1981, 
1982, 1985). Heparin has been shown to release tissue factor pathway 
inhibitor (TFPI) from endogenous sites, but there is no evidence of TFPI being 
released by hirudin (Fa reed, 1994). Recent clinical studies with rH have 
utilized APTT as the method to monitor hirudin activity (Antman, 1994; Gusto 
Ila investigators, 1994). However, the validity of the use of APTT to predict 
hirudin activity has not been established. Theoretically, hirudin would prolong 
APTT as it interferes with the final pathway of coagulation by inhibiting 
thrombin. It may be speculated that APTT is prolonged by hirudin due to the 
inhibition of thrombin mediated feedback activation of factors V and VIII, 
thereby interfering with the intrinsic system. 
Recent reports have debated the use of APTT as a suitable assay 
method to monitor rH therapy (Iyer et al., 1990; Lefkovitz and Topol, 1994). 
rH is a relatively weak inhibitor of thrombin generation when compared with 
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heparin (Kaiser et al., 1992). Hence, a clotting assay that would directly 
target the thrombin inhibitory activity of rH would be more appropriate, such 
as the TT or the modified ca+ 2rr, discussed in the following sections. 
Another important factor to be considered is the variability in the various 
reagents available to perform the APTT assays (Poller, 1980; Howarth, 1993). 
Tripodi et al. ( 1993) observed that there were significant, reagent based 
differences in the APTT responses in hirudinized normal human plasma using 
ten different APTT reagents. In addition, APTT responses have been reported 
to be highly sensitive to changes in storage time and temperature (Ho and Wu, 
1991). 
Two different APTT reagents were used in the experiments reported in 
this dissertation: APTT (OT) and APTT (Dade). The APTT (OT) reagent is 
composed of rabbit brain phospholipids with micronized silica as an activator 
and hence, has an insoluble contact activation matrix. The APTT (Dade) 
reagent contains cephalin extracted from dehydrated rabbit brain in ellagic 
acid. Ellagic acid is a soluble activator of the contact system, and it is 
stronger than micronized silica. Hence, the APTT (OT) assay is more sensitive 
than the APTT (Dade). In all in vitro and ex vivo analyses using the two APTT 
reagents, the baseline clotting values using the Dade reagent was at least 
50% lower than that obtained with the OT reagent. Furthermore, the results 
from most in vitro and ex vivo analyses indicate variable profiles of APTT (OT) 
and APTT (Dade) in different species, as discussed later. 
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A more specific coagulation assay to measure the direct thrombin 
inhibitory activity of rH is TT. However, the clotting response using this assay 
exhibited very little concentration dependency when rH was supplemented in 
normal rabbit plasma (NRP) (Figure 12), as well as in other plasma systems 
such as normal human, monkey, and dog plasma (Iyer et al., 1990). The TT 
( 1 O U/ml) values reached beyond 300 seconds which is the upper limit of 
sensitivity for this assay using the Fibrometer®, at a concentration as low as 
< 1 pM/mL (Figure 12), due to the strong affinity of rH for thrombin. 
To obtain more definite end points in the TT assay, the thrombin 
reagent was modified by reconstituting a-thrombin in 0.025M CaCl2 solution 
to obtain calcium thrombin reagent. This assay has been previously validated 
and has been used to monitor hirudin's anticoagulant activity in various 
plasma preparations (Iyer et al., 1990). It was observed that using an 
appropriate balance of thrombin and CaCl2 content in the reagent, a well 
defined, sigmoidal concentration-response curve could be obtained, using 
Ca+ 2TT ( 10 U/ml) and rHV2 supplemented NRP (Figure 12). 
In addition to the coagulation assays, a biochemically defined amidolytic 
anti-Ila assay that measures the release of pNA due to the action of the 
enzyme (thrombin) on the substrate (Spectrozyme®TH,) in the presence of the 
inhibitor (rHV2), was used. This method has been employed by previous 
investigators to study the antithrombin effects and pharmacokinetics of rH 
(Greissbach et al., 1985; Markwardt et al., 1988). 
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Concentration-response curves. The baseline clotting times using 
ca+ 2n ( 1 O U/ml) were similar between rabbit, dog and blood bank plasma. 
APTT (Dade) values did not significantly differ between species, either. 
However, the baseline APTT (OT) in rabbit plasma was significantly greater 
than that obtained with dog or blood bank plasma (57.05/NRP vs. 18.6/NDP 
vs. 27.56/BBP, p<0.05, one way ANOVA followed by Tukey test). This 
observation agrees with previous results with baseline APTT (OT) in rabbits 
(Racanelli, 1990). However, the reason for this finding is not clear. It has 
been shown that several clotting factors (II, VII, VIII, IX, XI and XII) were 
actually 2 to 28 fold higher in rabbits compared with humans (Walenga, 
1987). However, the functionality of clotting factors in rabbits in comparison 
to human or other species is not clear at this time. Furthermore, one cannot 
rule out the possibility of functional inhibitory effects due to endogenous 
inhibitors like antithrombin Ill. The results from baseline coagulation 
parameters emphasize the importance of species differences in clotting 
profiles. It is critical to use concentration-response curves from the same 
species during extrapolation of in vitro results to ex vivo experiments. 
The alignment of concentration-response curves in the plasma 
preparations studied (except NRatP) was very similar (Figures 13 to 15). 
Ca+ 2TT ( 10 U/ml) was the most sensitive assay to monitor rHV2 in NRP, 
NOP, and BBP, exhibiting linear increases in responses at very low 
concentrations i.e. 1 and 10 pM/mL. Therefore, this assay can be used to 
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monitor concentrations of rHV2 in the respective plasma in the above range, 
translating to original plasma concentrations of 10 to 100 ng/ml. 
APTT (OT) might be useful to monitor rHV2 concentrations in the range 
of about 10 to 250 pM/ml, which corresponds to original plasma 
concentrations of 0.2 to 3.0 pg/ml. APTT (Dade), on the other hand, 
exhibited linear ranges varying with individual plasma systems. The linear 
ranges for APTT (Dade) were about 150 to 250 pM/ml in NRP, 100 to 250 
pM/ml in NOP and 50 to 250 pM/ml in BBP, corresponding to an average 
range of 2 to 5 pg/ml, in terms of original plasma concentrations. 
The linear range of the chromogenic anti-Ila assay was between 0. 12 
and 1.2 pg/ml in rabbit, dog and blood bank plasma in terms of original rHV2 
concentrations. The concentration-response curve for anti-Ila assay in NRatP 
was shifted to the right when compared with that obtained in NRP, NOP and 
BBP, thereby shifting the linear range to 1.2 - 12.0 pg/ml. Higher 
concentrations of rHV2 were required to produce equivalent thrombin 
inhibitory activity in rat plasma. The reason for this finding is not known at 
this time. Rat blood was found to be hypercoagulable compared to other 
species. Glass activated (37°C) clotting times in rats have been reported to 
be 2-5 minutes (Ringler and Dabich, 1979) when compared to 8.6 minutes in 
dogs, 5 minutes in rabbits and 7.5 minutes in humans (Didisheim eta/., 1959). 
Rats have been shown to have a much higher platelet count ( 1000,000 to 
1275,000/pl, Schalm et al., 1975) than rabbits (750,000/pl, Kozma et al., 
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1974), dogs (250,000/µL, Schalm et al., 1975) and humans (293,000/µL, 
Didisheim et al., 1959). 
In the absence of a true maximal response in most of the coagulation 
assays, a slope analysis was carried out in the linear portions of each 
individual concentration-response curve. The slope represents the rate of 
change in intensity of responses with respect to variations in rHV2 
concentrations in the linear range. The dimensions of slopes were 
seconds/pM/mL for the coagulation assays and % inhibition of 
thrombin/pM/mL for the chromogenic anti-Ila assay. Evaluation of the slopes 
indicated that the Ca+ 2TT ( 10 U/ml) responses exhibited much higher slopes 
in comparison to the two APTT assays in rabbit, dog and blood bank plasma, 
as shown in Table 5. This meant that the Ca+ 2TT ( 10 U/ml) was more 
sensitive to small changes in rHV2 concentrations than the two APTT tests. 
This can be explained by the different biochemical mechanisms involved in the 
two clotting assays: thrombin is supplemented in the Ca+ 2TT ( 10 U/ml) 
assay, while thrombin is generated in the APTT assay. With regard to the 
anti-Ila assay results in NRatP, the response exhibited much lower sensitivity 
to changes in rHV2 concentrations than that observed in the other plasma 
systems. 
The results from the concentration-response curves generated in vitro 
point toward the need to choose an appropriate assay method to monitor rH. 
Walenga et al. ( 1991 a) have projected a circulating rH level of 5 to 10 µg/ml 
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tor therapeutic anticoagulation. In the case of Ca+ 2TT ( 10 U/ml), dilutions 
will be necessary to obtain final assay concentrations in the linear range. The 
use of this modified thrombin time is most logical, taking into account the 
mechanism of action of hirudin. Newer studies are warranted to establish a 
standardized calcium-thrombin reagent to decrease variability and improve the 
linear range of the assay. In the case of APTT, the assay may not be as 
sensitive and as appropriate as a direct, thrombin based coagulation assay. 
To emphasize, APTT reagents from the same source must be used for 
effective comparison studies. The biochemical, chromogenic anti-Ila assay is 
reproducible, but might require dilutions to monitor rH in therapeutic 
concentrations. 
Species dependence in concentration-response curves. A wide 
physiological variation on the hemostatic profile of various species has been 
noted by several investigators (Didisheim et al., 1959; Kozma et al., 1974; 
Schalm et al., 1975). Major differences are also obvious in the plasma 
composition of human, rabbit, rat and dog plasma. Since this dissertation 
addressed the pharmacological effects of rHV2 in various species, a detailed 
analysis of the effects of rHV2 in various plasma preparations was made. 
Besides the species dependent variations, assay dependent variations within 
the same species introduced complications in the interpretation of the results. 
Until now, there is no reliable method available to monitor the effects of rH in 
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pharmacological or clinical studies. In this dissertation, an attempt was made 
to validate the utility of some of the conventional assays such as APTT. 
Furthermore, since major differences among the APTT reagents were noted, 
a thrombin titration method to measure antithrombin activity of rH has been 
developed. 
The in vitro studies to determine the concentration-response curves in 
plasma from different species resulted in providing assay, and species specific 
concentration-response curves. With the exception of the amidolytic anti-Ila 
assay, all of the other assays provided distinct concentration-response curves 
and sensitivity ranges for rH in the rabbit, human and dog plasma systems. 
However, even in this assay, NRatP revealed a wide difference. These studies 
suggest that a cross-species, universal method to monitor rH is not feasible 
at this time. However, with proper standardization, both optimized clot based 
and amidolytic methods can be used to determine the anticoagulant and 
antithrombin activities of rH. 
The in vitro analysis of anticoagulant and antithrombin properties of 
rHV2 using various assay methods were performed in parallel with ex vivo 
analysis from in vivo experiments. However, the influence from various 
physiologic mechanisms including uptake and disposition mechanisms, 
feedback mechanisms and circadian rhythms as well as individual-to-individual 
physiological variations must be taken into consideration while relating in vitro 
results with ex vivo measurements of rHs. 
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2. Determination of Specific Activity of rHV2 using a Thrombin Titration 
Method 
The determination of potency of biological activity for various 
antithrombotic drugs still remains a major controversy. A standard method to 
evaluate the potency of hirudin has not been established to date. The 
thrombin titration method utilized in this dissertation is an extension of the 
chromogenic anti-Ila assay developed to monitor hirudin activity in plasma 
(Greissbach et al., 1985, J. Amiral-personal communication). The method is 
based on the 1: 1 stoichiometric reaction between hirudin and thrombin 
(Markwardt, 1970). The described method is simple, rapid and highly 
reproducible with a coefficient of variation of 2.1 % (Iyer and Fa reed, 1995). 
The average specific activity obtained of rHV2 used in this research was found 
to be = 15,873 ATU/mg (Figure 17). This was about 9% more than that 
claimed by the manufacturer which could be due to variations in additives 
such as fillers and preservatives. The three individual experiments were 
performed over a period of one week and no significant differences were 
found between the individual specific activities (Table 6). It is to be noted that 
the thrombin used during titration must be of known, high purity. The 
thrombin utilized in this study was composed of 95. 72% of a-thrombin. It 
may be noted that the shape of the curve (Figure 17) suggests that the rHV2-
thrombin interaction may not be of a 1: 1 binding ratio. The thrombin titration 
method has been agreed upon by the World Health Organization (WHO) and 
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International Society of Thrombosis and Haemostasis (ISTH) affiliate (Longstaff 
et al., 1993) as the reference method for potency evaluation of various 
hirudins. 
The thrombin titration method can be used to determine specific activity 
of incoming batches of rH for their antithrombin activity prior to in vitro as 
well as in vivo experiments in animal and human subjects. The method can 
be used to compare the potencies of different batches of rH, to relate to the 
potency of a reference standard, to determine variations in potency of hirudin 
during storage, and as part of routine stability studies in the development of 
hirudin as an antithrombotic agent. 
3. Determination of Protein Content of rHV2 using the fl. 215-225 Method 
Since homogeneous protein solutions of rHV2 were used, a 
spectrophotometric method was employed to measure protein content. The 
recovery of the protein content, as determined in rHV2 solutions of 25, 50 
and 100 µg/ml was found to be 109.6, 112.4 and 102.2%, respectively, with 
an average of 108%. The linear range for the !:::.. 215-225 method is 10 to 
100 µg/ml (Chaykin, 1966). This finding indicated that there was no loss of 
protein due to shipment, storage conditions or other degradation in the batch 
of rHV2 used. 
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In Vivo Studies 
1. Assessment of Antithrombotic Profile of rHV2 using a Modified Jugular 
Vein Stasis Thrombosis Model in Rabbits - A Dose-Ranging Study 
The dose-ranging experiments on the antithrombotic actions of rHV2 
were designed to demonstrate the relevance of different dosages on the 
antithrombotic actions of this agent. In this investigation, both intravenous 
and subcutaneous protocols were included. The results from this study were 
taken into consideration for the selection of a dosage of rHV2 for the time 
course experiments, using intravenously and subcutaneously administered 
rHV2. 
For the evaluation of in vivo antithrombotic actions of rHV2, a well-
defined and established model of rabbit stasis thrombosis was used employing 
activated prothrombin complex concentrates (FEIBA®) as the thrombogenic 
challenge (Fareed et al., 1985). This model has been extensively used in the 
evaluation of several antithrombotic and anticoagulant agents such as heparin, 
low molecular weight heparins, dermatan sulfate and site-directed thrombin 
inhibitors (Fareed et al., 1985; Walenga, 1987; Hoppensteadt, 1989; 
Racanelli, 1990; Bacher et al., 1993). However, in the current investigation, 
an additional modification was made by extending the stasis time to 20 
minutes on one jugular vein segment, in contrast to 10 minute stasis times for 
both segments in some of the earlier studies. This modification provided an 
additional parameter to compare the antithrombotic actions of rHV2 in 
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relatively stronger thrombogenic conditions. 
1.V. Administration. In comparison to the saline treated control groups, 
rHV2 produced a dose dependent antithrombotic effect in both 10 minute and 
20 minute stasis studies. In relation to the 10 minute stasis, the 
antithrombotic effect of rHV2 was relatively weaker when a 20 minute end 
point was used. This is primarily due to the stronger thrombogenic 
environment produced by the longer stasis time. Both end points exhibited a 
dose dependent antithrombotic activity of rHV2, with an apparent ED50 of 9 
µg/kg for the 10 minute stasis, and approximately 11.5 µg/kg for the 20 
minute stasis time. This is consistent with the pathophysiology of this model, 
as the 20 minute stasis time results in a stronger thrombogenic environment 
in which, stasis, along with activated coagulation factors, is capable of 
producing a relatively stronger thrombogenic environment. At the 25 µg/kg 
dosage, a complete absence of clot formation indicated total inhibition of the 
thrombogenic process at the 10 minute stasis interval. On the other hand, a 
residual thrombogenic activity was evident in the 20 minute stasis time 
results, where a 25% clotting response persisted. These results clearly 
indicated a dose, and experimental condition dependent antithrombotic effect 
of rHV2. These findings also point toward the fact that the antithrombotic 
action of thrombin inhibitors, such as rHV2, are dependent on experimental 
conditions and the type of the thrombogenic trigger used. 
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In order to relate the observed antithrombotic effects of rHV2 with the 
ex vivo tests which are currently used to measure the anticoagulant/ 
antithrombotic actions of rHV2, several methods were employed. 
Formulations of APTT using a particulate activator {APTT (OT)}, and an ellagic 
acid based soluble activator {APTT (Dade)} were used to test the 
anticoagulant effects of rHV2 in this study. With APTT (OT), at 6.25 and 
12.5 µg/kg, a moderate, dose dependent, though insignificant increase was 
noted in the 5 minute "post-drug" samples (Figure 19). At 25 µg/kg, no 
increase in clotting times was evident. When the three doses were compared 
with saline control, no significant differences were observed. Blood samples 
were collected 6 minutes after the administration of thrombogenic challenge, 
in addition to the post-drug samples. In the "post-FEIBA®" samples, at all 
doses, no significant difference was evident. Interestingly, the clotting times 
obtained after FEIBA® administration were significantly shortened. This 
significant shortening of the clotting time after FEIBA® administration supports 
the hypothesis that FEIBA® produces a thrombogenic environment capable of 
producing some neutralization of the anticoagulant actions of rHV2. In 
comparison to the APTT (Dade) studies (Figure 20), a wider scatter in the data 
was seen with this reagent. This indicates that different APTT reagents 
provide varying results. Thus, for uniform results, a single APTT reagent must 
be used. 
With APTT (Dade), the ex vivo analysis of the group of rabbits treated 
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with 6.25 µg/kg did not reveal any significant differences between saline and 
rHV2 treated groups (Figure 20). This was interesting, as at the 10 minute 
stasis time, using the same dosage, there was a significant (p < 0.05) 
reduction in clot scores compared with controls (Figure 18). Hence, while 
anticoagulation was not detectable using this APTT (Dade) reagent, a marked 
inhibition of clot scores was evident in the 6.25 µg/kg treatment group. At 
the 12.5 µg/kg dosage, a > 30% increase in APTT (Dade) was noted, 
compared with baseline value. At the 25 µg/kg dosage, although a further 
prolongation of APTT (Dade) was noted, it was not proportional to the 
administered doses of rHV2. The APTT increase at this dosage was about 2-
fold that of saline treated control rabbits. 
Although no difference in APTT (Dade) was noted after the 6.25 and 
12.5 µg/kg doses of rHV2 between the samples taken prior to, and after 
FEIBA® administration, a significant shortening of APTT (Dade) was observed 
after the 25 µg/kg dose. This is consistent with the observation that FEIBA® 
is capable of producing a thrombogenic environment. 
To analyze the direct antithrombin effects in the clot-based assays, the 
thrombin based tests, TT and Ca +2TT were performed. At a 6.25 µg/kg 
dose, a slight prolongation of TT ( 10 U/ml) was noted (Figure 21). At 12. 5 
and 25 µg/kg, the clotting times reached > 300 seconds. In the post-FE I BA® 
samples, no significant differences were noted in all three dosage groups 
when compared with corresponding post-drug samples. In the Ca +2TT (10 
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U/ml) assay, a dose dependent anticoagulant effect with a definite end point 
was obtainable at all dosages (Figure 22). The corresponding elevation of the 
clotting time was shorter in this group when compared to the TT (10 U/ml), 
as discussed earlier. A significant shortening of clotting time was noted in 
the post-FEIBA® samples in the 12.5 and 25 µg/kg groups, when compared 
with corresponding 5 minute post-drug samples. The fact that a progressive 
prolongation of the clotting times with definite end points was obtained with 
the Ca+ 2TT ( 10 U/ml) reagent suggests that this reagent is better for 
monitoring of the anticoagulant effects of rHV2. 
A chromogenic substrate based amidolytic assay capable of solely 
detecting the antithrombin activity of rHV2 was employed. A dose dependent 
inhibition of thrombin was noted with this assay (Figure 23). At 25 µg/kg, 
almost 80% thrombin inhibitory activity was observed. Interestingly, the post-
FEIBA® samples collected at different dosages exhibited marked decreases 
when compared to the corresponding post-drug samples. These results, once 
again, reinforce the notion that FEIBA® produces a strong thrombogenic 
environment where rHV2 is neutralized as measured by a decreased inhibition 
of thrombin. 
In this investigation, a parallel assessment of the anticoagulant actions 
of rHV2 was made using different clotting methods and a specific 
chromogenic anti-Ila assay to compare with the observed antithrombotic 
actions of rHV2. This provided a comparative assessment of the relative value 
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of some of these ex vivo tests in the monitoring of the antithrombotic actions 
of rHV2. The APTT (Dade), Ca+ 2TT ( 10 U/ml) and anti-Ila assays provided 
relatively consistent dose dependent effects. All three assays also detected 
the thrombogenic effects of FEIBA®. Since, rHV2 represents a monospecific 
thrombin targeting agent, these results provide supportive evidence on the use 
of antithrombin assays in the assessment of ex vivo activity of rHV2. 
S.C. Administration. rH has been reported to exhibit a short half-life 
after i. v. administration (Bichler et al., 1988; Richter et al., 1988). Previous 
studies have been performed using the subcutaneous route and have 
demonstrated an increase in the biological residence time of rHV2 (Iyer et al., 
1993a). The dose-ranging study to evaluate the antithrombotic activity 
employed this additional route (s.c.) to compare and contrast the in vivo and 
ex vivo activity of rHV2 after the two routes of administration. 
There was a dose dependent increase in the antithrombotic activity of 
rHV2 after s.c. administration at both the 10 minute and 20 minute stasis 
times (Figure 24). Clot-scores of approximately "+ 3" and "+ 4" were 
obtained in the saline treated group at 10 and 20 minutes, respectively, which 
were consistent with the results from the i.v. studies. A dose dependent 
antithrombotic effect was observed after rHV2 doses of 125, 250 and 375 
µg/kg. In the groups with 10 minute stasis times, results compiled at 250 and 
375 µg/kg indicated a complete inhibition of clot formation. However, at the 
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125 µg/kg, only a 60% inhibition of clot formation was noted. Relatively 
weaker antithrombotic activity of rHV2 was observed at the 20 minute stasis 
times than that obtained at the corresponding 10 minute stasis times (p < 0.05 
after saline, 125 and 250 µg/kg of rHV2). This finding confirms the fact that 
a 20 minute stasis time results in a relatively stronger thrombogenic 
environment, which was also observed in the i.v. studies. ED50 values were 
calculated to be approximately 90 and 220 µg/kg, after 10 and 20 minute 
stasis times, respectively. At 375 µg/kg, rHV2 exhibited a complete absence 
of clot formation at 10 minutes and a slight residual clotting response at 20 
minutes. 
A series of ex vivo coagulation tests were performed in the s.c. studies 
to relate to the observed antithrombotic effects in the stasis thrombosis 
model, similar to the i.v. studies. In the particulate based APTT (OT) assay, 
there was a dose dependent, significant increase in coagulation times with 
increasing rHV2 administration (Figure 25). In addition, there was a significant 
decrease in clotting activity after administration of FEIBA® when compared 
with the 5 minute post-drug samples. In contrast, with the APTT (Dade) 
assay, there was no clear dose dependency of the clotting times as the dose 
of rHV2 was increased (Figure 26). In fact, none of the three doses of rHV2 
increased the clotting times significantly beyond baseline values. There 
appeared to be a lesser thrombogenic effect of FEIBA® as was evident from 
the apparent almost equal clotting times in the post-FEIBA® samples when 
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compared with those obtained at 5 minutes after rHV2 administration. A 
possible explanation for this observation may be the presence of trace 
amounts of protein C in FEIBA® (Fa reed et al., 1984). 
The results from APTT (Dade) and APTT (OT) tests after s.c. 
administration provided inconsistent data in comparison to the corresponding 
results obtained after i.v. administration. APTT (Dade) exhibited a more clear 
gradation of responses with different escalating doses when compared to 
APTT (OT), in the case of i.v. administration. On the other hand, after s.c. 
administration, the APTT (OT) assay was a better test to effectively 
differentiate between the three rHV2 doses and saline, when compared with 
APTT (Dade). While the reason for this apparent discrepancy is not clear, it 
may be possible that the rHV2 molecule is enzymatically modified after s.c. 
administration, possibly leading to different binding characteristics of rHV2 to 
thrombin, and hence leading to differential responses to the coagulation 
process initiated by varying APTT reagents. 
After s.c. administration, the thrombin reagent based coagulation tests, 
TT ( 10 U/ml) and Ca+ 2TT (10 U/ml), were performed in a manner identical 
to the i.v. studies. Interestingly, there was no demonstrable difference in both 
the TT ( 10 U/ml) and the Ca+ 2TT ( 10 U/ml) responses between the three 
subcutaneous doses of rHV2 (Figures 27 and 28, respectively). In the case 
of TT ( 10 U/ml), there was a steep increase in clotting times beyond 300 
seconds with the lowest dose, i.e 125 µg/kg, when compared to saline. With 
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Ca+ 2rr ( 10 U/ml), there were definite end points in the post-drug and post-
FEIBA® samples from some of the rabbits in the lower two doses but the 
coagulation times exceeded the 300 second limit of sensitivity after 
administration of 375 µg/kg of rHV2 (Figure 28). Furthermore, there was no 
significant reduction in the coagulation times in the samples obtained after 
FEIBA® administration in comparison to those obtained after rHV2 
administration, using both tests. Addition of CaCl2 solution to the 
conventional thrombin reagent did not contribute significantly in facilitating the 
coagulation process initiated by FEIBA®, in this set of results. 
The specific antithrombin activity of rHV2 was also determined by using 
the amidolytic anti-Ila assay, as described earlier. The results from this assay 
after s.c. administration provided a clear, dose dependent prolongation of 
thrombin inhibitory activity with rHV2 administration in increasing doses 
(Figure 29). A 90% inhibition of thrombin was observed in plasma samples 
after administration of the 375 µg/kg dose. It was interesting to note that 
there was no significant difference in the antithrombin activity between the 
post-FEIBA® and corresponding post-drug samples after administration of each 
dose of rHV2. 
In contrast to the results from the i.v. studies, the APTT (OT) and the 
anti-Ila assay provided more consistent results with the ex vivo results after 
s.c. administration of rHV2. This finding, again, can be explained by possible 
chemical or structural alteration of rHV2 after s.c. administration, producing 
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differential responses with various ex vivo coagulation tests. The possible role 
of subcutaneous barriers in the bioavailability of rHV2 after this route of 
administration is discussed elsewhere in this dissertation. 
A dosage of 375 µg/kg of rHV2 was selected for subsequent time 
course studies. It is important to point that a 38% thrombin inhibitory activity 
was obtained two hours after rHV2 administration in the lowest dose of 125 
µg/kg (Figure 29). At this dosage, the corresponding clot score was "+ 1" 
(Figure 24) and the corresponding APTT (OT) value (Figure 25) was 
approximately 90 seconds (baseline = 65 seconds). The 125 µg/kg rHV2 
dose was strong enough to increase the clotting times close to or beyond 300 
seconds in both the TT ( 10 U/ml) and Ca+ 2TT ( 10 U/ml) assays. Even 
though this 125 µg/kg dose did produce considerable antithrombotic activity 
at the 10 minute stasis time, it was only partially effective at the 20 minute 
stasis time (clot score of"+ 2"). Hence, successive increments of rHV2 doses 
beyond this dosage to 250 and 375 µg/kg were made. A clearly detectable 
antithrombotic activity was obtained with 375 µg/kg at both 10 and 20 
minutes in the stasis thrombosis experiment. 
The results from the s.c. studies support the use of ex vivo antithrombin 
assays such as the chromogenic thrombin substrate based assay to monitor 
the antithrombotic activity of rHV2. The results from this assay correlated 
well with the observed antithrombotic actions of rHV2. Thus, the amidolytic 
anti-Ila assay may be useful in the monitoring of antithrombotic activity of rHs. 
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2. Assessment of Hemorrhagic Activity of rHV2 using a Modified Rabbit 
Ear Blood Loss Model 
The hemorrhagic profile of rHV2 was investigated using a modified ear 
blood loss model, as described by Cade et al., 1984. This model has been 
used previously and has also been shown to yield reproducible results 
(Hoppensteadt, 1989; Racanelli, 1990; Bacher et al., 1993). The mean RBC 
loss from saline treated control rabbits was 0.026 X 1 o9 RBCs/L, which 
agreed with previous results using the same model (Racanelli, 1990; Bacher 
et al., 1993). 
l.V. Administration. Intravenous administration of rHV2 in escalating 
doses exhibited a dose dependent increase in hemorrhagic effect (Figure 30). 
However, hemorrhagic responses were significant only with the higher doses 
of rHV2. When used in the experimentally determined antithrombotic i.v. dose 
of 25 µg/kg of the agent, the RBC loss was comparable to that obtained with 
saline treated control rabbits. 
There was an apparent decrease in RBC loss after injection of the 2.5 
mg/kg dose of rHV2 (Figure 30). Nonetheless, this decrease in bleeding 
response after the 2.5 mg/kg dose, was not significantly different from the 
response after 1 mg/kg, both at 5 and 15 minutes. Hence, it may be 
concluded that the maximal limit of the hemorrhagic effect was attained after 
the 1 mg/kg dose of rHV2. The apparent dose to produce 50% of maximal 
toxicologic (hemorrhagic) response (TD50) was calculated to be 0. 7 and 0.8 
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mg/kg, at time periods of 5 and 15 minutes, respectively. 
S.C. Administration. Similar to the i.v. studies, a dose dependent 
increase in bleeding was observed with increasing s.c. doses of rHV2, in the 
modified rabbit ear blood loss model (Figure 31). There was comparable 
intensity of bleeding between experimentally determined antithrombotic s.c. 
dose of rHV2 (375 µg/kg) and saline treated control rabbits. 
The blood loss after administration of 5 mg/kg was used as the maximal 
response as further increases of rHV2 beyond 5 mg/kg may become toxic. 
The TD50 for the bleeding response after s.c. administration of rHV2 was 
calculated to be 2.8 and 0.8 mg/kg, at time periods of 1 and 3 hours, 
respectively. 
Protective Index for rHV2. Using the calculated ED50 values for 
antithrombotic activity, and TD50 values for hemorrhagic activity of rHV2 in 
rabbits, a pharmacological term, known as protective index (P.I.) was 
calculated. P.I. is given by the ratio: TD50!ED50 (Kokate eta/., 1994). It is 
a measure of relative toxicity of a drug, and has been used previously to study 
the hemorrhagic indices of other antithrombotic drugs such as heparin and 
dermatan sulfate (Santoro et al., 1992). 
The P.l.s were obtained from the dose-ranging studies for 
antithrombotic activity at 5 minutes and hemorrhagic activities at 3 hours after 
rHV2 administration in rabbits. The calculated P.I. values for rHV2 were as 
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follows: 
l.V.: P.I. = TD50/ED50 = 700/9 = 78 
S.C.: P.I. = TD50/ED50 = 800/90 = .9. 
It is clear that rHV2 has very high safety index, when used intravenously. The 
reason for the lower safety after s.c. administration is the 10-fold increase in 
ED50 values after s.c. administration, for the antithrombotic activity. Jeske 
(1995) found that the P.I. for unfractionated heparin was 17, using the same 
models of venous thrombosis and blood loss in rabbits. Santoro et al. (1992) 
observed that the P.I. values for i.v. heparin and dermatan sulfate were 1 and 
4, respectively, using venous thrombosis model and tail transection bleeding 
time in rats. 
It may be concluded that rHV2 is a relatively safe antithrombotic agent, 
exhibiting little/no hemorrhagic activity at antithrombotic doses in normal 
rabbits. However, at the same time, caution needs to be exercised during use 
of this agent in critical situations, as was evident from the results from the 
recent clinical trials on target patient population (Antman, 1994; Gusto Ila 
investigators, 1994). The relevance of these findings in other species may 
have to be carefully established because of the significant variations in the 
hemostatic profile in each species. 
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3. Evaluation of Pharmacokinetics and Time Course of Antithrombotic 
Activity after rHV2 Administration in Rabbits 
The purpose of the time course study in rabbits using the jugular vein 
stasis thrombosis model was to integrate pharmacokinetics of rHV2 with 
pharmacodynamic effects, as measured using antithrombotic actions of this 
agent. The time dependency of both in vivo and ex vivo antithrombotic and 
anticoagulant effects of rHV2 was studied in rabbits. rHV2 was used at an 
i.v. dose of 25 µg/kg and a s.c. dose of 375 µg/kg. 
I. V. Administration. At the 10 minute stasis interval, a complete and 
sustained in vivo antithrombotic activity was observed up to about 30 minutes 
after i.v. administration of rHV2 (Figure 32). However, at the 20 minute stasis 
interval, this activity was decreased at each corresponding circulation time of 
rHV2. This observation agrees with the results from the dose-ranging 
experiments in rabbits using the same model, where a stronger thrombogenic 
environment was evident at the 20 minute stasis interval. 
A gradual increase in clot scores was obtained at the 10 minute interval 
with increasing circulation times of rHV2. The clot scores at the 20 minute 
stasis time remained steady at approximately + 4 from 15 minutes to 3 hours, 
indicating almost no antithrombotic effect of rHV2, under this condition. The 
ultimate physiological mechanism of action of hirudin has been predicted to 
be the inhibition of thrombin generation (Fenton II et al., 1991). Recent 
reports, however, indicate that rH is not as effective as heparin in the 
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inhibition of thrombin generation (Kaiser et al., 1992). Stasis for 20 minutes 
may have allowed for a greater amount of thrombin generation than that may 
have been generated at the 10 minute stasis time, thereby antagonizing the 
antithrombotic effect of rHV2. 
A sigmoidal relationship was found when the results from the stasis 
thrombosis model were integrated with pharmacokinetics of rHV2 in rabbits 
(Figure 37). This indicated a classical biological response with a sigmoidal 
shape with increasing concentrations of rHV2. A significant correlation 
coefficient of 0.93 was obtained in the linear portion of the sigmoidal curve. 
The relationship between measured plasma rHV2 concentrations and 
the observed antithrombotic responses after i. v. administration of rHV2 was 
further studied, using a sigmoidal Emax model (Holford and Sheiner, 1982). 
The sigmoidal Emax model is a modification of the classical Emax model, and 
accounts for the shape of the concentration-effect relationship (Holford and 
Sheiner, 1982). It is a modification of the Hill equation that was proposed to 
describe the association of oxygen with hemoglobin (Hill, 1910). 
The sigmoidal Emax may be described as follows: 
E = E . C n 
max 
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, where E is the antithrombotic effect at a concentration, C. Emax and EC50 
are the maximal effect and the concentration required to produce 50% of 
maximal effect, respectively. n is a parameter that describes the shape of the 
curve. Figure 92 illustrates this relationship, where the reciprocal of clot 
scores was used to express antithrombotic activity. The simulated responses 
correlated significantly with the observed responses with a correlation 
coefficient of 0.99 (Figure 92). The Emax' EC50, and n values obtained for 
the simulated curve were 21.5 ± 0.4 (clot-score of = 0.047), 0.238 ± 0.003 
µg/ml, and 4.4 ± 0.3, respectively (mean ± SEM). These values matched 
the observed the observed Em ax and EC50 values, closely. 
The sigmoidal curve after intravenous rHV2 administration in rabbits 
represents crucial information on the plasma concentration-antithrombotic 
effect relationship of rHV2. This model indicates a direct relationship between 
rHV2 concentrations measured in the plasma and the observed antithrombotic 
responses. The equation for this model suggests that it may be likely that the 
rHV2-thrombin interaction may not be of a 1: 1 binding ratio. This model may 
be used to predict magnitudes of antithrombotic responses after measuring 
plasma rHV2 concentrations. The significant correlation between the actual 
values and predicted responses may be due to the fact that the effector site 
of the rHV2 is represented by the sampling compartment. 
The sigmoidal Emax relationship between plasma rHV2 concentrations 
and antithrombotic responses may be affected by the probable conversion of 
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Figure 92. The sigmoidal Emax model describing the relationship between 
antithrombotic effects of rHV2 and measured plasma rHV2 concentrations. 
The antithrombotic activity was measured using a modified jugular vein stasis 
thrombosis model in rabbits (n = 5). Plasma concentrations were measured 
using the competitive ELISA method. Emax = 21.5 ± 0.4, EC50 = 0.238 ± 
0.003 µg/ml and n = 4.4 ± 0.3. 
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rHV2 to active or inactive metabolites. Another factor that can affect this 
relationship may be the possible formation of antibodies to recombinant forms 
of hirudin, when administered repeatedly. 
With regard to the ex vivo assays, the time course of Ca+ 2TT ( 10 
U/ml) (Figure 34) and amidolytic anti-Ila assay (Figure 35) were almost 
superimposable with the time course of plasma concentrations of rHV2 (Figure 
36). This observation was substantiated by the fact that significant 
correlations were obtained between the plasma rHV2 concentrations and the 
Ca+ 2TT ( 10 U/ml) (r = 0.87, Figure 39) as well as the thrombin inhibitory 
activity of rHV2 (r = 0.94, Figure 38). The time course of APTT (OT) and 
APTT (Dade) assays correlated poorly with pharmacokinetics of rHV2, 
compared to the above tests (Figure 38). Therefore, a direct relationship 
between pharmacokinetics and pharmacodynamics of rHV2 was observed 
after i. v. administration of rHV2 using the Ca+ 2TT ( 10 U/ml) and 
chromogenic anti-Ila assay. 
The pharmacokinetics of rHV2 in rabbits was analyzed using standard 
non-compartmental analysis (Gibaldi, 1984; Gibaldi and Perrier, 1982; 
Rowland and Tozer, 1989). The advantages and limitations of compartmental 
modeling techniques have been of major interest to investigators (Wagner, 
1975; Yates, 1978; Fleishaker and Smith, 1987; Rescigno and Beck, 1987). 
In this dissertation, non-compartmental analysis based on statistical moment 
theory was used, as "the distinction between a drug that follows single-
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compartment model and one that follows two-compartmental kinetics is often 
not clear" (Gwilt, 1990). Moreover, it was found that different subjects within 
the same species exhibited different multicompartment kinetics, similar to 
previously reported results on other drugs (Gibaldi, 1984). Hence, model 
independent parameters such as clearance and volume of distribution were 
estimated using the statistical moment theory (Yamaoka et al., 1978). 
The pharmacokinetic parameters determined in this study agreed with 
previous results in rabbits using a chromogenic thrombin substrate 
(Chromozym®TH) assay (Nowak, 1991; Markwardt et al., 1982). Terminal 
elimination half-life (t112) after single dose i. v. administration was about 55 
minutes using the competitive ELISA method, which agrees with results 
published on the natural hirudin by Markwardt et al. (1982, 62 minutes), and 
on recombinant hirudin by Nowak (1991, 70 minutes). 
The plasma rHV2 concentration-time curve (Figure 36) indicated an 
instantaneous distribution phase of rHV2 followed by an elimination phase 
with a rate constant of 0. 76 hr-1. The volume of distribution (V d) was found 
to be approximately 137 ml/kg. This indicated a significant extravascular 
component in the volume of distribution of rHV2 as normal blood volume in 
rabbits has been reported to be about 55-57 ml/kg (Kozma et al., 1974). This 
may also explain the lower than expected Cmax value of 0. 75 µg/ml at 3 
minutes. A significant amount of this agent may have instantaneously 
distributed to the extravascular compartments before the first sampling time 
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of 3 minutes. 
S.C. Administration. The time course of antithrombotic activity and 
pharmacokinetics of rHV2 were evaluated in rabbits in a similar manner, as 
performed in the i. v. studies. Detailed information on the pharmacokinetics 
and pharmacodynamics of recombinant hirudin after s.c. administration in 
rabbits is not available to date. 
There was a major difference in the time course of physiological 
antithrombotic activity of rHV2 after s.c. administration, depending on the 
time period of stasis induced in the experimental conditions. Administration 
of a 375 µg/kg dose of rHV2 coupled with a 10 minute stasis period, resulted 
in an almost complete antithrombotic state (Figure 40). On the other hand, 
increasing the time of stasis to 20 minutes resulted in a progressive increase 
in antithrombotic activity up to 2 hours with a decline in activity, thereafter. 
A possible explanation for this finding may be that the dose of rHV2 employed 
was considerably strong to maintain an antithrombotic state up to 9 hours 
after administration and to oppose the thrombogenicity provided by the stasis 
period of 10 minutes. In addition, the clot score grading system employed, 
i.e. 0 to +4, provides a general gradation of antithrombotic activity. If it were 
possible to further differentiate the antithrombotic responses between a clot 
score of 0 and that of + 1 at various levels, a more clear, step-wise gradation 
of antithrombotic activity would have been made available. If such a grading 
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system was available, it would be possible to detect differences in the 
antithrombotic activity of rHV2 at various levels after different circulation 
times. 
Increasing the stasis time to 20 minutes resulted in a pattern of 
antithrombotic effect that was more appropriate for s.c. administration, with 
a peak, absorption phase and elimination phase {Figure 40). A sharp peak in 
in vivo activity was observed at 2 hours using a 20 minute stasis time. In 
contrast, a sustained, steady maximal response was observed between 
approximately 1 and 4 hours, using ex vivo tests such as Ca+ 2TT { 10 U/ml) 
(Figure 42) and chromogenic anti-Ila assay {Figure 43). This can again be 
explained by the fact that the responses in the stasis thrombosis model are 
graded on an ordinal scale, while the responses in coagulation tests, anti-Ila 
assay and plasma rHV2 concentrations are measured on an interval scale. 
When the in vivo antithrombotic activity in rabbits was related with 
plasma concentrations of rHV2 {Figure 45), a relationship similar to a counter-
clockwise hysteresis loop was obtained when the points of observation were 
joined in a sequence of time {Holford and Shein er, 1981; 1982). According 
to Holford and Sheiner { 1982), "this form of hysteresis is characteristic of a 
delay in equilibration between plasma drug concentration and the 
concentration of active substance at the effect site". A characteristic lag 
phase was observed to elicit maximal antithrombotic activity. In Figure 45, 
as the time progressed from 0.5 to 2 hours, increasing concentration of rHV2 
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was "available" in the plasma, thereby increasing the antithrombotic activity. 
There was a steep decline in antithrombotic response from 2 to 2.5 hours and 
3 hours, even though the corresponding plasma concentrations were 
approximately 0.3 and 0.26 µg/ml, respectively. This can again be explained 
by the ordinal nature of the clot score grading system. 
A clot score of approximately + 3.5 at 4 hours was obtained even 
though the plasma rHV2 concentration was at its maximum (0.38 µg/ml). 
This may be explained by the possible degradation of rHV2 after s.c. 
administration to products that are functionally inactive or less active, but 
maintain their immnunogenicity and hence, are detected by the ELISA method. 
The fate of hirudin after extravascular administration is not clear to this date. 
Enzymatic degradation of the hirudin molecule into products that may or may 
not be active is a good possibility. Information on the possible interaction of 
hirudin with components and enzymes in the endothelium is not clear. Pizzo 
et al. ( 1990) have shown that recombinant hirudin forms a complex with 
factor Xa and displaces factor Xa from endothelial binding sites. Previous 
preliminary studies in dogs with rHV2 have indicated an increased 
bioavailability and decreased sensitivity in coagulation tests and chromogenic 
anti-Ila assay after s.c. administration when compared with equal dose of i.v. 
administration (Iyer et al., 1993a). 
With regard to the ex vivo coagulation tests, no time dependency was 
exhibited by APTT (Dade) assay after s.c. administration of rHV2 (Hgure 41 ). 
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APTT (OT) and APTT (Dade) responses correlated poorly (r = 0.60 and 0. 19, 
respectively) when compared with corresponding responses after i. v. 
administration (Figure 46). As observed in the i.v. studies, the time course of 
Ca+ 2TT ( 10 U/ml) (Figure 42) and chromogenic anti-Ila assay (Figure 43) 
were almost identical to the plasma concentration-time curve (Figure 44). 
Ca+ 2TT ( 10 U/ml) responses correlated less significantly (r = 0. 73) with 
pharmacokinetics after s.c. administration when compared to i.v. 
administration (r = 0.87). The chromogenic anti-Ila assay correlated 
significantly with plasma concentrations after s.c. administration (r = 0.89). 
As mentioned earlier, the pharmacokinetics of rH has not been studied 
extensively after s.c. administration in rabbits. The bioavailability after s.c. 
administration of rHV2 was found to be approximately 45%, in these studies 
(Table 3). The total clearance rate was found to be identical to that found 
after i.v. administration, i.e. 104 ml/hr/kg. The volume of distribution (V d) 
was about the same as blood volume in rabbits, i.e. 58 ml/kg. This may be 
due to the decreased exposure of the drug across the subcutaneous barrier. 
In addition, the terminal elimination half-life (t 112) was only half of that 
found after i.v. administration. The t 112 after i.v. administration is a better 
indication of the elimination characteristics of a drug than extravascular 
administration. The increase in terminal elimination rate (ke) after s.c. 
administration may be an example of a reverse "flip-flop" model (Byron and 
Notari, 1976) where the estimate of elimination is driven by the estimate of 
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absorption. According to Byron and Notari (1976), the negative slopes of log 
linear plots of plasma concentration-time curves following extravascular drug 
administration may not represent reasonable estimates for the first order 
elimination rate constant. Absorption after s.c. administration is a complicated 
process involving the different layers of the skin and the presence of several 
enzymes. A flip-flop phenomenon or "vanishing exponential terms" in 
pharmacokinetic analysis of extravascular data may be observed due to the 
problems and uncertainties associated with the definition and differentiation 
of absorption and disposition profiles of a drug (Chan and Gibaldi, 1985). 
Due to such disparity in the t 112 values of rHV2 between the two routes 
of administration, the mean residence times (MRT) were used as a better 
indication of the biological residence time of rHV2. The MRT indicates the 
time taken for the elimination of 63.2% of a drug from the body; it is the non-
compartmental counterpart of the biological half-life (Gibaldi and Perrier, 
1982). Clearly, the MRT after s.c. administration was at least five times 
higher after i.v. administration. From the ke values after i.v. and s.c. 
administration, a significant portion of the MRT must be due to the absorption 
phase. 
A critical evaluation of the results from the i.v. and s.c. experiments in 
rabbits indicated that the biological residence time may be increased by using 
the s.c. route. However, caution needs to be exercised while using ex vivo 
coagulation tests to monitor rHV2 during s.c. administration due to an 
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apparent, comparatively poor correlation of some of the tests with plasma 
concentrations. The fate of rHV2 in terms of metabolic degradation after s.c. 
administration still remains to be delineated. 
4. Determination of Pharmacokinetic Characteristics and Ex Vivo 
Antithrombin Activity of rHV2 in Rats 
The purpose of this study was to profile the pharmacokinetics of rHV2 
in rats after administration of escalating doses via two routes of administration 
(i.v. and s.c.). Furthermore, the pharmacokinetics was integrated with ex vivo 
thrombin inhibitory activity of rHV2, using the amidolytic anti-Ila assay. 
l.V. Administration. There was a dose dependent increase in plasma 
concentrations of rHV2 with escalating doses in rats (Figure 49). The peak 
plasma concentration (Cmax) and area under the plasma concentration-time 
curve (AUC0_00 ) increased with the administration of each increasing dose, in 
a linear fashion (Table 8). Hence, it may be assumed that rHV2 exhibits linear 
pharmacokinetics in rats. At the same time, the total clearance rate and 
volume of distribution did not vary with increasing doses (Table 8). This 
finding agrees with previous results using escalating doses of rH in human, 
male subjects (Meyer et al., 1990). Therefore, the use of rH may be more 
advantageous than heparin in clinical indications, as heparin has been known 
to exhibit non-linear pharmacokinetics (Bjornsson and Levy, 1979a, 1979b; 
Emanuele, 1987). This may ease the dose adjustments that may be necessary 
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during monitoring of subjects on rH therapy. 
It must be mentioned that the V dafter the lowest dose was lower (0.94 
L/kg) with the lowest dose, when compared with that obtained with the higher 
two doses (1.7 and 1.8 L/kg). However, appropriate statistical analysis could 
not be done, as the pharmacokinetic parameters listed in Table 8 (as well as 
those in Table 9/rat and Tables 17 and 18/dog) were calculated from the 
composite plasma concentration-time curve. The parameters exhibited a wider 
scatter in rats, than those obtained after escalating rHV2 administration in 
dogs (discussed later). 
Extravascular distribution of rHV2 was evident from the V d parameters, 
as the blood volume in rats is reported to be = 64 ml/kg (Ringler and Dabich, 
1979). The elimination half-life (t112) in the terminal portion of plasma 
concentration-time curve did not alter after administration of each dose, with 
an average t 112 of about 22 minutes. This was found to be approximately 
three times smaller than corresponding observation (64 minutes) made by 
Markwardt et al. ( 1988a)., using recombinant hirudin in rats. In this study, 
the t 112 after i. v. administration was about 22 minutes after all three doses, 
with at least 24 rats in each treatment (dose) group. However, the methods 
used for the determination of plasma concentration of rH in the two studies 
are different: chromogenic anti-Ila assay versus the competitive ELISA 
method. In addition, Markwardt et al. (1988a) used recombinant hirudin 
variant 1 (rHV1) in Wistar rats, while this study employed the use of variant 
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2 of rH in Sprague-Dawley rats. 
With regard to the ex vivo antithrombin activity, rHV2 exhibited 
proportional increases in anti-Ila activity, with increasing i. v. doses (Figure 50). 
Significant correlations ( > 0.90) was obtained with plasma rHV2 
concentrations after administration of all three i.v. doses of rHV2. 
S.C. Administration. Similar to the i.v. studies, there was a dose 
dependent increase in Cmax values after s.c. administration (Figure 51, Table 
9). The terminal elimination half-life was about an hour after all three s.c. 
doses of rHV2. Most pharmacokinetic parameters led to the conclusion that 
rHV2 exhibits linear pharmacokinetic after s.c. administration. 
It has been shown that the clearance of rH in rats is largely extra-renal, 
when compared to other species, after i.v. (bolus and infusion) and s.c. 
administration of rHV2 (Richter et al., 1988). Previous results from the 
Hemostasis Research Laboratories, Loyola University Chicago, also confirm the 
decreased renal clearance of rHV2 in rats (cumulative urinary excretion, CUE, 
after i. v. dose = 5 % of dose, data not shown). It may be possible that with 
increasing s.c. administration, there is a saturation of enzymatic degradation 
of rHV2 in organs such as the liver. More studies are needed to investigate 
the exact mechanisms of non-renal clearance of rHV2 in species such as the 
rat. 
The results from the ex vivo antithrombin activity (Figure 52) after s.c. 
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administration exhibited good correlations with corresponding plasma rHV2 
concentrations determined by the ELISA method. 
In conclusion, it may be stated that rHV2 exhibited linear 
pharmacokinetics in rats on the basis of proportional increases in peak 
concentrations and area under the curve values, after increasing doses. This 
is substantiated by the similar elimination half-lives, total clearance and 
volumes of distribution after all three doses via both routes of administration. 
5. Evaluation of Renal Function after rHV2 Administration in Rats 
It has been proposed that recombinant hirudin would be an ideal drug 
for use as a prophylactic antithrombotic agent in the prevention of deep 
venous thrombosis, unstable angina and during cardiopulmonary bypass 
surgery (Fareed et al., 1989; Fareed et al., 1991 b; Johnson, 1994). Hence, 
it was important to determine the effect of rH on renal function. This 
becomes particularly important with the knowledge that rH has been shown 
to be primarily excreted unchanged (up to 92%) by the kidney (Markwardt, 
1991 b). To investigate the effect of rHV2 on renal function, a 3H-inulin 
clearance study was performed in rats at 24 hours, after i.v. and s.c. 
administration of rHV2. 
lnulin is a polysaccharide that is not metabolized in the body, and is 
uniquely excreted from the body only by glomerular filtration without tubular 
reabsorption or secretion (Alving and Miller, 1940). Hence, the measurement 
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of inulin clearance has been shown to be a highly reliable method to evaluate 
renal function via estimation of glomerular filtration rate (GFR) (Alving and 
Miller, 1940; Ferguson et al., 1950; Barnard et al., 1955; Prescott et al., 
1991). In this dissertation, a pharmacokinetic approach has been employed 
to measure the rate of inulin clearance (Clin), using time-decay curves of 
radioactivity in plasma after a single i.v. bolus injection of 3H-inulin. This 
method has been used previously and has been shown to reflect GFR, closely 
(Luke et al., 1991; Prescott et al., 1991). This method was simple and rapid, 
permitting Clin rates to be measured from plasma time-decay curves, thereby 
eliminating repeated collections of urine samples from subjects. 
The results from the 3H-inulin clearance studies in rats indicated that 
rHV2 did not alter renal function at a dose of 0.5 mg/kg, i.v., and 1.0 mg/kg, 
s.c., when compared with corresponding saline treated controls. The plasma 
time-decay curves of radioactivity were almost identical in the four treatment 
groups (Figure 53). The calculated Clin rates were approximately 1. 10 and 
1.36 ml/min/100g body weight, after i.v. and s.c. administration of rHV2 
respectively (Table 7). The corresponding values obtained after saline 
administration were 1.3 and 1.46 ml/min/100g body weight, respectively. 
These values for Clin closely matched the reported value for normal GFR in 
rats, i.e., approximately 1.02 ml/min/1 OOg body weight (Ringler and Dabich, 
1979). 
Concern over the delayed clearance of rHs, resulting in .extended 
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anticoagulant effects and bleeding complications, have been expressed, 
recently (Lefkovitz and Topal, 1994). This is primarily due to renal 
compromise in a select group of patients, such as the elderly. The 
pharmacokinetics of hirudin may be altered in patients with varying degrees 
of renal compromise. The 3H-inulin clearance studies reported here clearly 
indicate that rHV2 itself does not produce any renal compromise. Thus, a 
patient's own predisposing factors may be responsible for the observed 
sustained anticoagulant and bleeding complications in certain clinical trials 
(Antman, 1994; Gusto Ila Investigators, 1994). 
Sa. Serum Chemistry Profile in Rats after Administration of rHV2 
Serum chemistry parameters were analyzed prior to, and 24 hours after 
rHV2 administration, in order to evaluate any acute effects of rHV2 on renal, 
cardiac, liver and other general functions in rats. 
l.V. Administration. All baseline serum chemistry markers evaluated 
(except lactic dehydrogenase/LDH) were within reported, normal ranges in 
rats, as shown in Tables 11 and 12 (Ringler and Dabich, 1979; Lang, 1993b). 
Evaluation of liver function enzymes such as alkaline phosphatase (ALP), 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT), 
indicated that a 0.5 mg/kg dose of rHV2 did not alter hepatic function and 
integrity, when compared with saline treated controls. Hence, rHV2 
administration did not induce jaundice, hepatobiliary disease or hepatitis 
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(Zimmerman, 1984). Normal values of y-GT in the rHV2 treated group 
indicated an absence of hepatobiliary disease. The significant decrease in y-
GT in the saline treated group at 24 hours may be a result of stress, induced 
during the blood sampling procedure. The normal values of albumin (ALB) and 
total protein (T PROT) showed no defects in protein metabolism by the liver. 
Normal total bilirubin (T BIL) indicated absence of jaundice (Zimmerman, 
1984). 
Plasma cholesterol level was unchanged after rHV2 administration, 
when compared to saline treated control values. The significant decrease in 
triglyceride (TRIG) level after administration of rHV2, when compared to 
corresponding baseline, may also be due to the stress induced during 
collection of blood samples. This decrease in TRIG level was found in the 
saline treated groups, as well. Hyper- or hypoglycemia was not observed after 
rHV2 administration, as illustrated by normal glucose levels at baseline and 24 
hours after rHV2 administration. 
Serum LOH levels in rats from all groups were much higher than 
reported normal values of 15 IU/L (Loegering et al., 1974). However, 
according to Ringler and Oabich ( 1979), normal LOH values vary widely with 
each assay method used. Rat serum LOH has been shown to increase 
following bacterial infection (Mitruka and Jonas, 1969), administration of 
adrenergic stimulants (Marmo et al., 1973) and exercise (Loegering, 1974; 
Ringler and Oabich, 1979). In this study, there was no evidence of any 
282 
infection, nor were the rats administered with any adrenergic agents. It was 
observed that baseline LDH levels were similar between rats acclimated to 
normal housing and metabolic cages (data not shown). Furthermore, the LDH 
level was higher than expected at baseline, even before saline or rHV2 
treatment, as shown in Table 9. The reason for the slight, yet significant 
(p < 0.1), lowering of LDH 24 hours after saline treatment is not known. 
There were no changes in serum electrolyte values such as those of 
sodium (Na+), potassium (K +) and chloride (Cr), after i. v. administration of 
rHV2 (Table 9), indicating normal renal regulation of electrolytes (Murphy et 
al., 1984). In addition, normal kidney function was illustrated by serum 
creatinine (CREAT) and blood urea nitrogen (BUN) levels, which were also 
unchanged between saline and rHV2 treated groups. Calcium (Ca+ 2) and 
inorganic phosphorous (PHOS) levels were indicative of normal calcium and 
phosphorous homeostasis (Table 9). 
It is not clear if the slight increase in total co2 value at 24 hours was 
due to the administration of rHV2, or a result of hypoventilation or ventilation/ 
perfusion inequalities (Murphy et al., 1984), due to the inhalation of 
halothane. 
In summary, rHV2 did not significantly alter most serum biochemical 
markers, except total co2 and triglycerides, at 24 hours, when used in an i. v. 
dose of 0.5 mg/kg. 
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S.C. Administration. As observed in the i.v. studies, all baseline serum 
chemical markers (Tables 13 and 14) were within normal ranges reported 
(Ringler and Dabich, 1979; Lang, 1993b). Recent work has shown that rH 
(15 mg, s.c., b.i.d.) exhibited a lesser influence on liver enzymes, such as 
ALT, AST, y-GT, and ALP, when compared with unfractionated heparin (5000 
IU, s.c., t.i.d.), in patients undergoing total hip replacement (Lindbratt et al., 
1995). 
In general, there were no significant alterations in most parameters after 
s.c. administration of rHV2 (1.0 mg/kg), compared with saline treated 
controls. This indicated normal cardiac, renal and kidney functions after rHV2 
administration. However, there was a significant decrease in TRIG level in 
rHV2 treated rats at 24 hours, when compared with baseline, in agreement 
with the i. v. results (Table 13). Moreover, a slight, yet insignificant, reduction 
in TRIG was also observed in the saline treated control group. 
A significant decrease in LDH levels was observed after rHV2 
administration, which again, may be due to the stress of blood sampling 
procedure (Table 14). A moderate, yet significant, increase was observed in 
albumin level only in saline treated groups, after 24 hours. The increased 
serum albumin value (2.6 mg/dL) still fell within the normal range for albumin 
levels in rats (Ringler and Dabich, 1979). 
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5b. Hematological Profile in Rats after Administration of rHV2 
The variations in hematological parameters were evaluated after i. v. and 
s.c. administration of rHV2 in rats. Hematological markers such as cell 
counts, hemoglobin content and related parameters were measured. The 
hematology profile in rats used in this study (Tables 15 and 16) indicated 
normal baseline values for all markers, as reported in previous studies (Ringler 
and Dabich, 1979; Lang, 1993a). 
l.V. Administration. There was no significant variation in white blood 
cell (WBC) count after rHV2 treatment, when compared to saline treated 
control rats (Table 15). The significant decreases in red blood cell (RBC) 
number, hemoglobin (HGB) and hematocrit (HCT) observed in both the saline 
and rHV2 treated groups may be due to blood loss during repeated blood 
sampling. However, in both treatment groups, erythrocyte indices such as 
mean cell volume (MCV), mean cell hemoglobin (MCH) and mean cell 
hemoglobin concentration (MCHC) did not vary from corresponding baseline 
values, at 24 hours. This rules out the presence of any microcytic or 
macrocytic anemia (Nelson and Morris, 1984), as the above parameters are 
calculated from corresponding RBC count, HGB and HCT values. 
The platelet count was reduced moderately (significant, p < 0.05) in 
rHV2 treated rats, compared to baseline and saline treated rats. This 
reduction in platelet count may not be critically thrombocytopenic as the 
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platelet count still remained within the reported normal range for rats (Lang, 
1993a). In addition, there was no variation in the mean platelet volume (MPV) 
after rHV2 administration. Nonetheless, this observation of moderately 
reduced platelet count needs to studied more extensively in different 
experimental settings. 
S.C. Administration. There was no change in WBC count after s.c. 
rHV2 administration (Table 16), as seen in the i.v. studies. Again, there were 
significant reductions in RBC count, HGB and HCT after rHV2 administration, 
compared to corresponding baseline values. This finding can be explained by 
the blood loss due to repeated sampling procedure as there was a decrease 
in HCT in saline treated groups, as well (Table 16). Once again, no variations 
were observed in erythrocyte indices such as MCV, MCH and MCHC. 
The platelet count was normal and unchanged after s.c. administration 
of rHV2, though there was a trend toward a slight, but insignificant, decrease 
in thrombocytes after rHV2 administration (Table 16). More studies are 
required to rule out the possibility of any thrombocytopenia induced by 
recombinant hirudin, particularly after long term therapy. 
It may be concluded that none of the observed alterations in serum 
chemistry and hematological parameters after single dose administration in 
rats, may be considered drug-related. 
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6. Investigation of Pharmacokinetics and Pharmacodynamics of rHV2 after 
Single Dose Administration in Dogs 
The purpose of this set of experiments was to evaluate the 
pharmacokinetics and pharmacodynamics of rHV2 after increasing single dose 
administration in dogs. These studies were similar to the experiments in rats, 
but also included a series of ex vivo coagulation results. Both intravenous and 
subcutaneous routes were used, as before. The results from the single dose 
studies in dogs enabled the selection of an appropriate dose for the multiple 
dose study in dogs, to be discussed in the following section. 
l.V. Administration. The pharmacokinetic analysis of i.v. administration 
indicated that rHV2 exhibits linear pharmacokinetics, in agreement with the 
results obtained in rats. The t 112, V d and Cltot values did not vary between 
the three increasing doses of rHV2 (Table 17). At the same time, the AUC0_00 
and Cm ax values increased dose dependently. The V d values of 200 to 250 
ml/kg indicated that there was an extravascular component in the distribution 
of rHV2 in dogs. 
The time course of ex vivo coagulation tests was very similar to that 
obtained in the time course studies in rabbits. The progression of APTT (OT) 
(Figure 55) and APTT (Dade) (Figure 56) was comparable to the 
pharmacokinetic curve of rHV2 after single dose, i.v. administration. Dose 
dependent peak increases were obtained in both APTT (OT) and APTT (Dade). 
However, in the case of APTT (Dade), no distinction was observed in the 
287 
decline of responses between the three doses, after the peak response. 
The time course of ex vivo antithrombin activity was also evaluated 
using the thrombin based coagulation tests: TT (20 U/ml), Ca+ 2TT ( 10 U/ml) 
and Ca + 2TT (20 U/ml), as depicted in Figures 57, 58 and 59, respectively. 
The TT (20 U/ml) pointed toward the fact that rHV2 was a highly potent 
inhibitor of thrombin, leading to antithrombin responses that are beyond the 
sensitivity range ( > 300 seconds), at very low plasma rHV2 concentrations. 
As the TT (20 U/ml) values started declining after 30 minutes, the dose 
dependent antithrombin effect of rHV2 became more clear (Figure 57). 
Ca+ 2TT ( 10 U/ml and 20 U/ml) tests were performed to obtain more 
definite end points at high concentrations of rHV2 in plasma. However, 
coagulation responses remained steady at > 300 seconds using both of these 
tests, up to at least 15 to 30 minutes after rHV2 administration, in escalating 
i. v. doses. Again, as the clotting responses using Ca+ 2TT ( 10 and 20 U/ml) 
declined, the time response curves were oriented in a dose dependent fashion. 
An attempt was made to evaluate the antithrombin activity of rHV2 after 
increasing the calcium-thrombin content in the reagent to obtain Ca+ 2TT (30 
U/ml). However, the baseline value obtained for this test was only 3 to 4 
seconds. Plasma samples from time intervals after varying circulation times 
of rHV2 exhibited no measurable increase beyond the baseline values. These 
results indicated that a delicate balance is required to be maintained in the 
composition of the calcium-thrombin reagent, in order to obtain clotting 
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responses within the sensitivity range of the assay using the Fibrometer®. 
The anti-Ila assay, using the chromogenic thrombin substrate method, 
appeared to be the most reliable ex vivo method to predict antithrombin 
activity of rHV2. Thrombin inhibitory responses increased linearly with 
increasing i. v. doses of rHV2. The progression of anti-Ila responses matched 
the time course of plasma concentrations of rHV2 after i. v. administration in 
dogs. 
S.C. Administration. The pharmacokinetics of rHV2 after s.c. 
administration indicated that rHV2 exhibits linear pharmacokinetics, similar to 
the i.v. results. This was evident from the dose dependent increases in Cmax 
and AUC0_00 values (Table 18). Also, there were no significant differences 
between the three doses in V d• t 112, and Cltot rates. 
The average bioavailability of rHV2 after s.c. administration was almost 
equal to 98%, when compared to that after i.v. administration. However, the 
Cmax values obtained after each s.c. dose were considerably lower than 
obtained with corresponding i.v. doses (Figure 54, i.v. and Figure 61, s.c.). 
A lower antithrombin activity was also observed at the peak rHV2 levels after 
each s.c. administration (Figure 60, i.v. and Figure 67, s.c.). The relative F of 
98% after s.c. administration may be due to the sustained levels of rHV2 in 
plasma for an extended period of time ( 1 to 4 hours). In addition, it may be 
possible that the rHV2 molecule is modified after s.c. administration, to 
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produce a lower functional activity (anti-Ila assay, Figure 67), whilst retaining 
its immunological activity in the ELISA method. This finding agrees with 
previous results with single dose i.v. and s.c. administration of rHV2 (Iyer et 
al. , 1 993a). 
The time course study of ex vivo antithrombin activity of rHV2 after s.c. 
administration exhibited considerable variability in the responses between 
various dogs. The reason for this finding may be due to the possible 
differences in the subcutaneous barrier between dogs. 
It was evident that the bioavailability after s.c. administration varied 
between rats, rabbits and dogs. It may be speculated that this may be due to 
differential metabolic pathways and degradation patterns of rHV2 between the 
three species. Differential bioavailability patterns may be observed due to 
variations in enzymatic degradation and thickness of cutaneous barrier. rH has 
been shown to exhibit significant extra-renal clearance in rats (Appendix I). 
The exact mechanism of rHV2 metabolism in rats is not known. 
There was no definite distinction in the time course of APTT (OT) after 
the higher two doses (0.5 and 1.0 mg/kg, s.c.) of rHV2 (Figure 62). In the 
case of APTT (Dade), there was no difference between the three doses in the 
absorption phase, though the decline of responses after the peak appeared to 
be dose dependent (Figure 63). 
The thrombin based coagulation tests were performed in the s.c. 
studies, in an effort to obtain dose dependent dose-response curves. 
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Evaluation of ex vivo antithrombin effects of rHV2 using TT (20 U/ml) 
exhibited a sustained maximum response between about 60 and 180 minutes 
after s.c. administration of the higher two doses (Figure 64). A sharp peak 
was obtained in Ca+ 2TT ( 10 U/ml) and Ca+ 2TT (20 U/ml) responses, after 
administration of 0.5 and 1.0 mg/kg of rHV2, as shown in Figures 65 and 66, 
respectively. These results indicated that more definite end points in 
responses could be obtained using calcium-thrombin reagents to monitor ex 
vivo anticoagulant effects of rHV2. 
The time course of amidolytic anti-Ila activity exhibited distinct dose 
dependent increases in thrombin inhibitory activity of rHV2 (Figure 67). It was 
interesting to note that the peak anti-Ila response was only about 50%, after 
administration of the highest s.c. dose, i.e. 1.0 mg/kg, of rHV2. This may be 
due to the decreased availability of rHV2 after s.c. administration, or possible 
chemical modifications in rHV2 after s.c. administration, resulting in functional 
modifications of this agent. 
7. Investigation of Pharmacodynamics of rHV2 after Repeated 
Administration in Dogs 
The purpose of repeated administration of rHV2 was to determine any 
possible accumulation of rHV2 in dogs with time. This could lead to an 
increased sensitivity in antithrombotic activity of rHV2, and possibly to 
untoward side effects such as bleeding. On the other hand, repeated rHV2 
administration could lead to formation of neutralizing antibodies to rHV2, 
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resulting in decreased intensity of functional responses, and hence, a 
compromised therapeutic efficacy. 
l.V. Administration. Measurement of plasma concentrations of rHV2 at 
time periods of 6, 30 and 60 minutes, after each dose, showed that there was 
no significant accumulation or loss of rHV2 from plasma (Figure 68). No 
major alterations in the availability or disposition of the drug was noted with 
repeated i. v. administration (Table 19). Similarly, no major changes were 
observed in the ex vivo analysis tests, such as APTT (Dade), Ca+ 2TT ( 10 
U/mL) and anti-Ila assay (Figures 69 to 71, respectively). 
S.C. Administration. Similar to the i.v. results, there was no indication 
of possible accumulation or inactivation of rHV2 in plasma after repeated, 
daily, s.c. administration of rHV2, with respect to individual plasma levels 
(Figure 72). However, there was a trend toward a slight accumulation of 
rHV2, as indicated by the increase in AUC values and decrease in clearance 
values (Table 19). This finding may be due to the probable conversion of 
rHV2 to inactive metabolites, which may retain their immunogenicity. This 
argument is substantiated by the fact that there was no major variation in the 
ex vivo responses, as shown by the time course of APTT (Dade), Ca+ 2TT ( 10 
U/mL), and anti-Ila assay (Figures 73 to 75, respectively). 
No visible signs of excessive bleeding were evident at injection sites and 
blood sampling sites on the dogs used in the study, after each dose of rHV2. 
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Previous studies with repeated administration of rHV2 (2 mg/kg, i.v.) at a 
dosing interval of one week (for three weeks), pointed toward possible 
accumulation of rHV2 in plasma, and a trend toward sensitization of ex vivo 
antithrombin responses (Iyer et al., 1993b). However, the dose used was 
twice the current dose, and the dosing regimen was different. Bichler et al. 
( 1991) observed no formation of hirudin specific antibodies after repeated i. v. 
administration of natural and recombinant hirudin in baboons. 
The results from these studies indicated that recombinant hirudin may 
be used safely at daily i.v. and s.c. injections up to a period of one week 
without any significant accumulation of rHV2, or sensitization or 
desensitization of ex vivo antithrombin responses. The experiments were 
carried out in apparently healthy dogs, with normal renal function. It has been 
shown that plasma rH levels remained constant up to 120 minutes after i. v. 
administration in nephrectomized dogs (Nowak et al., 1988). Hence, it is to 
be emphasized that a renal function compromise due to age, drug or disease, 
may significantly alter the results. Therefore, individual studies are needed in 
the stated groups, as the study outcome is dependent on several factors. 
7a. Serum Chemistry Profile in Dogs after Repeated rHV2 Administration 
The purpose of this study was to investigate possible changes in 
physiological function in dogs after chronic administration for one week. 
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l.V. Administration. The serum chemistry markers at baseline agreed 
with reported normal values on some parameters in dogs (Schalm et al., 1975) 
and routine profiles performed in Hemostasis Research Laboratories. There 
were no fluctuations in liver enzymes at a daily i.v. dose of 1 mg/kg of rHV2, 
as indicated by the normal levels of ALP, AST and ALT (Figure 78) when 
compared to baseline, prior to initial dose, using the two-way repeated 
measures ANOV A. The significant (p < 0. 1) day-to-day variation in y-GT 
values (Figure 79) may not be of major concern, as the values returned to 
normal levels, by the sixth day. Serum electrolytes (Figure 77), as well as 
BUN and creatinine (Figure 78) did not vary with repeated rHV2 
administration, indicating normal renal function. The observed normal levels 
of total protein, total bilirubin and albumin indicated normal protein synthesis 
(Figure 76 and 79). Normal phosphorous and calcium homeostasis were also 
evident (Figures 76 and 77, respectively). 
The significant (p < 0.1) day-to-day fluctuations in total co2 may be due 
to the stress of daily rHV2 administration and repeated blood sampling. 
Conscious dogs were used; hence, any ventilation/ perfusion disorders due to 
anesthetics may be ruled out. There were normal levels of LDH, triglycerides, 
glucose and cholesterol throughout the period of repeated rHV2 administration 
(Figure 80). 
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S.C. Administration. Normal electrolyte and lipid levels, renal function, 
protein synthesis, calcium and phosphorous homeostasis and functional 
hepatic integrity, and a non-diabetic state were observed after repeated s.c. 
administration of rHV2, at a dose of 1 mg/kg (Figures 81 to 85). The 
significant step-wise decrease in LDH levels after rHV2 administration on most 
days may be due to the stress induced by repeated blood sampling. 
Nonetheless, this observation requires further clarifications. 
7b. Hematological Profile after Repeated rHV2 Administration in Dogs 
l.V. Administration. The hematological profile after repeated i.v. 
administration of rHV2 indicated that there were no major variations in most 
parameters (Figures 86 to 88). However, by the sixth day of the study, there 
was almost a 13% decrease in HCT, and a 20% decrease in HGB levels. This 
finding may be due to the repeated blood draws for an extended period of 
time. 
S.C. Administration. There was a significant variation in HCT and HGB 
levels after repeated rHV2 administration, in agreement with the results from 
the i.v. study. Most other parameters exhibited negligible variations with time 
(Figures 89 to 91). 
In conclusion, it may be stated that the observed alterations in some of 
the serum chemistry and hematological parameters after multiple rHV2 
administration in dogs, may not be drug-related. 
CHAPTER VI 
SUMMARY 
This dissertation addressed the pharmacokinetic and pharmacodynamic 
investigation of rHV2, with particular reference to the utilization of existing 
global tests for the monitoring of the anticoagulant effects. In addition, 
thrombin inhibition assays and absolute quantitation of rHV2 were 
accomplished by developing optimized methods. From the pharmacodynamic 
studies, additional information on the relative therapeutic safety and potential 
toxicity of rHV2 was obtained. A summary of results from the major 
experimental protocols included in this study, is listed below: 
In Vitro Studies 
1 . Species and assay dependent anticoagulant effects of rHV2 were 
observed, utilizing the existing APTT reagents, modified TT assays and an 
amidolytic anti-Ila assay. These methods were capable of detecting hirudin 
in original concentration ranges of 0.01 to 5 µg/ml. However, the linear 
ranges varied markedly. In the amidolytic anti-Ila assay, while the rabbit, rat 
and dog plasma provided similar results, the rat plasma required much higher 
(10-fold) concentrations to exhibit linear inhibitory responses. 
295 
296 
2. This dissertation provided valid data on thrombin titration method 
as a means to evaluate the potency of rHV2 and related antithrombin agents. 
rHV2 was found to exhibit a specific activity of = 15,873 ATU/mg (1.1 x 108 
ATU/mM). 
3. A polyclonal antibody based competitive ELISA method provided 
a procedure to measure the absolute concentrations of rHV2 in plasma 
obtained from different species. A concentration dependence on the 
immunoreactivity of rHV2 enabled the quantitation of rHV2 in various plasma 
systems for the determination of pharmacokinetic parameters. The linear 
range of this assay was between 25 and 1000 ng/ml. 
In Vivo Studies 
Antithrombotic and Hemorrhagic Profile of rHV2 
1 . rHV2 produced a dose dependent antithrombotic effect in a 
modified rabbit jugular vein stasis thrombosis model. The apparent ED50 after 
i. v. administration of rHV2 was in the range of 9-11 µg/kg, at a time period 
of 5 minutes. The apparent ED50 after s.c. administration of rHV2 was 90-
220 µg/kg, at 2 hours. 
2. rHV2 also produced a dose dependent increase in the blood loss, 
as measured in a modified ear blood loss model in rabbits. The apparent TD50 
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values of rHV2 after i.v. and s.c. administration were 0.7-0.8 mg/kg, and 0.8-
2.8 mg/kg, respectively. No significant blood loss was measured after 
administration of experimentally determined therapeutic doses of rHV2, when 
compared to saline treated control rabbits. 
3. The protective index, as calculated from antithrombotic and 
bleeding responses at circulation times of rHV2 corresponding to observed 
peak plasma rHV2 levels in rabbits, was found to be 78 (i.v.) and 9 (s.c.)., 
indicating a wide margin of safety. 
Pharmacokinetic Profile of rHV2 
1 . The pharmacokinetic parameters in all three species were 
calculated from the absolute levels (ELISA method) using non-compartmental 
methods. In rabbits, the terminal elimination half-life (t 112) was 55 and 24 
minutes after i.v. and s.c. dosing of rHV2, respectively. The results from this 
study were consistent with previously reported data. The biological residence 
time after s.c administration was much higher after s.c. administration (mean 
residence time/MRT of > 3 hours after s.c. administration). The Vd obtained 
from the i. v. studies demonstrated that there was an extravascular component 
in the distribution of rHV2 in rabbits. The relative bioavailability (F) after s.c. 
administration was 45%, when compared with i.v. administration. 
2. The pharmacokinetics of rHV2 was studied in rats after escalating 
i.v. (0.1, 0.4 and 0.5 mg/kg) and s.c. (0.1, 0.5 and 1.0 mg/kg) administration. 
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The mean t 112 was= 22.2 and 40 minutes, after i.v. and s.c. administration, 
respectively. No differences in t 112, time to reach maximum concentration 
(tmax), clearance rate (Cltot) and volume of distribution (V d) values were noted 
after step-wise dose increment in both i.v. and s.c. studies. However, a dose 
dependent increase in area under the plasma concentration-time curves 
(AUC0_00 ) and maximum concentrations (Cmax) values was apparent. These 
results indicated that rHV2 exhibited linear pharmacokinetics in rats. The V d 
values indicated extravascular distribution, as observed in rabbits. 
3. The pharmacokinetics of rHV2 was also studied in a dog model 
after increasing i.v. (0.25, 0.5 and 1.0 mg/kg) and s.c. (0.25, 0.5 and 1.0 
mg/kg) doses. The mean t 112 was = 60 minutes after i.v. and s.c. 
administration in dogs, consistent with previous results. rHV2 exhibited linear 
pharmacokinetics in the dog model, as well. This was evident from dose 
dependent increases in Cmax and AUC0_00 , and no major variations in t 112, V d 
and Cltot parameters between the three i.v. and s.c. doses. Extravascular 
distribution was also observed in dogs, similar to the results from the rat and 
rabbit studies. The F value was = 98% after s.c. administration of rHV2 in 
dogs, indicating species differences in absorption, distribution and degradation 
mechanisms of rHV2. 
4. Utilizing the single dose 3H-inulin clearance method, no effect on 
renal function was observed when compared with saline treated rats. rHV2 
was used in doses of 0.5 mg/kg, i.v. and 1 mg/kg, s.c. Thus, rHV2, by itself, 
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did not produce any renal compromise in rats. 
Pharmacodynamic Profile of rHV2 
1 . In the dose-ranging study in rabbits, rHV2 exhibited dose and 
route of administration dependent ex vivo anticoagulant and anti-Ila activity. 
rHV2 also exhibited a time dependent ex vivo anticoagulant and anti-Ila 
activity in rabbits, as observed in the time-course experiments. 
2. The in vivo antithrombotic activity of rHV2 was found to be time 
dependent, after the administration of a dose of 25 µg/kg {i.v.) and 375 {s.c.). 
In the i.v. studies, the apparent t 112 of antithrombotic effect at 10 minute 
stasis, was greater than 75 minutes, whereas after the 20 minute stasis time, 
the t 112 was approximately 10 minutes. In the s.c. studies, persistent, 
complete antithrombotic response lasted for up to 6 hours, at the 10 minute 
stasis time. In the 20 minute stasis study, complete inhibition of the thrombus 
formation was noted at 2 hours, after which time, there was a gradual loss of 
antithrombotic activity, reverting to baseline level at 4 hours. 
3. The time course of ex vivo antithrombin activity of rHV2 was also 
studied in rats, using the amidolytic anti-Ila assay. There were dose 
dependent increases and time and route dependent variations in anti-Ila 
activity of rHV2 in this study. 
4. Dose, time and route dependent ex vivo anticoagulant/ 
antithrombin activity was also observed after increasing i.v. and s.c. 
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administration of rHV2 in dogs. 
Integrated Pharmacokinetics and Pharmacodynamics of rHV2 
1 . Significant correlations were obtained between plasma 
concentrations of rHV2 determined from the ELISA method, and 
antithrombotic as well as antithrombin/ anticoagulant activity of rHV2. This 
finding depended on the species, route of administration and individual assay 
method used. 
2. The concentration-effect relationship after i. v. administration of 
rHV2 in rabbits could be described by the sigmoidal Emax model. This 
indicated a direct relationship between plasma rHV2 concentrations and 
observed in vivo antithrombotic responses. The model can be used to predict 
magnitudes of responses in future. 
3. To simulate the prophylactic use of rHV2, a repeated dosage 
study was performed in dogs ( 1 mg/kg, i. v. and s.c. for one week). In the 
anticoagulant assays, no evidence of accumulation or loss of this agent was 
evident. However, in the ELISA method, an initial phase of equilibration, 
resulting in a progressive increase in circulating rHV2 levels was noted for a 
period of up to two days after i.v. administration. After this, a uniform 
concentration profile was evident. In contrast, in the s.c. studies, all assays 
revealed a uniform concentration and antithrombin profile after all doses. 
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Clinical Laboratory Profile after rHV2 Administration 
1 . The ex vivo analysis of the sera samples from rats treated with 
0.5 mg/kg (i.v.) and 1 mg/kg (s.c.) did not reveal any alteration of 
hematological parameters, when compared to saline treated rats. All 
parameters were comparable in the clinical chemistry profile, with the 
exception of a decrease in triglycerides and lactic dehydrogenase (LDH). 
These results indicate that rHV2 administration, at these doses and route, 
does not produce any toxic responses, as measured by clinical laboratory 
profile. 
2. Clinical laboratory profile was also studied after repeated rHV2 
administration in dogs (1 mg/kg, i.v. and s.c., for one week). The ex vivo 
analysis of sera obtained from the repeated i.v. and s.c. studies did not reveal 
any major alterations in hematological and clinical profile. However, a 
suggestive day-to-day variation in total co2 (i.v.) and LDH (s.c.) was noted, 
however. Consistent with rat studies, these data, once again, indicate the 
non-toxic nature of rHV2 at the given dosage schedule in dogs. 
CHAPTER VII 
CONCLUSIONS 
1 . Thrombin titration and polyclonal antibody based ELISA methods have 
been developed to determine functional potency and absolute 
concentrations of recombinant hirudin variant 2 (rHV2), respectively. 
2. While species dependent variations in the anticoagulant and anti-Ila 
responses with rHV2 were obvious, these methods can be used to 
monitor the antithrombin effects of this drug. 
3. rHV2 represents a drug that exhibits a wide margin between 
antithrombotic and hemorrhagic responses after i.v. administration: 
broad therapeutic window. 
4. rHV2 did not compromise renal function, or produce significant any 
alterations in clinical laboratory profile. 
5. rHV2 exhibited linear pharmacokinetics in two animal species, i.e. rats 
and dogs, and demonstrated extravascular distribution in all three 
species. 
6. This agent may be used safely in repeated i.v. administration protocols. 
7. The time course studies indicated a direct correlation between 
pharmacokinetics and pharmacodynamics of rHV2. 
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8. The in vivo pharmacodynamic/pharmacokinetic relationship of rHV2 
may be described using a sigmoidal Em ax model, after i. v. 
administration in rabbits. 
9. These studies demonstrated that rHV2 is a potent anticoagulant and 
antithrombotic agent with a predictable pharmacokinetic/ 
pharmacodynamic relationship, and a desirable therapeutic index. 
APPENDIX I 
PHARMACOKINETIC SURVEY OF NATURAL 
AND RECOMBINANT HIRUDIN 
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Reference 
Markwardt 
et al., 
1982 
Markwardt 
et al., 
1984 
TABLE 20 
PHARMACOKINETIC SURVEY ON NATURAL AND RECOMBINANT HIRUDIN (PART I) 
Hirudin Subjects Dose & Assay Results 
Route 
Natural Rats 10,000 Chromogenic t 112 (a)=10 min. 
Rabbits A TU/kg, Substrate t 112 !Bl= 51 min. (dogs);62 min.(rabbits);56 min.(rats) 
Dogs i.v. bolus. Method 70% of hirudin administered was found in urine within 
200 the first hour. 
A TU/kg, 
infusion 
(rats) 
Natural Humans 1000 Chromogenic i.v.bolus s.c. 
(male) A TU/kg, Substrate t 1 !2(a) =0.15 hr. t 1/Z(B) =0.64 hr. 
i.v. bolus, Method t 1/Z(B) =0.84 hr. ka=1.1 1/hr. 
s.c. V d(ss) = 12.9 L F=36% 
AUC = 5.69 ATU.hr./ml 30% of 
Cltot = 230 ml/min. administered 
Clren = 99.5 ml/min. hirudin 
45% of hirudin administered recovered 
was recovered in urine in urine 
.......... 
w 
0 
01 
Reference 
Richter 
et al., 
1988 
Bichler 
et al., 
1988 
TABLE 21 
PHARMACOKINETIC SURVEY ON NATURAL AND RECOMBINANT HIRUDIN (PART 11) 
Hirudin Subjects Dose & Assay Results 
Route 
Natural; Dog 0.5 mg/kg Thrombin Rat 
125_1 Rat (dog) Binding i.v. infusion %recover)l 
labelled 1 mg/kg Assay t 112(a) = 12.4 min. t 112 =2hr. 15.1 %-i.v. (rat) (microcolumns t 112u31 =65 min. 11.0%-s.c. 
i.v., s.c., of thrombin- Vd(ssl=0.22 l 14.8%-inf. 
i. v. infusion sepharose) AUC0_5h = 1. 74 pg.hr/ml 
Cltot = 170 ml/min 
Dog 
i.v. infusion %recover)l 
t 112 (al = 12.5 min. t 112 (13) = 5 hr. 87.6%-i.v. 
t 112 (13) = 56.6 min. 58.7%-s.c. 
V d(ss) =4.55 l 67.6%-inf. 
AUC0_5h = 1.38 pg.hr/ml 
Cltot = 7060 ml/min. 
Natural Humans 600, 800, Radioimmuno s.c. i.v. 
(3 females 1000 bioassay t 1121ai=74.8 min. t 112(a) =9.2 min. 
9 males) ATU/kg,s.c. (RIBA) t 1121131 =101.3 min. t 1121131 =64. 7 min. 
Cltot = 153 ml/min. Cltot = 187. 1 ml/min. 
1000 Clren = 92.6 ml/min. Clren = 79.9 ml/min. 
ATU/kg, i.v. CUE=61.2% AUC=0.677 pg.hr/ml 
V d(ss) =0.24 L/kg 
CUE=42.5% 
....... 
w 
0 
m 
Reference 
Markwardt 
et al., 
1988a 
Markwardt 
et al., 
1988b 
TABLE 22 
PHARMACOKINETIC SURVEY ON NATURAL AND RECOMBINANT HIRUDIN (PART Ill) 
Hirudin Subjects Dose & Assay Results 
Route 
Recom- Rats 1 mg/kg, Chromogenic Rats 
binant; Dogs i.v., s.c., Substrate i.v. s.c. 
(£.Coli, i.v. Assay t 112(a) = 0.15 hr. k8 = 2.3 1 /hr. 
Genbiot infusion, t 112~Bl = 1 .07 hr. t 112(B) = 1.9 hr 
eel intratracheal % AU 0_5h = 1.64 µg.hr/ml 1251- instillation radioactivity Vd(ss6=0.66 L/kg Instillation labelled rectal measured Ve= .31 L/kg t 112(B) = 200 min. 
in urine Cltot = 3.05 ml/min. 
Urinary excretion 
i.v.-15.1 %, inf.-14.8%, s.c.-11 %, inst.-1.8% 
No marked absorption after rectal administration 
Dogs 
i.v. Cltot = 1 83 ml/min 
t 112(a) = 0.25 hr. Clren = 1 52ml/min 
t 112~al = 1 .22 hr s.c. 
AU 0_6h = 1.54 µg.hr/ml t 1 /~Bl=5.75 hr. 
V d(ss) = 0.28 L/kg 70°0 recovered in 
urine in active form 
Recom- Humans 0.1 mg/kg, Chromogenic i.v. bolus s.c. 
binant (females) i.v. bolus, Substrate t 112(a) = 0.15 hr. k8 =1.1 1 /hr. (S.cere- i.m., s.c. Method t1/2(B)=0.91 hr. 28.5% recovery in urine. 
viaseae AUC0_6 = 0.54 µg.hr/ml 
Hoech- Vd(ss1=8.9 L i.m. 
st AG) Cltot = 168 ml/min. ka = 1 1 /hr. 
Clren = 58.2 ml/min. 40. 7% recovery in urine. 
34.6% recovery in urine. 
,........, 
c.u 
0 
......i 
.......... 
Reference 
Nowak 
et al., 
1988 
Markwardt 
et al., 
1989 
Meyer 
et al., 
1990 
TABLE 23 
PHARMACOKINETIC SURVEY ON NATURAL AND RECOMBINANT HIRUDIN {PART IV) 
Hirudin Subjects Dose & Assay Results 
Route 
Recom- Dogs, 0.5 mg/kg, Chromogenic ~ s.c. 
binant normal, i.v., s.c., Substrate 70% excreted within 1 hr. t 112~~) = 5. 75 hr. (£.Coli, nephrect- i. v. infusion Assay Plasma rH levels remained AU 0_6 = 1.71 
Genbio- omized constant after 120 min. pg.hr/ml 
tee) in nephrectomized dogs 
More pronounced renal clearance of rH 
than natural hirudin 
Recom- Rats 1 mg/kg Thrombin t 112(a) = 0.08 hr. 
binant 2 mg/kg Clotting t 1121~1 =1.18 hr. (CGP i.v. bolus time Vd(ss)=0.63 l/kg 
39393, AUC0_3h = 3.81 pg.hr/ml 
Ciba) Cltot = 2.09 ml/min. 
rHV2 
Recom- Humans 0.01, 0.02, Chromogenic Existence of third compartment cannot be excluded 
binant (males) 0.04, 0.07, Substrate AUC and Cmax - dose related, Cl and V d(ssr constant 
(Hoech 0.1 mg/kg; Assay with increasing doses, total urinary excretion 
st AG) i.v. bolus proportional to increasing doses - Linear 
Pharmacokinetics 
0.1 .m.gLkg 
t1/2(a)=0.1 hr. Cltot = 205 ml/min. 
t, /2(~) = 0.82 hr. Clren = 94.2 ml/min. 
V d(ss) = 14.3 L. 
.......... 
w 
0 
CX> 
.......... 
Reference 
Markwardt 
et al., 
1991 
TABLE 24 
PHARMACOKINETIC SURVEY ON NATURAL AND RECOMBINANT HIRUDIN {PART V) 
Hirudin Subjects Dose & Assay Results 
Route 
Dextran Rabbits 10000 Thrombin Dextran 40-hirudin: 
bound Rats A TU/kg Inhibition Rats 
recombi (rats, Assay 1000 ATU/kg: 10,000 ATU/kg: 
nant rabbits), t 112(a) = 0.28hr. t 112(a) = 0.2 hr. 
hirudin 10,00 t 1121.tl1=6.3 hr. t, t2ttg = 6.9 hr. (Hoech A TU/kg Vd=36.1 ml Vd= 6.6 ml 
st AG) (rats) AUC0_6h = 50.2 A TU.hr/ml AUC0_6h = 370 
ATU.hr/ml 
Rabbits 
1000 A TU/kg: 
t 112(a) = 0.4hr. 
t, /21.tll = 6.3 hr. 
Vd=336ml 
AUC0_6h =46 A TU.hr/ml 
Similar results with dextran 70-hirudin 
.......... 
w 
0 
c.o 
........ 
TABLE 25 
PHARMACOKINETIC SURVEY ON NATURAL AND RECOMBINANT HIRUDIN (PART VI) 
Reference Hirudin Subjects Dose & Assay Results 
Route 
Bichler Natural Baboons 1000 Indirect ELISA No evidence of immune response to natural and 
et al., and A TU/kg Competitive recombinant hirudin - poor immunogenic potential. 
1991 recombi on days 1, ELISA for 
nant 3, 8 and 42 detection of 27 % of administered dose recovered in urine. 
hirudin antibodies. 
(plantor Radioimmuno Half-life of urinary elimination was 27 minutes 
gan) bioassay for (shorter than humans - 120 min.) 
measurement 
of hirudin 
(Direct Skin 
test and in 
vitro 
histamine 
release) 
Bichler Recomb Rats 20-60 µg/kg Chromogenic Majority of radioactivity recovered in kidney for all three 
et al., inant for hirudin, substrate labelled entities. 
1993 hirudin, 5-20 µg/kg assay Conjugation of * 1-DL T to hirudin did not influence its 
dilactito for hirudin- Measurement pharmacokinetic behavior. 
I 1251_ thrombin of Hirudin is catabolized in kidney; thrombin-hirudin 
tyramin complex, radioactivity complex is catabolized in liver and kidney. 
e (*I- 5 µg/kg for in tissues 
DLT)- thrombin-
labelled AT complex 
APPENDIX II 
SPECIFICATIONS ON rHV2 
(BATCH RHE 15, Sanofi Recherche, France) 
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SANOR RECHERCHE - CENTRE DE TOULOUSE 
195, ROUTE D'ESFAGNE 
B.P.1169 - 31036 TOULOUSE CEOEX (RW'CE) 
TEL: 61432200 
TELEX: 531 535. 
TELECOPIE: 61432201 
~sanoFi 
Ms Lalitha Iyer 
Dept of Pharmacology 
Loyola University 
2160 South First Avenue 
MAYWOOD 
Illinois 60656 
U.S.A. 
Our ref. : JPM/ AJP /130/91 
Dear Ms Iyer, 
10th October 1991 
In response to the questions you asked in your letter, you will find hereafter some. 
answers and articles which may be of use to you. 
1. The compound in solution is stable for 24h at 25°C and for 7 days at s·c. 
Concerning the second part of your question, a thorough study has not been 
carried out but we think that hirudin which has been frozen and thawed once 
can be used without any problem. It is however advisable not to freeze and 
thaw several times. 
2. RHElS vials contain 10.9 mg of hirudin. The specific activity is 14495 ATU/mg. 
3. The complete amino acid sequence is shown in the enclosed article : The 
structure of a complex of recombinant hirudin and human a-thrombin, RYDEL 
TJ et al. 
4. Yeast expression vector used : plasmid is an E.coli yeast shuttle vector designed 
to direct the secretion of foreign proteins in yeast. It contains the 2-µm segment 
and the yeast LEU2 gene as well as the ApR gene and the origins of replication 
ofpBR322. 
5. Molecular weight is 6906 as determined by MS analysis. 
6. Plasma concentration determination by the following methods : (see attached 
sheets) 
- thrombin time (TT) 
- activated cephalin time (TCA) 
- chromogenous substrate 
(313] 
Urine concentration determination by chromogenous substrate assay. 
7. We do not have any radiolabelled hirudin available. See attached article : Site 
specific radioiodination of recombinant hirudin, TUONG et al. 
Trusting that this information will help you in your doctoral dissertation, 
Encl. 
cc: J. FAREED, J.M. HERBERT 
Yours Sincerely 
Jean-Pierre MAFFRAND 
Scientific Director 
Toulouse Research Centre 
SANOR RECHERCHE ·CENTRE DE TOULOUSE 
195. ROUTE D'ESPJ\GNE 
B.P.1169 ·.31036 TOULOUSE CEDEX 
Ta.: 61432200 
TB.EX: 531 535 
TELECOPIE: 61432201 
CERTIFICATE OF ANALYSIS 
SR 29010 
I~ 
- Analysis n° 
- Date of the request 
- Page 
[314] 
2775 
26-NOv-1990 
1/3 
10 mg SR 29010 PCMDER FOR PARENTERAL USE 
- SUpplier SANOFI RECHER.am MONTPELLIER - Date of receipt : 26-Nov-1990 
- Reference : lA1 - Manufacture date : 15-May-1990 
- Batch RHElS - Expiration date : 15-May-1991 
- Batch size: 782 units - Number of containers : 1 
- Quantity : 581 Units 
- Storage conditions : + 4° c 
- Monograph : CCR4416 - Edition 1 
TESTS SPECIFICATIONS RESULTS 
CHARACTERS 
Appearance Complies Complies 
(1) 
IDENTIFICATION 
Mannitol Complies Complies 
(1) 
Active ingredient 
-
Reverse phase chromatography Complies Complies 
-
Anionic exchange chromatography Complies Complies 
-
Exclusion chromatography Complies Complies 
TESTS 
Uniformity of mass Complies Complies 
(1) 
Reconstituted solution Not more opales- Not more opales-
appearence cent than referen- cent than referen-
ce suspension II, ce suspension II, 
colorless colorless 
pH of the reconstituted solution 3.5 to 5.5 5.43 
SANOR RECHERCHE ·CENTRE DE TOULOUSE 
195. ROUTE O'ESFAGNE 
B.P. 1189 • 31038 TOULOUSE CB>EX 
TB..:81432200 
TB.EX: 531 535 
TB.ECOPIE: 8143 2201 
CERTIFICM'E OF MW.'!SIS (cont'd) 
SR 29010 
10 mg SR 29010 PamER FOR PABEN'l'ERAL USE 
[315] 
Ana,lysis n° : 2775 Date of the request 26-Nov-1990 
2/3 Batch : BBEJ.5 Page 
TESTS SPECIFICATICH; RESULTS 
water content not more than 1.4 per cent 
3.0 per cent (l) 
Impurities by reverse phase not more than 2.4 per cent 
chromatography 5.0 per cent 
Impurities by anionic exchange not more than 0.6 per cent 
chromatography- 5.0 per cent 
Impurities by exclusion chroma- not more than 0.8 per cent 
tography 3.0 per cent 
Sterility Complies Complies 
Ul 
Pyrogens Complies Complies 
(l) 
Abnormal toxicity Complies not performed 
Tightness Complies not performed 
ASSAY 
Reverse phase chromatography 9.0 to 11.0 mg ll.18 mg 
(on the substance as it is, per 
vial) 
OBSERVATIONS 
( l) Results of the initial control • 
SANOR ,RECHERCHE ·CENTRE DE TOULOUSE 
195. ROUTE D'ESPAGNE 
B.P. 1169 • 31036 TOULOUSE CEDEX 
TEL:61432200 
Ta£X: 531535 
taECOPIE: '8143 22 01 
CERTIFICATE OF ANALYSIS (cont'd) 
SR 29010 
10 mq SR 29010 PCH)ER FOR PAimn'ERAL USE 
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sanoFi 
RECHERCHE 
ArJa+ysis n° : 2775 Date of the request 26-Nov-1990 
3/3 Batch : RHE15 Page 
Decision : RELEASED 
Remarks 
not for human use 
QUALITY CONTROL 
Analyst in charge of study : Pascal CARDON ~ _ 07-Dec-1990' 
Head of Quality Control : Gerard MAIRE 
COMPLEMENTARY RESULTS 
SR .29010 
Analysis n° 
Batch 
2775 
RHE15 
TESTS 
COMPLEMENTARIES RESULTS 
TESTS 
Residual oxygen content 
ASSAY 
Biological activity 
(on the substance as it is) 
Date of the request 
Complementary Page 
26-Nov-1990 
1/1 
SPECIFICATIONS RESULTS 
not more than 0.5 per cent 
2.0 per cent (1) 
13060 to 15960 not performed 
AIIa U. per mg 
[317) 
TABLE 26 
AMINO ACID COMPOSITION OF VARIOUS RECOMBINANT HIRUDIN 
PREPARATIONS AS DETERMINED BY PICO-TAG METHOD8 
HV1 Preparationsb HV2 Preparationsb 
AA Cale Ciba HHF Knoll Cale Hoech Sanofi HPF F1c - F2c 
Asp 9 6.4 8.3 5.1 9 8.5 8.5 6.5 1.1 - 3. 7 
Glu 13 10.8 12.6 10.1 11 13.6 11.7 8.6 1.4 - 4.4 
Ser 4 4.3 4.3 5.9 4 4.5 4.9 4.2 1 .3 - 2.1 
Gly 9 9.6 10.4 11.3 10 11 12.5 11.4 2.2 - 4.4 
His 1 1 . 1 1 . 1 1. 1 1 1 . 1 1. 1 1.4 1.2 - 1 .9 
Arg 0 0 0 0.8 0 0 0 0 0.5 - 0.4 
Thr 4 4.1 3.9 3.6 5 5.2 5.1 4.2 0.8 - 2.2 
Ala 0 0 0 1.6 0 0 0 1.6 1.4 - 1 .3 
Pro 3 3.5 3.6 3.4 3 3.6 3.6 5.8 1.0 - 2.2 
Tyr 2 2.0 2.0 2.0 2 2.0 2.0 2.0 0.6 - 1 .1 
Val 4de (3.31 (2.71 (3.01 2 2.0 2.2 1.7 1.4 - 1. 7 
Met 0 0 0 0 0 0 0 0 0.0 - 0.0 
Cys 5df (2.91 (4.61 (2.61 5df (4.31 (3.61 (3.71 (2.8 - 2.01 
lie 2 2.0 1.9 1.9 3 1.8 3.0 2.2 0.8-1.5 
Leu 4 4.0 3.9 3.8 4 4.8 4.3 2.7 1.2 - 1 .9 
Phe 1 1.3 1.2 1.4 1 1.3 1.2 1.4 1 .0 - 1.0 
Lys 3 3.4 3.2 2.6 4 3.0 3.9 3.3 2.1 - 4.8 
a-Analyses that do not agree with the calculated values within ± 20% are underlined. 
b-The N-terminal sequences, i.e., VVTY of HV-1 and ITYT of rHV2, were checked by 
using an ABI 471 A protein/peptide sequencer. c-Fraction 1 and 2 isolated by HPLC 
from Biopharm's preparation as its two main components being present in a ratio of 
about 25:75. d-Under the conditions of acid hydrolysis used, the val-val of HV1 does 
not split completely and a partial decomposition of cys takes place, thus the values 
obtained for eval and fcys are uncertain. 
This is an excerpt from a letter from Dr. Sandor Bajusz, Institute for Drug 
Research, dated October 29, 1991, addressed to Dr. Jawed Fareed, Director, 
Hemostasis Research Laboratories, Loyola University Medical Center. 
Reprinted, by permission. 
APPENDIX Ill 
COPYRIGHT PERMISSION FORMS 
Permission was obtained from authors of publications from which 
excerpts were reproduced or modified. The letters of permission obtained 
from each author are contained in the following pages. 
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LO YO IA 
UNIVERSITY 
CHICAGO >ti:;
0 (j :f'~. o'i-'> LOYOL\ UNIVERSITY MEDICAL CENTER 
January 30, 1995 
Ms. Alina Ozimek, 
The Yale Medical Historical Library, 
333, Cedar Street, 
P.O. Box 3333, 
New Haven, CT 06510. 
Dear Ms. Ozimek, 
Lalitha Iyer 
2160 South Fi"t .\\enue 
\lan\CXl<l, Illinois l'(Jl.i3 
Tclephonl': l~ll~J 21M-"t~l0 
Tel: (708) 216-3262 
Fax: 708-216-6660 
[319] 
I am completing a doctoral dissertation at the department of Pharmacology, Loyola 
University Chicago entitled "Phannacokinetics and Phannacodynamics of Recombinant Hirudin 
Variant 2 (rHV2) in Animal Models". I would like your permission to modify and reproduce 
in my dissertation an excerpt from the following: 
An illustration of the 1827 lithograph showing a physician placing leeches on patient's 
neck. Enclosed please find a copy of this illustration, as reproduced in my dissertation. 
The requested permission extends to any future revisions and editions of my 
dissertation, including non-exclusive world rights in all languages, and to the prospective 
publication of my dissertation by University Microfilms, Inc. These rights will in no way 
restrict republication of the material in any other form by you or by others authorized by you. 
Your signing of this letter will also confirm that you own the copyright to the above-described 
material. 
[320] 
If these arrangements meet with your approval, please sign this letter where indicated 
below and return it to me in the enclosed return envelope. I would really appreciate it if could 
please send the approval by February 10, 1995. 
Thank you. very much. 
Sincerely, 
Lalitha Iyer, 
Dept. of Phannacology, 
Loyola University Chicago. 
PERMISSION GRANTED FOR TIIE 
USE REQUESTED ABOVE: 
Date: ~/ / f,:i.:{' 
Pharrn.aceutlcals Division 
Lalitha Iyer 
Dept. of Pharmacology 
Loyola University Chicago 
Medical Center 
2160 South First Avenue 
Maywood, Illinois 216-9000 I U.S.A. 
FAX: 708-216-6660 
Your letter to Dr. R. Wallis, January 20, 1995 
e.g. Copyright request on enclosed illustration 
Dear Mrs. Iyer, 
Ciba-Geigy Limited 
CH-4002 Basie 
Switzerland 
Dr. W. Mllrld 
[321] 
Core Drug Olscovely Techn. 
PH 2.251 
l<-681.3.43 
Tel. (+61)896.55.84 
Fax (+61)696.40.69 
Basel, J3nuary 27, 1995 
On request of Dr. Wallis from Biopharm (U.K.) Ltd. I give you the permission to include I use the 
enclosed figure on the primary structures of hirudin isoinhibitors in your doctoral dissertation. 
I hope to have been of assistance to you. 
With kind regards, 
W. Marki 
Telefax 
i Empfanger 
' Receiver Lalitha·Iyer 
Dept.or Pharmacology 
Loyola University Chicago 
Maywood, IL 
Fax: 001·708-216-6660 
Dear Mrs.Iyer: 
~Schauauer 
F. K. Schatraucr Ver!agsgesellschaft mbH 
~edizin und :-lacurwissen.scnaften 
Stuttgart • New York 
: An:i:ahl dcr Seicen einschl. diescr: 
j number of pages including this one: 
I Telefax (07 lll 2 29 87 SO 
, Te!cfon (07 11 l 2 29 81. 
! Phone 
: Datum 
Date I February 17,1995/he 
Thank you for your letter of rebruary 11,1995, received by fax. We 
grant you permission to reproduce the modified illustration (fig.1) 
of the article by M~rk1 and Wa1lis "The Anticoagulant and Antithrombo· 
tic Properties of Hfrudins", published in Thrombosis and Haemostasis 
64 (3): 344-348 in your doctoral dissertation. 
Please give appropriate credit to original publication in a standard 
credit line. 
Yours sincerely, 
~·~W-
Hannelore Hensen 
Manager Thrombosis and Haemostasis 
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LO YO IA 
~rm· . ~ UNIVERSITY ~ · x CHICAGO 
J> :; 
01' .s ~i\.f-D~\: LOYOL\ UNIVERSITY 'vtEDICAL CENTER 
STRITCH SCHOOL OF 'vtEDICINE 
2160 South First Avenue 
MaV\,oo<l. lllin01s 60133 
Telephone: r~OSl 216·3261 
fox: I ~08 I 2lb·6596 
Department ot Pharmacolog~' & Expenmcmal TherJ.peucic:; 
January 11, 1995 
A. Tulinsky, Ph.D., 
Dept. of Chemistry, 
Michigan State University, 
320, Chemistry Bldg .. 
East Lansing, MI 48824-1322. 
Dear Dr. Tulinsky, 
Lalitha Iyer 
Tel: (708) 216-3262 
Fax: 708-216-6660 
This letter will confirm my conversation with your secretary. I am completing a 
doctoral dissertation at the department of Pharmacology, Loyola University Chicago entitled 
"Pharmacokinetics and Pharmacodynamics of Recombinant Hirudin Variant 2 (rHV2) in 
Animal Models". I would like your permission to modify and reproduce in my dissertation. 
an excerpt from the following: 
Rydel, T.J., Ravichandran, K.G., Tulinsky, A., Bode. W., Huber, R., Roitsch, C., 
and Fenton II, J.W. 1990. The structure of a complex of recombinant hirudin and 
human a-thrombin. Science. 249:277-280. 
The excerpt to be reproduced is an illustration on the sequence of recombinant hirudin 
variant 2-Lys47 on page 278 (figure 1) of the above mentioned article. I have reprod11ced the 
sequence of native hirudin alogside this figure, indicating differences between native and 
recombinant hirudin in the "Review of Literature" chapter of my dissertation. Enclosed 
please find a copy of this illustration as modified in my dissertation. 
The requested permission extends to any future revisions and editions of my 
dissertation, including non-exclusive world rights in all languages, and to the prospective 
publication of my dissertation by University Microfilms, Inc. These rights will in no way 
restrict republication of the material in any other form by you or by others authorized by you. 
Your signing of this letter will also confirm that you own the copyright to the above-described 
material. 
[324) 
If these arrangements meet with your approval, please sign this letter where indicated 
below and return it to me in the enclosed return envelope. 
Thank you very much. 
Sincerely, 
Lalitha Iyer, 
Dept. of Pharmacology, 
Loyola University Chicago. 
PERMISSION GRAi~TED FOR THE 
USE REQUESTED ABOVE: 
,.,.- r J A 1.J.~, ., 
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LOYOLA 
~SJ· , ~ UNIVERSITY 3: ~CHICAGO 
;)> ~ 0 .-./ ~~'If.\)~\:'-> LOYOL-\ UNIVERSITY :v!EDICAL CENTER 
STRITCH SCHOOL OF VIEDICINE 
!160 Soulh First Awnue 
11.laywoo<l. lllinms 60153 
Telephone: (~081 !lb-3261 
Fa.<: I ~OS l 216-65% 
Depanmc:m oi Pharmacology & Experimental Therapeuucs 
January 20, 1995 
Claudine Picard, Ph.D., 
Service Analyse de Reserche, 
Analytic Research, 
Sanofi Reserche. 
195 route d'Espagne, 
B.P. 1169, 31036 Toulouse Cedex, 
France. 
Dear Dr. Picard, 
Lalitha Iyer 
Tel: (708) 216-3262 
Fax: 708-216-6660 
This letter will confirm our recent fax messages. As you know, I am completing a 
doctoral dissertation at the department of Pharmacology_, Loyola University Chicago entitled 
"Pharmacokinetics and Pharmacodynamics of Recombinant Hirudin Variant 2 (rHV2) in 
Animal Models". I would like your permission to modify and reproduce in my dissertation 
an excerpt from the following: 
Tuong et al., 1992. Characterization of the deamidated fonns of recombinant hirudin. 
Biochemistry. 31: 8291-8299. 
The excerpt to be reproduced is an illustration on the primary structure of recombinant 
hirudin variant 2 (rHV2-Lys 47) that appears on page 8291 (figure 1) of the above article. 
Enclosed please find a copy of this illustration, as modified in my dissertation. 
The requested pennission extends to any furure revisions and editions of my 
dissertation, including non-exclusive world rights in all languages, and to the prospective 
publication of my dissertation by University Microfilms, Inc. These rights will in no way 
restrict republication of the material in any other form by you or by others authorized by you. 
Your signing of this letter will also confinn that you own the copyright to the above-described 
material. 
If these arrangements meet with your approval, please sign this letter where indicated 
below and return it to me in the enclosed return envelope. I would really appreciate it if could 
please send the approval by January 31, 1995. 
Thank yo.u very much. 
Sincerely, 
, I\. iJ.A/ 
' .• )J~. 
Lalitha Iyer, 
Dept. of Pharmacology, 
Loyola University Chicago. 
PERMISSION GRANTED FOR THE 
uSE REQUESTED ABOVE: 
//.-,.........-:i. .. o( 
--~ 
( c.. _ ~ \c. Fl R. D 
Date: 20"/0/l I 05 
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LOYOLA 
~·11· . ~ UNIVERSITY i: ~CHICAGO 
> = o.f> .s ~--o~" LOYOL\ lJNIVERSITY :V!EDICAL CENTER 
STRITCH SCHOOL OF MEDICINE 
2160 South First . .\venue 
Maywood. lllinois 60153 
Telephone: (7081 216-3261 
Fax: ( 708 i 216-6596 
Department oi Pharmacology & Experimental Therapeutics 
January 11, 1995 
Professor Fritz Markwardt, 
Institute of Pharmacology and Toxicology 
Medical Academy Erfurt, 
Erfurt, 
Germany. 
Dear Prof. Markwardt, 
Lalitha Iyer 
Tel: (708) 216-3262 
Fax: 708-216-6660 
This letter will confirm my recent telephone conversation with Prof. Breddin. I am 
completing a doctoral dissertation at the department of Pharmacology, Loyola Universiry 
Chicago entitled "Pharmacokinetics and Pharmacodynamics of Recombinant Hirudin Variant 
2 (rHV2) in Animal Models". I would like your permission to modify and reproduce in my 
dissertation an excerpt from the following: 
Markwardt, 1991. Past, present and future of hirudin. Haemostasis. 21(suppl. 1): 11-
26. 
The excerpt to be reproduced is an illustration on the scheme of hirudin-thrombin 
reaction that appears on page 13 (figure 1) of the above article. Enclosed please find a copy 
of this illustration, as modified in my dissertation. 
The requested permission extends to any future rev1S1ons and editions of my 
dissertation, including non-exclusive world rights in all languages, and to the prospective 
publication of my dissertation by University Microfilms, Inc. These rights will in no way 
restrict republication of the material in any other form by you or by others authorized by you. 
Your signing of this letter will also confirm that you own the copyright to the above-described 
material. 
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If these arrangements meet with your approval, please sign this letter where indicated 
below and return it to me in the enclosed return envelope. I would really appreciate it if could 
please send the approval by February 10, 1995. 
Thank you very much. 
Sincerely, 
Lalitha Iyer, 
Dept. of Pharmacology, 
Loyola University Chicago. 
PERMISSION GRANTED FOR THE 
USE REQUESTED ABOVE: 
/i~4:r£tt-
( i::.:~:. ~ ..... - ::;~;- ) 
Date: -?. . :.:t. 2£ 
LOYOLA 
? !j· , ~ UNIVERSITY 
s: ::::: CHICAGO 
,,. :: 
0 $' :f'~ilf.u~" LOYOL\ CNIVERSITY MEDICAL CE:-.ITER 
STRITCH SCHOOL OF '.'llEDICINE 
Department ol Pharmacolo~v & Experimental Therapeutic> 
February 20, 1995 
Jawed Fareed, Ph.D., 
Professor of Pathology and Pharmacology, 
Loyola University Medical Center, 
2160, S.First Avenue, 
Maywood, IL 60153. 
Dear Dr. Fareed, 
llbll South First Avenue 
~avwxxl. Illinm.s 60153 
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Telephone: (~08) 116·3261 
Fa.<: (~08) 216·65% 
Lalitha Iyer 
Tel: (708) 216-3262 
Fax: 708-216-6660 
This letter will confirm our recent conversation. As you know, I am completing a 
doctoral dissertation at the department of Pharmacology, Loyola University Chicago entitled 
"Pharmacokinetics and Pharmacodynamics of Recombinant Hirudin Variant 2 (rHV2) in 
Animal Modelsu I would like your permission to modify and reproduce in my dissertation, 
an excerpt from the following: 
Fareed et al., 199 lb, "An objective perspective on recombinant hirudin: a new 
anticoagulant and antithrombotic agent", Blood Coag. Fibrinol., 2:135-147. 
The excerpt to be reproduced is a table on the laboaratory assays for measurement 
of hirudin, that appears on page 138 of the above mentioned article. I have reproduced the 
sequence of native hirudin alogside this figure, indicating differences between native and 
recombinant hirudin in the "Review of Literature" chapter of my dissertation. Enclosed 
please find a copy of this illustration as modified in my dissertation. 
The requested permission extends to any future revisions and editions of my 
dissertation, including non-exclusive world rights in all languages, and to the prospective 
publication of my dissertation by University Microfilms, Inc. These rights will in no way 
restrict republication of the material in any other form by you or by others authorized by 
you. Your signing of this letter will also confirm that you own the copyright to the above-
described material. 
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If these arrangements meet with your approval, please sign this letter where indicated 
below and return it to me in the enclosed return envelope. 
Thank you very much. 
Sincerely, 
Lalitha Iyer, 
Dept of Pharmacology, 
Loyola University Chicago. 
PER;\1ISSION GR.At'ITED FOR THE 
USE REQUESTED ABOVE: 
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LO YO IA 
~~-. ~ UNIVERSITI i: ~CHICAGO 
> -0 $1 ~~\.f.tJ~\: LOYOL\ UNIVERSITY '.\llED!C..\L CENTER 
STRITCH SCHOOL OF '.\llED!CINE 
2160 South First Avenue 
Mavwood. Illinois 60133 
Telephone: (~08) 216-3261 
Fax: ( ~08) 216·63% 
Department oi Pharma-:olo~v & Experimental Therapeutics 
January 11, 1995 
Jeanine Walenga, Ph.D., 
Associate Professor, 
Department of Pathology & 
Thoracic and Cardiovascular Surgery, 
Loyola University Medical Center, 
2160, S. First Avenue, 
Maywood, IL 60153. 
Dear Dr. Walenga, 
Lalitha Iyer 
Tel: (708) 216-3262 
Fax: 708-216-6660 
This letter will confirm our recent conversation. I am completing a doctoral 
dissertation at the depanment of Pharmacology, Loyola University Chicago entitled 
"Pharmacokinetics and Pharmacodynamics of Recombinant Hirudin Variant 2 (rHV2) in 
Animal Models". I would like your permission to modify and reproduce in my dissertation 
an excerpt from the following: 
Walenga, 1987. Factor Xa inhibition in mediating antithrombotic actions: application 
of a synthetic heparin pentasaccharide. Ph.D. diss., University of Paris. 
The excerpt to be reproduced is an illustration on the modified rabbit jugular vein 
stasis thrombosis model on page number 82 of your Ph.D. dissertation. Enclosed please find 
a copy of this illustration as modified in my dissertation. 
The requested permission extends to any future rev1s10ns and editions of my 
dissertation, including non-exclusive world rights in all languages, and to the prospective 
publication of my dissertation by University Microfilms, Inc. These rights will in no way 
restrict republication of the material in any other form by you or by others authorized by 
you. Your signing of this letter will also confirm that you own the copyright to the above-
described material. 
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If these arrangements meet with your approval, please sign this letter where indicated 
below and return it to me in the enclosed return envelope. 
Thank you very much. 
Sincerely, 
Lalitha Iyer, 
Dept. of Pharmacology, 
Loyola University Chicago. 
PERMISSION GRANTED FOR THE 
USE REQUESTED ABOVE: 
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LOYOLA 
~ mJ· , ~ UNIVERSTIY 3:: ~CHICAGO 
> :: 
"O $'' :j>~Af·D~\'. LOYOL\ UNl'./ERSlTY '.'v1ED!CAL CENTER 
STRITCH SCHOOL OF '.VIED!CINE 
2160 South First Avenue 
Maywood. Illinois 60153 
Telephone: f 708 l 216-3261 
Fax: 1708) 216-6596 
Department ui Phannarnlo~v & Experimental TI1erapeut1cs 
January 11, 1995 
Jeanine Walenga, Ph.D., 
Associate Professor, 
Department of Pathology & 
Thoracic and Cardiovascular Surgery, 
Loyola University Medical Center, 
2160, S. First Avenue, 
Maywood, IL 60153. 
Dear Dr. Walenga, 
Lalitha Iyer 
Tel: (708) 216-3262 
Fax: 708-216-6660 
This letter will confirm our recent conversation. I am completing a doctoral 
dissertation at the department of Pharmacology, Loyola University Chicago entitled 
"Pharmacokinetics and Pharmacodynamics of Recombinant Hirudin Variant 2 (rHV2) in 
Animal Models". I would like your permission to modify and reproduce in my dissertation, 
an excerpt from the following: 
Walenga, 1987. Factor Xa inhibition in mediating antithrombotic actions: application 
of a synthetic heparin pentasaccharide. Ph.D. diss., University of Paris. 
The excerpt to be reproduced is an illustration on the clot-score grading system in the 
modified rabbit jugular vein stasis thrombosis model on page number 83 of your Ph.D. 
dissertation. Enclosed please find a copy of this illustration as modified in my dissertation. 
The requested permission extends to any future revisions and editions of my 
dissertation, including non-exclusive world rights in all languages, and to the prospective 
publication of my dissertation by University Microfilms, Inc. These rights will in no way 
restrict republication of the material in any other form by you or by others authorized by 
you. Your signing of this letter will also confirm that you own the copyright to the above-
described material. 
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If these arrangements meet with your approval, please sign this letter where indicated 
below and return it to me in the enclosed return envelope. 
Thank you very much. 
Sincerely, 
·\~ j. \ . )J , 
Lalitha Iyer, 
Dept. of Pharmacology, 
Loyola University Chicago. 
PERMISSION GRANTED FOR THE 
USE REQUESTED ABOVE: 
- ""' -(~-~~~::--=--==~:o 
( ~c,..,i...,e 1,bl~"- ) 
,< 
Date: :.).."t.-"""'°"112;. l"i'1 >" 
LOYOL.\ 
UNI\TRSITY 
CHICAGO 
January 16, 1995 
Adrienne Racanelli, Ph.D, 
DuPont Merck Pharmaceutical Company, 
Experimental Station Bldg. E400/3213, 
Wilmington, DE 19880-0400. 
Dear Dr. Racanelli, 
Lalitha Iyer 
2lti0 South Fir~t .\H'llllt.' 
\l;I\ \\IKRI. Illinoi~ Mll53 
fdq1ho1tL': I ~OS I 2lb-YIXM) 
Tel: (708) 216-3262 
Fax: 708-216-6660 
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This letter will confirm our recent telephone messages. I am completing a 
doctoral dissertation at the department of Pharmacology, Loyola University Chicago 
entitled "Pharmacokinetics and Pharmacodynamics of Recombinant Hirudin Variant 2 
(rHV2) in Animal Models". I would like your permission to modify and reproduce in my 
dissertation an excerpt from the following: 
Racanelli, 1990. Biochemical and pharmacological studies on the interaction of protamine 
with heparins. Ph.D. diss., Loyola University Chicago. 
The excerpt to be reproduced is an illustration on the modified rabbit ear blood 
loss modei 011 page r1urnba 332 of your I'h.8. dissertation. Eacloscd please find a copy 
of this illustration, as modified in my dissertation. 
The requested permission extends to any future rev1S1ons and editions of my 
dissertation, including non-exclusive world rights in all languages, and to the prospective 
publication of my dissertation by University Microfilms, Inc. These rights will in no way 
restrict republication of the material in any other form by you or by others authorized by 
you. Your signing of this letter will also confirm that you own the copyright to the above-
described material. 
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If these arrangements meet with your approval, please sign this letter where 
indicated below and return it to me in the enclosed return envelope. 
Thank you very much. 
Sincerely, 
v~ 
Lalitha Iyer, 
Dept. of Pharmacology, 
Loyola University Chicago. 
PERMISSION GRA."JTED FOR THE 
USE REQUESTED ABOVE: 
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LO YO IA 
~ ". . ~ UNIVERSTIY ~ :;;: CHICAGO 
> :: 
f3 $' 'f>~l.f-D~" LOYOL\ UNI\. 'ERSITY '.\1EDICAL CE:'JTER 
STRITCH SCHOOL OF '.'AEDIC!NE 
2160 South First Avenue 
:\laV\HJo<l, Illinois 60153 
Telephone: I ~08) 21&-3261 
Fax: 1~08) 21&-6596 
Department of Phannawlogy & Experimental Therapeutll·s 
March 27, 1995 
Sandor Bajusz, Ph.D., 
Institute for Drug Research, 
H-1325, Budapest, POB 82, 
Szabadsagharcosok u. 47-49, 
Hungary. 
Dear Dr. Bajusz, 
Lalitha Iyer 
Tel: (708) 216-3262 
Fax: 708-216-6660 
This letter will confirm our recent conversation. I am completing a doctoral 
dissertation at the department of Pharmacology, Loyola University Chicago entitled 
"Pharmacokinetics and Pharmacodynamics of Recombinant Hirudin Variant 2 (rHV2) in 
Animal Models". I would like your permission to modify and reproduce in my dissertation 
an excerpt from the following: 
A letter written by you, addressed to Dr. Jawed Fareed, Director, Hemostasis 
Research Laboratories, Loyola University Medical Center, dated October 29, 1991. 
The excerpt to be reproduced is a table listing the amino acid composition of different 
variants of hirudin. Enclosed please find a copy of this table as modified in my dissertation. 
The requested permission extends to any future revisions and editions of my 
dissertation, including non-exclusive world rights in all languages, and to the prospective 
publication of my dissertation by University Microfilms, Inc. These rights will in no way 
restrict republication of the material in any other form by you or by others authorized by 
you. Your signing of this letter will also confirm that you own the copyright to the above-
described material. 
If these arrangements meet with your approval, please sign this letter where indicated 
below and return it to me in the enclosed return envelope. 
Thank you very much. 
Sincerely,. 
Lalitha Iyer, 
Dept. of Pharmacology, 
Loyola University Chicago. 
PERMISSION GRANTED FOR THE 
USE REQUESTED ABOVE: 
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LO YO IA 
E; m· , ~ UNIVERSITY 3:: ~CHICAGO 
;;> ~ 
0 ·" :f>~A.f.o't.\;'-' LOYOL\ UNIVERSITY ~IEDICAL CENTER 
STRITCH SCHOOL OF YIEDICINE 
2160 South First Avenue 
Maywood, Illinois 60153 
Telephone: (~08) 216-3261 
Fax: (~08) 216-6596 
Department oi Pharmarnlo~\' & Experimental Therapeu11cs 
March 27, 1995 
Jawed Fareed, Ph.D., 
Professor of Pathology and Pharmacology, 
Director, Hemostasis Research Laboratories, 
Loyola University Medical Center, 
2160, S. First Avenue, 
Maywood, IL 60153. 
Dear Dr. Fareed, 
Lalitha Iyer 
Tel: (708) 216-3262 
Fax: 708-216-6660 
This letter will confirm our recent conversation. I am completing a doctoral 
dissertation at the department of Pharmacology, Loyola University Chicago entitled 
"Pharmacokinetics and Pharmacodynamics of Recombinant Hirudin Variant 2 (rHV2) in 
Animal Models". I would like your permission to modify and reproduce in my dissertation 
an excerpt from the following: 
A letter written by Dr. Sandor Bajusz, Institute for Drug Research, Budapest, 
Hungary, dated October 29, 1991, and addressed to you. 
The excerpt to be reproduced is a table listing the amino acid composition of different 
variants of hirudin. Enclosed please find a copy of this table as modified in my dissertation. 
The requested permission extends to any future revisions and editions of my 
dissertation, including non-exclusive world rights in all languages, and to the prospective 
publication of my dissertation by University Microfilms, Inc. These rights will in no way 
restrict republication of the material in any other form by you or by others authorized by 
you. Your signing of this letter will also confirm that you own the copyright to the above-
described material. 
[340] 
If these arrangements meet with your approval, please sign this letter where indicated 
below and return it to me in the enclosed return envelope. 
Thank you very much. 
Sincerely, 
tW 
Lalitha Iyer, 
Dept. of Pharmacology, 
Loyola University Chicago. 
PERMISSION GR.-\NTED FOR THE 
··USE REQUESTED ABOVE: 
' .:-:< ... •~:~,.~;, 
\j ·~ 1J;,ttl~ ------~~+-----1-----7-( <l;w!P PJ.~L~ ) 
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